



US012391762B2

(12) **United States Patent**
Sato et al.

(10) **Patent No.:** US 12,391,762 B2
(45) **Date of Patent:** Aug. 19, 2025

- (54) **METHODS AND COMPOSITIONS RELATING TO GLP1R VARIANTS**
- (71) Applicant: **Twist Bioscience Corporation**, South San Francisco, CA (US)
- (72) Inventors: **Aaron Sato**, Burlingame, CA (US); **Pankaj Garg**, Burlingame, CA (US); **Qiang Liu**, Palo Alto, CA (US); **Fumiko Axelrod**, Palo Alto, CA (US)
- (73) Assignee: **Twist Bioscience Corporation**, South San Francisco, CA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 431 days.
- (21) Appl. No.: 17/412,139
- (22) Filed: Aug. 25, 2021
- (65) **Prior Publication Data**
- US 2022/0064313 A1 Mar. 3, 2022
- Related U.S. Application Data**
- (60) Provisional application No. 63/081,801, filed on Sep. 22, 2020, provisional application No. 63/070,734, filed on Aug. 26, 2020.
- (51) **Int. Cl.**
C07K 16/28 (2006.01)
- (52) **U.S. Cl.**
CPC *C07K 16/2869* (2013.01); *C07K 2317/24* (2013.01); *C07K 2317/565* (2013.01); *C07K 2317/75* (2013.01); *C07K 2317/76* (2013.01); *C07K 2317/92* (2013.01)
- (58) **Field of Classification Search**
CPC C07K 16/2869; C07K 2317/24; C07K 2317/565; C07K 2317/75; C07K 2317/76; C07K 2317/92
- See application file for complete search history.

- (56) **References Cited**
U.S. PATENT DOCUMENTS

5,368,823 A	11/1994	McGraw et al.
5,474,796 A	12/1995	Brennan
5,534,507 A	7/1996	Cama et al.
5,677,195 A	10/1997	Winkler et al.
5,843,767 A	12/1998	Beattie
6,013,440 A	1/2000	Lipshutz et al.
6,028,189 A	2/2000	Blanchard
6,419,883 B1	7/2002	Blanchard
6,472,147 B1	10/2002	Janda et al.
6,492,107 B1	12/2002	Kaufman et al.
6,709,841 B2	3/2004	Short
6,893,816 B1	5/2005	Beattie
7,163,660 B2	1/2007	Lehmann
7,202,264 B2	4/2007	Ravikumar et al.
7,947,809 B2 *	5/2011	Yan C07K 14/723 530/387.3
8,198,071 B2	6/2012	Goshoo et al.
9,403,141 B2	8/2016	Banyai et al.
9,409,139 B2	8/2016	Banyai et al.
9,555,388 B2	1/2017	Banyai et al.

9,677,067 B2	6/2017	Toro et al.
9,745,619 B2	8/2017	Rabbani et al.
9,765,387 B2	9/2017	Rabbani et al.
9,833,761 B2	12/2017	Banyai et al.
9,839,894 B2	12/2017	Banyai et al.
9,889,423 B2	2/2018	Banyai et al.
9,895,673 B2	2/2018	Peck et al.
9,981,239 B2	5/2018	Banyai et al.
10,053,688 B2	8/2018	Cox
10,272,410 B2	4/2019	Banyai et al.
10,384,188 B2	8/2019	Banyai et al.
10,384,189 B2	8/2019	Peck
10,417,457 B2	9/2019	Peck
10,583,415 B2	3/2020	Banyai et al.
10,618,024 B2	4/2020	Banyai et al.
10,632,445 B2	4/2020	Banyai et al.
10,639,609 B2	5/2020	Banyai et al.
10,669,304 B2	6/2020	Indermuhle et al.
10,744,477 B2	8/2020	Banyai et al.
10,754,994 B2	8/2020	Peck
10,773,232 B2	9/2020	Banyai et al.
10,844,373 B2	11/2020	Cox et al.
10,894,242 B2	1/2021	Marsh et al.
10,894,959 B2	1/2021	Cox et al.
10,907,274 B2	2/2021	Cox
10,936,953 B2	3/2021	Bramlett et al.
10,969,965 B2	4/2021	Malina et al.
10,975,372 B2	4/2021	Cox et al.
10,987,648 B2	4/2021	Peck et al.
11,214,798 B2	1/2022	Brown
11,407,837 B2	8/2022	Glanville
11,562,103 B2	1/2023	Peck
11,884,736 B2	1/2024	Okamoto et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	101277758 A	10/2008
EP	3030682 A2	6/2016

(Continued)

OTHER PUBLICATIONS

Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988).*

(Continued)

Primary Examiner — Vanessa L. Ford

Assistant Examiner — Danaya L Middleton

(74) Attorney, Agent, or Firm — McNeill PLLC

- (57)

ABSTRACT

Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for immunoglobulins that bind to GLP1R. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

16 Claims, 29 Drawing Sheets

Specification includes a Sequence Listing.

US 12,391,762 B2

Page 2

(56)	References Cited					
U.S. PATENT DOCUMENTS						
2001/0018512 A1	8/2001	Blanchard	2019/0135926 A1	5/2019	Glanville	
2002/0025561 A1	2/2002	Hodgson	2019/0314783 A1	10/2019	Banyai et al.	
2002/0094533 A1	7/2002	Hess et al.	2019/0352635 A1	11/2019	Toro et al.	
2002/0095073 A1	7/2002	Jacobs et al.	2019/0366293 A1	12/2019	Banyai et al.	
2002/0160536 A1	10/2002	Regnier et al.	2019/0366294 A1	12/2019	Banyai et al.	
2002/0164824 A1	11/2002	Xiao et al.	2020/0017907 A1	1/2020	Zeitoun et al.	
2003/0120035 A1	6/2003	Gao et al.	2020/0102611 A1	4/2020	Zeitoun et al.	
2003/0171325 A1	9/2003	Gascoyne et al.	2020/0156037 A1	5/2020	Banyai et al.	
2004/0087008 A1	5/2004	Schembri	2020/0181667 A1	6/2020	Wu et al.	
2004/0259146 A1	12/2004	Friend et al.	2020/0222875 A1	7/2020	Peck et al.	
2005/0049402 A1	3/2005	Babcock et al.	2020/0283760 A1	9/2020	Nugent et al.	
2005/0137805 A1	6/2005	Lewin et al.	2020/0299322 A1	9/2020	Indermuhle et al.	
2005/0227235 A1	10/2005	Carr et al.	2020/0299684 A1	9/2020	Toro et al.	
2006/0127920 A1	6/2006	Church et al.	2020/0308575 A1	10/2020	Sato	
2007/0196834 A1	8/2007	Cerrina et al.	2020/0325235 A1	10/2020	Tabibiazar et al.	
2008/0085511 A1	4/2008	Peck et al.	2020/0330953 A1	10/2020	Banyai et al.	
2008/0085514 A1	4/2008	Peck et al.	2020/0342143 A1	10/2020	Peck	
2008/0227160 A1	9/2008	Kool	2021/0002710 A1	1/2021	Gant et al.	
2008/0287320 A1	11/2008	Baynes et al.	2021/0040476 A1	2/2021	Cox et al.	
2008/0300842 A1	12/2008	Govindarajan et al.	2021/0071168 A1	3/2021	Nugent et al.	
2009/0062129 A1	3/2009	McKernan et al.	2021/0102192 A1	4/2021	Tabibiazar et al.	
2009/0239759 A1	9/2009	Balch	2021/0102195 A1	4/2021	Sato et al.	
2009/0285825 A1	11/2009	Kini et al.	2021/0102198 A1	4/2021	Cox et al.	
2010/0004143 A1	1/2010	Shibahara	2021/0115594 A1	4/2021	Cox et al.	
2010/0099103 A1	4/2010	Hsieh et al.	2021/0129108 A1	5/2021	Marsh et al.	
2010/0111768 A1	5/2010	Banerjee et al.	2021/0142182 A1	5/2021	Bramlett et al.	
2010/0216648 A1	8/2010	Staehler et al.	2021/0170356 A1	6/2021	Peck et al.	
2010/0311960 A1	12/2010	Dellinger	2021/0179724 A1	6/2021	Sato et al.	
2011/0172127 A1	7/2011	Jacobson et al.	2021/0180046 A1	6/2021	Cox et al.	
2011/0217738 A1	9/2011	Jacobson	2021/0207197 A1	7/2021	Gant et al.	
2012/0129704 A1	5/2012	Gunderson et al.	2021/0332078 A1	10/2021	Wu	
2012/0164691 A1	6/2012	Eshoo et al.	2021/0348220 A1	11/2021	Zeitoun et al.	
2012/0231968 A1	9/2012	Bruhn et al.	2021/0355194 A1	11/2021	Sato et al.	
2012/0264653 A1	10/2012	Carr et al.	2021/0395344 A1	12/2021	Sato et al.	
2013/0017642 A1	1/2013	Milgrew et al.	2022/0032256 A1	2/2022	Lackey et al.	
2013/0017977 A1	1/2013	Oleinikov	2022/0064206 A1	3/2022	Fernandez et al.	
2013/0065017 A1	3/2013	Sieber	2022/0064313 A1	3/2022	Sato et al.	
2013/0109595 A1	5/2013	Routenberg	2022/0064628 A1	3/2022	Toro et al.	
2013/0109596 A1	5/2013	Peterson et al.	2022/0106586 A1	4/2022	Nugent et al.	
2013/0130321 A1	5/2013	Staehler et al.	2022/0106590 A1	4/2022	Arbiza et al.	
2013/0164308 A1	6/2013	Foletti et al.	2022/0135690 A1	5/2022	Sato et al.	
2013/0165328 A1	6/2013	Previte et al.	2022/0135965 A1	5/2022	Gant et al.	
2014/0106394 A1	4/2014	Ko et al.	2022/0145289 A1	5/2022	Lackey et al.	
2014/0178992 A1	6/2014	Nakashima et al.	2022/0206001 A1	6/2022	Sato	
2015/0038373 A1	2/2015	Banyai et al.	2022/0243195 A1	8/2022	Nugent et al.	
2015/0120265 A1	4/2015	Amirav-Drory et al.	2022/0246236 A1	8/2022	Amirav-Drory	
2015/0196917 A1	7/2015	Kay et al.	2022/0259319 A1	8/2022	Sato et al.	
2016/0089651 A1	3/2016	Banyai	2022/0259638 A1	8/2022	Brown	
2016/0090592 A1	3/2016	Banyai et al.	2022/0277808 A1	9/2022	Arbiza et al.	
2016/0096160 A1	4/2016	Banyai et al.	2022/0281989 A1	9/2022	Glanville	
2016/0251651 A1	9/2016	Banyai et al.	2022/0307010 A1	9/2022	Sato et al.	
2016/0297883 A1	10/2016	Gallo et al.	2022/0315971 A1	10/2022	Wu et al.	
2016/0303535 A1	10/2016	Banyai et al.	2022/0323924 A1	10/2022	Lackey et al.	
2016/0333340 A1	11/2016	Wu	2022/0325276 A2	10/2022	Banyai et al.	
2016/0339409 A1	11/2016	Banyai et al.	2022/0325278 A1	10/2022	Nugent et al.	
2016/0340672 A1	11/2016	Banyai et al.	2022/0348659 A1	11/2022	Sato et al.	
2016/0354752 A1	12/2016	Banyai et al.	2022/0356463 A1	11/2022	Shen et al.	
2017/0037124 A1	2/2017	Gusarova et al.	2022/0356468 A1	11/2022	Sato et al.	
2017/0066844 A1	3/2017	Glanville	2022/0411784 A1	12/2022	Sato et al.	
2017/0081716 A1	3/2017	Peck	2023/0002478 A1	1/2023	Sato et al.	
2017/0095785 A1	4/2017	Banyai et al.	2023/0054232 A1	2/2023	Peck	
2017/0159044 A1	6/2017	Toro et al.	2023/0086062 A1	3/2023	Banyai et al.	
2017/0253644 A1	9/2017	Steyaert et al.	2023/0096464 A1	3/2023	Sato	
2017/0327819 A1	11/2017	Banyai et al.	2023/0115861 A1	4/2023	Nugent et al.	
2017/0357752 A1	12/2017	Diggans	2023/0153452 A1	5/2023	Peck et al.	
2017/0362589 A1	12/2017	Banyai et al.	2023/0158469 A1	5/2023	Lackey et al.	
2018/0029001 A1	2/2018	Banyai et al.	2023/0175062 A1	6/2023	Lackey et al.	
2018/0104664 A1	4/2018	Fernandez	2023/0185971 A1	6/2023	Peck	
2018/0142289 A1	5/2018	Zeitoun et al.	2023/0192818 A1	6/2023	Sato et al.	
2018/0253563 A1	9/2018	Peck et al.	2023/0192819 A1	6/2023	Sato et al.	
2018/0264428 A1	9/2018	Banyai et al.	2023/0193383 A1	6/2023	Peck	
2018/0282721 A1	10/2018	Cox et al.	2023/0193513 A1	6/2023	Tabibiazar et al.	
2018/0326388 A1	11/2018	Banyai et al.	2023/0211308 A1	7/2023	Banyai et al.	
2019/0062441 A1	2/2019	Yan et al.				
2019/0083596 A1	3/2019	Orentas et al.				

FOREIGN PATENT DOCUMENTS

JP	H07505530 A	6/1995
JP	2001518086 A	10/2001
JP	2002538790 A	11/2002

(56)

References Cited

FOREIGN PATENT DOCUMENTS

JP 2004268394 A 9/2004
 JP 2006503586 A 2/2006
 JP 2007314746 A 12/2007
 JP 2008214343 A 9/2008
 JP 2009294195 A 12/2009
 JP 2012507513 A 3/2012
 JP 2016527313 A 9/2016
 JP 2020536504 A 12/2020
 WO WO-9320242 A1 10/1993
 WO 2000043507 A1 7/2000
 WO WO-02072791 A2 9/2002
 WO WO-2004039953 A2 5/2004
 WO WO-2005018536 A2 3/2005
 WO WO-2005059096 A2 6/2005
 WO 2008003116 A2 1/2008
 WO WO-2008054543 A2 5/2008
 WO WO-2008063135 A1 5/2008
 WO WO-2010053443 A1 5/2010
 WO 2010063818 A2 6/2010
 WO 2011056644 A2 5/2011
 WO WO-2011109031 A1 9/2011
 WO WO-2012078312 A2 6/2012
 WO WO-2012154201 A1 11/2012
 WO 2013134881 A1 9/2013
 WO WO-2014021938 A1 2/2014
 WO 2015021080 A2 2/2015
 WO 2015063331 A1 5/2015
 WO 2016161244 A2 10/2016
 WO 2016173719 A1 11/2016
 WO WO-2022010934 A2 1/2022
 WO WO-2022046944 A2 3/2022
 WO WO-2022076326 A1 4/2022
 WO WO-2022086866 A1 4/2022
 WO WO-2022087293 A1 4/2022
 WO WO-2022098662 A2 5/2022
 WO WO-2022159620 A1 7/2022
 WO WO-2022178137 A1 8/2022
 WO WO-2022204309 A1 9/2022
 WO WO-2022204316 A2 9/2022
 WO WO-2022217004 A1 10/2022
 WO WO-2022235579 A1 11/2022
 WO WO-2022235584 A1 11/2022
 WO WO-2022271884 A2 12/2022
 WO WO-2023023183 A2 2/2023
 WO WO-2023023190 A2 2/2023
 WO WO-2023023285 A2 2/2023
 WO WO-2023069367 A1 4/2023
 WO WO-2023076419 A2 5/2023
 WO WO-2023076420 A2 5/2023
 WO WO-2023076687 A1 5/2023
 WO WO-2023091609 A2 5/2023
 WO WO-2023091614 A2 5/2023
 WO WO-2023102034 A2 6/2023
 WO WO-2023114432 A2 6/2023

OTHER PUBLICATIONS

Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue. *J. Cell Biol.* 111:2129-2138, 1990 (Year: 1990).*

Brown et al., *J Immunol.* May 1996;156(9):3285-91 (Year: 1996).*

Greenspan et al. 1999 Defining epitopes: It's not as easy as it seems; *Nature Biotechnology*, 17:936-937 (Year: 1999).*

Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. *Genome Research*, 2000, 10:398-400 (Year: 2000).*

Skolnick et al., *Trends Biotechnol.* Jan. 2000;18(1):34-9 (Year: 2000).*

Vajdos et al., *J Mol Biol.* Jul. 5, 2002;320(2):415-28 at 416 (Year: 2002).*

Miosge, *Proc Natl Acad Sci U S A.* Sep. 15, 2015;112(37):E5189-98 (Year: 2015).*

Kulmanov et al., *Bioinformatics*, 34(4), 2018, 660-668 (Year: 2018).*

Agbaavwe et al.: Efficiency, Error and Yield in Light-Directed Maskless Synthesis of DNA Microarrays. *Journal of Nanobiotechnology*. 9(5):1-17 (2011).

Hasin-Brumshtein et al.: The Effects of Mismatches on DNA Capture by Hybridization. *Twist WhitePaper*. 6 pages (May 7, 2019).

PCT/US2021/047616 International Preliminary Report on Patentability dated Mar. 9, 2023.

PCT/US2021/047616 International Search Report and Written Opinion dated Feb. 15, 2022.

PCT/US2021/047616 Invitation to Pay Additional Fees dated Dec. 1, 2021.

U.S. Appl. No. 16/039,256 Office Action dated May 10, 2022.

U.S. Appl. No. 16/737,401 Final Office Action dated Jun. 13, 2022.

U.S. Appl. No. 16/737,401 Office Action dated Jan. 5, 2022.

U.S. Appl. No. 16/737,401 Restriction Requirement dated Nov. 15, 2021.

Al-Lazikani et al. Standard conformations for the canonical structures of immunoglobulins. *J Mol Biol.* 273(4):927-48 (1997).

Altschul et al.: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic acids research* vol. 25, 17 (1997): 3389-402, doi:10.1093/nar/25.17.3389.

Arkles et al.: The Role of Polarity in the Structure of Silanes Employed in Surface Modification. *Silanes and Other Coupling Agents*. 5:51-64 (2009).

ATDBio. Nucleic Acid Structure, Nucleic Acids Book, 9 pages, published on Jan. 22, 2005. from: <http://www.atdbio.com/content/5/Nucleic-acid-structure>.

ATDBio. Solid-Phase Oligonucleotide Synthesis, Nucleic Acids Book, 20 pages. Published on Jul. 31, 2011. from: <http://www.atdbio.com/content/17/Solid-phase-oligonucleotide-synthesis>.

Berg: *Biochemistry*. 5th ED. New York (2002) 148-149.

Blanchard et al.: High-Density Oligonucleotide Arrays. *Biosensors & Bioelectronics*, 11(6/7):687-690 (1996).

Buermans et al.: Next Generation sequencing technology: Advances and applications, *Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease*, 1842:1932-1941 (2014).

Cheng et al.: High throughput parallel synthesis of oligonucleotides with 1536 channel synthesizer. *Nucleic Acids Res.* 30(18):e93 (2002).

Cleary et al.: Production of complex nucleic acid libraries using highly parallel *in situ* oligonucleotide synthesis. *Nat Methods*. 1(3):241-248 (2004).

Cohen et al.: Human population: The next half century. *Science*. 302:1172-1175 (2003).

Cruse et al.: *Atlas of Immunology*. Third Edition. Boca Raton:CRC Press (pp. 282-283) (2010).

Elsik et al.: The Genome sequence of taurine cattle: A window of ruminant biology and evolution. *Science*. 324:522-528 (2009).

Fodor et al.: Light-directed, spatially addressable parallel chemical synthesis. *Science*. 251(4995):767-773 (1991).

Gao et al.: A method for the generation of combinatorial antibody libraries using pIX phage display. *PNAS* 99(20):12612-12616 (2002).

GE Healthcare. AKTA oligopilot plus. Data File 18-114-66 ADC. 8 pages (2006).

GE Healthcare. Robust and cost-efficient oligonucleotide synthesis. Application Note 28-4058-08 AA. 4 pages (2005).

Gibson et al.: Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome. *Science*. 329(5989):52-56 (2010).

Honegger et al. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. *J Mol Biol* 309(3):657-70 (2001).

Hudson: *Matrix Assisted Synthetic Transformations: A Mosaic of Diverse Contributions*. *Journal of Combinatorial Chemistry*. 1(6):403-457 (1999).

Kabat et al. Sequences of proteins of immunological interest. NIH Publ. No. 91-3242 1:647-669 (1991).

Karlin et al.: Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. *Proc. Natl. Acad. Sci.* 87: 2264-2268 (1990).

(56)

References Cited**OTHER PUBLICATIONS**

- Karlin et al.: Applications and statistics for multiple high-scoring segments in molecular sequences. *PNAS USA* 90(12):5873-5878 (1993).
- Kong et al.: Parallel gene synthesis in a microfluidic device. *Nucleic Acids Res.* 35(8):e61 (2007).
- Kosuri and Church. Large-scale de novo DNA synthesis: technologies and applications. *Nature Methods.* 11:499-507 (2014) Available at: <http://www.nature.com/nmeth/journal/v11/n5/full/nmeth.2918.html>.
- Kosuri et al.: A scalable gene synthesis platform using high-fidelity DNA microchips *Nat.Biotechnol.* 28(12):1295-1299 (2010).
- Krayden, Inc.: A Guide to Silane Solutions. Silane coupling agents. 7 pages. Published on May 31, 2005 at: http://kayden.com/pdf/xia_silane_chemistry.pdf.
- Lausted et al.: POSaM: a fast, flexible, open-source, inkjet oligonucleotide synthesizer and microarrayer. *Genome Biology.* 5:R58, 17 pages (2004) available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC507883/>.
- Lebl et al.: Economical Parallel Oligonucleotide and Peptide Synthesizer—Pet Oligator. *Int. J. Peptide Res. Ther.* 13(1-2):367-376 (2007).
- Lefranc et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. *Dev Comp Immunol* 27(1):55-77 (2003).
- Leproust et al.: Synthesis of high-quality libraries of long (150mer) oligonucleotides by a novel depurination controlled process. *Nucleic Acids Research.* 38(8):2522-2540 (2010).
- Lewontin and Hartl. Population genetics in forensic DNA typing. *Science,* 254:1745-1750, 1991.
- Ma et al.: DNA synthesis, assembly and application in synthetic biology. *Current Opinion in Chemical Biology.* 16:260-267 (2012).
- Ma et al.: Versatile surface functionalization of cyclic olefin copolymer (COC) with sputtered SiO₂ thin film for potential BioMEMS applications. *Journal of Materials Chemistry.* 11 pages (2009).
- MacCallum et al. Antibody-antigen interactions: contact analysis and binding site topography. *J Mol Biol.* 262(5):732-745 (1996).
- Mazor et al.: Isolation of Full-Length IgG Antibodies from Combinatorial Libraries Expressed in *Escherichia coli*; Antony S. Dimitrov (ed.), *Therapeutic Antibodies: Methods and Protocols*, vol. 525, Chapter 11, pp. 217-239 (2009).
- McBride & Caruthers. An investigation of several deoxynucleoside phosphoramidites useful for synthesizing deoxyoligonucleotides. *Tetrahedron Lett.* 24:245-248 (1983).
- Mitra et al.: In situ localized amplification and contact replication of many individual DNA molecules. *Nucleic Acids Res.* 27(24):e34 (1999).
- Morin et al.: Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. *Biotechniques.* 45:81-94 (2008).
- Opposition to European Patent No. 3030682 filed Mar. 3, 2021. PCT/US2014/049834 International Preliminary Report on Patentability dated Feb. 18, 2016.
- PCT/US2014/049834 International Search Report and Written Opinion mailed Mar. 19, 2015.
- PCT/US2014/049834 Invitation to Pay Additional Fees and, where applicable, protest fee mailed Jan. 5, 2015.
- Pirrung. How to make a DNA chip. *Angew. Chem. Int. Ed.* 41:1276-1289 (2002).
- Pray. Discovery of DNA Structure and Function: Watson and Crick. *Nature Education*. 6 pages (2008) available at: <http://www.nature.com/scitable/topicpage/discovery-of-dna-structure-and-function-watson-397>.
- Quan et al.: Parallel on-chip gene synthesis and application to optimization of protein expression. *Nature Biotechnology.* 29:449-452 (2011).
- Rafalski and Morgante, Corn and humans: recombination and linkage disequilibrium in two genomes of similar size. *Trends in Genetics.* 20(2):103-111. (2004).
- Rogozin et al.: Origin and evolution of spliceosomal introns. *Biology Direct,* 7:11 (2012).
- Saaem et al.: In situ synthesis of DNA microarray on functionalized cyclic olefin copolymer substrate ACS Applied Materials & Interfaces. 2(2):491-497 (2010).
- Sargolzaei et al.: Extent of linkage disequilibrium in Holstein cattle in North America. *J.Dairy Science.* 91:2106-2117 (2007).
- Srivannavit et al.: Design and fabrication of microwell array chips for a solution-based, photogenerated acid-catalyzed parallel oligonucleotide DNA synthesis. *Sensors and Actuators A.* 116:150-160 (2004).
- Steel. The Flow-Thru Chip a Three-dimensional biochip platform. In: Schena, Microarray Biochip Technology, Chapter 5, Natick, MA: Eaton Publishing, 2000, 33 pages.
- Taylor et al.: Impact of surface chemistry and blocking strategies on DNA microarrays. *Nucleic Acids Research,* 31(16):e87 19 pages (2003).
- Tian et al.: Accurate multiplex gene synthesis from programmable DNA microchips. *Nature.* 432(7020):1050-1054 (2004).
- Van Tassell et al.: SNP discovery and allele frequency estimation by deep sequencing of reduced representation libraries. *Nature Methods.* 5:247-252 (2008).
- Whitelegg et al. WAM: an improved algorithm for modelling antibodies on the WEB. *Protein Eng.* 13:819-24 (2000).
- Wootton et al. Statistics of local complexity in amino acid sequences and sequence databases. *Computers & Chemistry* 17(2):149-163 (Jun. 1993).
- Xu et al.: Design of 240,000 orthogonal 25mer DNA barcode probes. *PNAS.* 106(7):2289-2294 (2009).
- Zhang et al., "Rational Design of a 1-15 Humanized Glucagon-Like Peptide-1 Receptor Agonist Antibody", *Angewandte Chemie International Edition*, Verlag Chemie, vol. 54, No. 7, Dec. 29, 2014 (Dec. 29, 2014), pp. 2126-2130.
- Chan et al., "Virtual screening of human Class-A GPCRs using ligand profiles built on multiple ligand-receptor interactions," *J Mol Biol.* Aug. 7, 2020; 432(17): 4872-4890. doi:10.1016/j.jmb.2020.07.003.
- Douthwaite, J., et al., "Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1," *mAbs*, vol. 7, No. 1, pp. 152-166 (2015).
- Extended European Search Report issued in European Application No. 18853509.0, dated May 11, 2021, (9 pages).
- Fernández-Quintero et al.: Characterizing the Diversity of the CDR-H3 Loop Conformational Ensembles in Relationship to Antibody Binding Properties. *Front. Immunol.* 9:1-11 (2019).
- Frederickson, S., et al., "A rationally designed agonist antibody fragment that functionally mimics thrombopoietin," *PNAS*, vol. 103, No. 39, pp. 14307-14312 (2006).
- Hennen, S., et al., "Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor," *Scientific Reports,* 6:26236 (2016).
- International Preliminary Report on Patentability issued in International Application No. PCT/US2018/050511, dated Mar. 26, 2020, by X. Wang (11 pages).
- International Search Report & Written Opinion of International Application No. PCT/US2018/050511 dated Jan. 11, 2019, by B. R. Copenhagen (13 pages).
- International Search Report and Written Opinion of International Application No. PCT/US20/19986, dated Jul. 29, 2024, (18 pages).
- Jo, M., et al., "Engineering therapeutic antibodies targeting G-protein-coupled receptors," *Experimental & Molecular Medicine*, vol. 48, No. e207, pp. 1-9 (2016).
- Liu et al., "Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control," *MABS*, vol. 13, No. 1, Jan. 1, 2021.
- Munk et al., "An Online Resource for GPCR Structure Determination and Analysis," *Nat Methods.* Feb. 1, 2019; 16(2): 151-162. doi:10.1038/s41592-018-0302-x.
- Peterson et al., "Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism", *Diabetes*, vol. 72, No. 9, Jun. 26, 2023, pp. 1320-1329.

(56)

References Cited

OTHER PUBLICATIONS

- Pigott, C., et al., "Peptide Grafting Approach The Use of a Novel Discovery Platform to Identify Peptide-Grafted Antibodies that Activate GLP-1 Receptor Signaling," URL:<http://www.innovativetargeting.com/wp-content/uploads/2013/12/Pigott-et-al-Antibody-Engineering-2013.pdf> (2013).
- Regep et al.: The H3 loop of antibodies shows unique structural characteristics. *Proteins*. 85(7):1311-1318 (2017).
- Supplemental European Search Report issued in European Application No. EP 21 86 2681, dated Aug. 22, 2024, (13 pages).
- Supplementary Partial European Search Report issued in European Application No. EP 20762890, dated Nov. 3, 2022, (17 pages).
- Xu, Y., et al., "Coordination between the Polymerase and 5'-Nuclease Components of DNA Polymerase I of *Escherichia coli*," *Journal of Biological Chemistry*, vol. 275, No. 27, pp. 20949-20955 (2000).

* cited by examiner



FIG. 1A



FIG. 1B





FIG. 2

**FIG. 3**




FIG. 4




FIG. 5




FIG. 6




FIG. 7



FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 10




FIG. 11




FIG. 12A




FIG. 12B




FIG. 13




FIG. 14

HCDR3

Glucagon-like peptide 1

GLP1R-3 (SEQ ID NO: 20)	HAEGTFTSDVSSYLEGQAAKEFIIAWLVKGRG
GLP1R-8 (SEQ ID NO: 21)	CAKHMSMQEGAVT T GEQAAKEFI IA WLVKGRVRA D LVGDAFDVW
GLP1R-56 (SEQ ID NO: 27)	CARDGRGSLPRPKGGPOTV G EQAAKEFI IA WLVKGG T YDSSED S GGAA F DIW
GLP1R-58 (SEQ ID NO: 28)	CARANQHFFSGAEGEGQAAKEFI IA WLVKG T IPGYHY Y GM D VW
GLP1R-60 (SEQ ID NO: 29)	CARANQHFFGLHAQCEGQAAKEFI IA WLVKGS G TYGYHY Y GM D VW
GLP1R-72 (SEQ ID NO: 32)	CAKHMSMQDYLIVIGEQAAKEFI IA WLVKGGPARADLVGDAFDVW
	CARDMYYDFHPE G TFTSDVSSYLEGQAAKEFI IA WLVKGS L IYEVVPADD A FDI W

Glucagon-like peptide 2

GLP1R-25 (SEQ ID NO: 23)	HADGSFSDEMNTILDNLAARDEINWLIQTKITD
GLP1R-30 (SEQ ID NO: 25)	CARANQHFLSHAGAARD E FINWL I QT K ITD G IGSGYHY Y GM D VW
GLP1R-70 (SEQ ID NO: 30)	CARDMYYDFLKI G DNL A ARDE E FINWL I QT K ITD G TDTEVV P ADD A FDI W
GLP1R-98 (SEQ ID NO: 36)	CARDGRGSLPRPKGGPSSGRD E FINWL I QT K ITD G FRYDSSED S GGAA F DIW
	CARDMYYDFCGYFTG M NTILDNLAARDE E FINWL I QT K ITD R GGSGGGSGGGSEVV V PADD A FDI W
GLP1R-2 (SEQ ID NO: 19)	CARDMYYDFETVVEGIQWYEALKAGKLG E VVPADD A FDI W
GLP1R-10 (SEQ ID NO: 22)	CARANQHFFVPGSLK V WLKGVA S SESYD S SED S GGAA F DI W
GLP1R-26 (SEQ ID NO: 24)	CAKHMSMQEGVLQGQQIPSTIDWEGLILH I RADLVGDAFDVW

FIG. 15




FIG. 16A






FIG. 16B



	+ no Ab	+ GLP1R-3
E_{C_50}	5.6	23.4

FIG. 16C

GLP-1 (7-36)



GLP1R-2

FIG. 17




FIG. 18A






FIG. 18B




	GLP1R59-2	GLP-1 (7-36)
EC ₅₀	6.7	34.6

FIG. 18C



GLP1R-3 2 Hrs



GLP1R-59-2 2 Hrs

FIG. 19A

FIG. 19B




FIG. 20A




FIG. 20B





FIG. 21A



a: Ctrl vs **GLP1R-3** <0.0001

b: Ctrl vs Exendin 1 mg/kg p<0.0001

*: **GLP1R-3** vs Exendin 0.23 mg/kg p<0.03

c: Exendin 1 mg/kg vs Exendin 0.23 mg/kg p=0.03

FIG. 21B




FIG. 22A




FIG. 22B




FIG. 23A




FIG. 23B





FIG. 24A



Round 1	Round 2	Round 3	Round 4	Round 5
3.0x10 ¹² 2.0x10 ⁶	1.6x10 ¹³ 1.8x10 ⁷	2.0x10 ¹³ 1.5x10 ⁷	5.4x10 ¹² 1.7x10 ⁷	1.8x10 ¹³ 4.6x10 ⁷

FIG. 24B




FIG. 25A




FIG. 25B




FIG. 26

1**METHODS AND COMPOSITIONS
RELATING TO GLP1R VARIANTS****CROSS-REFERENCE**

This application claims the benefit of U.S. Provisional Patent Application No. 63/070,734 filed on Aug. 26, 2020, and U.S. Provisional Patent Application No. 63/081,801 filed on Sep. 22, 2020, each of which is incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 22, 2021, is named 44854-808_201_SL.txt and is 838,237 bytes in size.

BACKGROUND

G protein-coupled receptors (GPCRs) are implicated in a wide variety of diseases. Raising antibodies to GPCRs has been difficult due to problems in obtaining suitable antigens because GPCRs are often expressed at low levels in cells and are very unstable when purified. Thus, there is a need for improved agents for therapeutic intervention which target GPCRs.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF SUMMARY

Provided herein are antibodies or antibody fragments that binds GLP1R, comprising an immunoglobulin heavy chain and an immunoglobulin light chain: (a) wherein the immunoglobulin heavy chain comprises an amino acid sequence at least about 90% identical to that set forth in Table 9; and (b) wherein the immunoglobulin light chain comprises an amino acid sequence at least about 90% identical to that set forth in Table 10. Further provided herein are antibodies or antibody fragments, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment thereof is chimeric or humanized. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment has an EC50 less than about 25 nanomolar in a cAMP assay. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment has an EC50 less than about 20 nanomolar in a cAMP assay. Further provided herein are anti-

2

bodies or antibody fragments, wherein the antibody or antibody fragment has an EC50 less than about 10 nanomolar in a cAMP assay. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment is an agonist of GLP1R. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment is an antagonist of GLP1R. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment is an allosteric modulator of GLP1R. Further provided herein are antibodies or antibody fragments, wherein the allosteric modulator of GLP1R is a negative allosteric modulator.

Provided herein are methods of treating a metabolic disease or disorder comprising administering an antibody or antibody fragment that binds GLP1R, wherein the antibody or antibody fragment comprises a sequence set forth in Tables 7-13. Further provided herein are methods, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are methods, wherein the antibody or antibody fragment thereof is chimeric or humanized. Further provided herein are methods, wherein the antibody or antibody fragment has an EC50 less than about 25 nanomolar in a cAMP assay. Further provided herein are methods, wherein the antibody or antibody fragment has an EC50 less than about 20 nanomolar in a cAMP assay. Further provided herein are methods, wherein the antibody or antibody fragment has an EC50 less than about 10 nanomolar in a cAMP assay. Further provided herein are methods, wherein the antibody or antibody fragment is an agonist of GLP1R. Further provided herein are methods, wherein the antibody or antibody fragment is an antagonist of GLP1R. Further provided herein are methods, wherein the antibody or antibody fragment is an allosteric modulator of GLP1R. Further provided herein are methods, wherein the allosteric modulator of GLP1R is a negative allosteric modulator. Further provided herein are methods, wherein the antibody or antibody fragment is an allosteric modulator. Further provided herein are methods, wherein the antibody or antibody fragment is a negative allosteric modulator. Further provided herein are methods, wherein the metabolic disease or disorder is Type II diabetes or obesity.

Provided herein are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH 55 comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 441-619; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 620-798; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 799-977; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 978-1156; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 1157-1335; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 1336-1347 and 1353-1519. Further

provided herein are antibodies or antibody fragments, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment thereof is chimeric or humanized. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment has an EC50 less than about 25 nanomolar in a cAMP assay. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment has an EC50 less than about 20 nanomolar in a cAMP assay. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment has an EC50 less than about 10 nanomolar in a cAMP assay. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment is an agonist of GLP1R. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment is an antagonist of GLP1R. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment is an allosteric modulator of GLP1R. Further provided herein are antibodies or antibody fragments, wherein the allosteric modulator of GLP1R is a negative allosteric modulator. Further provided herein are antibodies or antibody fragments, wherein the VH comprises a sequence at least about 90% identical to any one of SEQ ID NOs: 58-77. Further provided herein are antibodies or antibody fragments, wherein the VH comprises a sequence of any one of SEQ ID NOs: 58-77. Further provided herein are antibodies or antibody fragments, wherein the VL comprises a sequence at least about 90% identical to any one of SEQ ID NOs: 92-111. Further provided herein are antibodies or antibody fragments, wherein the VL comprises a sequence of any one of SEQ ID NOs: 92-111.

Provided herein are methods of treating a metabolic disease or disorder comprising administering an antibody or antibody fragment that binds GLP1R comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 441-619; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 620-798; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 799-977; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 978-1156; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 1157-1335; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 1336-1347 and 1353-1519. Further provided herein are methods, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a

single chain antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. Further provided herein are methods, wherein the antibody or antibody fragment thereof is chimeric or humanized. Further provided herein are methods, 10 wherein the antibody or antibody fragment has an EC50 less than about 25 nanomolar in a cAMP assay. Further provided herein are methods, wherein the antibody or antibody fragment has an EC50 less than about 20 nanomolar in a cAMP assay. Further provided herein are methods, wherein the antibody or antibody fragment has an EC50 less than about 10 nanomolar in a cAMP assay. Further provided herein are methods, 15 wherein the antibody or antibody fragment is an agonist of GLP1R. Further provided herein are methods, wherein the antibody or antibody fragment is an antagonist of GLP1R. Further provided herein are methods, wherein the antibody or antibody fragment is an allosteric modulator of GLP1R. Further provided herein are methods, wherein the allosteric modulator of GLP1R is a negative allosteric modulator. Further provided herein are methods, wherein the antibody or antibody fragment is an allosteric modulator. 20 Further provided herein are methods, wherein the antibody or antibody fragment is a negative allosteric modulator. Further provided herein are methods, wherein the VH comprises a sequence at least about 90% identical to any one of SEQ ID NOs: 58-77. Further provided herein are methods, wherein the VH comprises a sequence of any one of SEQ ID NOs: 58-77. Further provided herein are methods, wherein the VL comprises a sequence at least about 90% identical to any one of SEQ ID NOs: 92-111. Further provided herein are methods, 25 wherein the VL comprises a sequence of any one of SEQ ID NOs: 92-111. Further provided herein are methods, wherein the metabolic disease or disorder is Type II diabetes or obesity.

Provided herein are nucleic acid compositions comprising: a) a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein (i) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 441-619; (ii) an amino acid sequence of 40 CDRH2 is as set forth in any one of SEQ ID NOs: 620-798; (iii) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 799-977; b) a second nucleic acid encoding a variable domain, light chain region (VL) comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (i) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 978-1156; (ii) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 1157-1335; and (iii) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 1336-1347 and 1353-1519.

Provided herein are nucleic acid compositions comprising: a) a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 58-77; b) a second nucleic acid encoding a variable domain, light chain region (VL) comprising at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 92-111; and an excipient. Further provided herein are nucleic acid compositions, 60 wherein the VH comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 58-77. Further provided herein are nucleic acid compositions, wherein the VL com-

prises an amino acid sequence as set forth in any one of SEQ ID NOS: 92-111. Further provided herein are nucleic acid compositions, wherein the VH comprises an amino acid sequence as set forth in any one of SEQ ID NOS: 58-77, and wherein the VL comprises an amino acid sequence as set forth in any one of SEQ ID NOS: 92-111.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A depicts a first schematic of an immunoglobulin. FIG. 1B depicts a second schematic of an immunoglobulin.

FIG. 2 depicts a schematic of a motif for placement in an immunoglobulin.

FIG. 3 presents a diagram of steps demonstrating an exemplary process workflow for gene synthesis as disclosed herein.

FIG. 4 illustrates an example of a computer system.

FIG. 5 is a block diagram illustrating an architecture of a computer system.

FIG. 6 is a diagram demonstrating a network configured to incorporate a plurality of computer systems, a plurality of cell phones and personal data assistants, and Network Attached Storage (NAS).

FIG. 7 is a block diagram of a multiprocessor computer system using a shared virtual address memory space.

FIG. 8A depicts a schematic of an immunoglobulin comprising a VH domain attached to a VL domain using a linker.

FIG. 8B depicts a schematic of a full-domain architecture of an immunoglobulin comprising a VH domain attached to a VL domain using a linker, a leader sequence, and pIII sequence.

FIG. 8C depicts a schematic of four framework elements (FW1, FW2, FW3, FW4) and the variable 3 CDR (L1, L2, L3) elements for a VL or VH domain.

FIG. 9A depicts a structure of Glucagon-like peptide 1 (GLP-1) in complex with GLP-1 receptor (GLP-1R), PDB entry 5VAI.

FIG. 9B depicts a crystal structure of CXCR4 chemokine receptor in complex with a cyclic peptide antagonist CVX15, PDB entry 3ORO.

FIG. 9C depicts a crystal structure of human smoothened receptor with the transmembrane domain and extracellular domain (ECD), PDB entry 5L7D. The ECD contacts the TMD through extracellular loop 3 (ECL3).

FIG. 9D depicts a structure of GLP-1R in complex with a Fab, PDB entry 6LN2.

FIG. 9E depicts a crystal structure of CXCR4 in complex with a viral chemokine antagonist Viral macrophage inflammatory protein 2 (vMIP-II), PDB entry 4RWS.

FIG. 10 depicts a schema of the GPCR focused library design. Two germline heavy chain VH1-69 and VH3-30; 4 germline light chain IGKV1-39 and IGKV3-15, and IGLV1-51 and IGLV2-14.

FIG. 11 depicts a graph of HCDR3 length distribution in the GPCR-focused library compared to the HCDR3 length distribution in B-cell populations from three healthy adult donors. In total, 2,444,718 unique VH sequences from the GPCR library and 2,481,511 unique VH sequences from human B-cell repertoire were analyzed to generate the length distribution plot.

FIG. 12A depicts the design of the over-expressing GLP-1R CHO cells for the phage antibody library selection. GLP-1R expression was confirmed by the gating of double detection of GFP green fluorescence and the surface expression of Flag tag on the cell surface.

FIG. 12B depicts a cell-based panning process.

FIG. 13 depicts a graph of percent unique HCDR3 in the output pools of the five GLP-1R panning rounds.

FIG. 14 depicts a graph of binding plots of the 13 unique GLP-1R Hits, compared to the parental CHO cell binding.

FIG. 15 depicts HCDR3 loop sequences of the 13 unique GLP1R binders. Six of the clones have a GLP-1 motif, four of the clones have a GLP-2 motif, and three clones do not have a GLP-1 or GLP-2 motif. For the clones that have the GLP-1 or GLP-2 motif (bolded), residues that are similar to the GLP-1 sequence or the GLP-2 sequence are bolded and the residues that are different are left unbolded. Functional antagonists in the CAMP assay are enclosed by a box. FIG. 15 discloses SEQ ID NOS 1528, 1-2, 27, 12, 3, 32, 1529, 23, 25, 30, 1530, 19, 22 and 24, respectively, in order of appearance.

FIG. 16A depicts a graph of orthosteric inhibition of GLP1R-3 binding in the absence and presence of GLP-1 (7-36).

FIG. 16B depicts a graph of effects of GLP1R-3 on GLP-1 activation in the CAMP assay.

FIG. 16C depicts a graph of effects of GLP1R-3 on GLP-1 induced β -arrestin recruitment.

FIG. 17 depicts a design of GLP1R-59-2. The GLP1 (7-36) peptide (SEQ ID NO: 1528) was linked to the N-terminal of light chain of the functionally inactive GLP-1R binding antibody GLP1R-2.

FIG. 18A depicts a graph of GLP1R-59-2 binding specifically to the GLP-1R with an EC₅₀ of 15.5 nM.

FIG. 18B depicts a graph of GLP1R-59-2 in the CAMP assay with a similar EC₅₀ as the GLP-1 7-36 peptide.

FIG. 18C depicts a graph of GLP1R-59-2 on inducing the β -arrestin recruitment in GLP-1R expression cells.

FIGS. 19A-19B depict in vivo pharmacokinetic (PK) and pharmacodynamic (PD) effects of GLP1R-3 and GLP1R-59-2. Based on the beta phase calculation, GLP1R-3 has a 1-week half-life in rat (FIG. 19A). GLP1R-59-2 has a 2-day half-life in rat (FIG. 19B).

FIG. 20A depicts a graph of GLP1R-59-2 on glucose after glucose challenge.

FIG. 20B depicts a graph of Area Under the Curve (AUC) in a glucose tolerance test (GTT).

FIG. 21A depicts a graph of GLP1R-3 and GLP-1 peptide Exendin 9-39 treatment, 19+2 hour dosing regimen

FIG. 21B depicts a graph of Area Under the Curve (AUC) in an insulin tolerance test (ITT).

FIG. 22A depicts a graph of GLP1R-3 treatment, single 6 hour dosing regimen after insulin challenge, as compared to GLP-1 peptide Exendin 9-39 (1.0 or 0.23 mg/kg dose) or control.

FIG. 22B depicts a graph of Area Under the Curve (AUC) of GLP1R-3 (20 mg/kg) treatment at 6 hours in an ITT.

FIG. 23A depicts a graph of GLP1R-3 treatment, single 6 hour dosing regimen after insulin challenge, as compared to GLP1R-226-1, GLP1R-226-2, or control.

FIG. 23B depicts a graph Area Under the Curve (AUC) of GLP1R-3 treatment, single 6 hour dosing regimen after insulin challenge, as compared to GLP1R-226-1, GLP1R-226-2, or control.

FIGS. 24A-24B are schemas of panning strategy for GLP1R-221 and GLP1R-222 variants.

FIGS. 25A-25B are graphs of competition data for GLP1R-221 and GLP1R-222 variants.

FIG. 26 is a graph of GLP1R-221 and GLP1R-222 variants in a CAMP assay.

DETAILED DESCRIPTION

The present disclosure employs, unless otherwise indicated, conventional molecular biology techniques, which are

within the skill of the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art.

Definitions

Throughout this disclosure, various embodiments are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of any embodiments. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range to the tenth of the unit of the lower limit unless the context clearly dictates otherwise. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual values within that range, for example, 1.1, 2, 2.3, 5, and 5.9. This applies regardless of the breadth of the range. The upper and lower limits of these intervening ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, unless the context clearly dictates otherwise.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of any embodiment. As used herein, the singular forms "a," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, components, and/or groups, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

Unless specifically stated or obvious from context, as used herein, the term "about" in reference to a number or range of numbers is understood to mean the stated number and numbers +/-10% thereof, or 10% below the lower listed limit and 10% above the higher listed limit for the values listed for a range.

Unless specifically stated, as used herein, the term "nucleic acid" encompasses double- or triple-stranded nucleic acids, as well as single-stranded molecules. In double- or triple-stranded nucleic acids, the nucleic acid strands need not be coextensive (i.e., a double-stranded nucleic acid need not be double-stranded along the entire length of both strands). Nucleic acid sequences, when provided, are listed in 5' to 3' direction, unless stated otherwise. Methods described herein provide for the generation of isolated nucleic acids. Methods described herein additionally provide for the generation of isolated and purified nucleic acids. A "nucleic acid" as referred to herein can comprise at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or more bases in length. Moreover, provided herein are methods for the synthesis of any number of polypeptide-segments encod-

ing nucleotide sequences, including sequences encoding non-ribosomal peptides (NRPs), sequences encoding non-ribosomal peptide-synthetase (NRPS) modules and synthetic variants, polypeptide segments of other modular proteins, such as antibodies, polypeptide segments from other protein families, including non-coding DNA or RNA, such as regulatory sequences e.g. promoters, transcription factors, enhancers, siRNA, shRNA, RNAi, miRNA, small nucleolar RNA derived from microRNA, or any functional or structural DNA or RNA unit of interest. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, intergenic DNA, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), small nucleolar RNA, ribozymes, complementary DNA (cDNA), which is a DNA representation of mRNA, usually obtained by reverse transcription of messenger RNA (mRNA) or by amplification; DNA molecules produced synthetically or by amplification, genomic DNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. cDNA encoding for a gene or gene fragment referred herein may comprise at least one region encoding for exon sequences without an intervening intron sequence in the genomic equivalent sequence.

GPCR Libraries for GLP1 Receptor

Provided herein are methods and compositions relating to G protein-coupled receptor (GPCR) binding libraries for glucagon-like peptide-1 receptor (GLP1R) comprising nucleic acids encoding for an immunoglobulin comprising a GPCR binding domain. Immunoglobulins as described herein can stably support a GPCR binding domain. The GPCR binding domain may be designed based on surface interactions of a GLP1R ligand and GLP1R. Libraries as described herein may be further variegated to provide for variant libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries that may be generated when the nucleic acid libraries are translated. In some instances, nucleic acid libraries as described herein are transferred into cells to generate a cell library. Also provided herein are downstream applications for the libraries synthesized using methods described herein. Downstream applications include identification of variant nucleic acids or protein sequences with enhanced biologically relevant functions, e.g., improved stability, affinity, binding, functional activity, and for the treatment or prevention of a disease state associated with GPCR signaling.

Provided herein are libraries comprising nucleic acids encoding for an immunoglobulin. In some instances, the immunoglobulin is an antibody. As used herein, the term antibody will be understood to include proteins having the characteristic two-armed, Y-shape of a typical antibody molecule as well as one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Exemplary antibodies include, but are not limited to, a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv) (including fragments in which the VL and VH are joined using recombinant methods by a synthetic or natural linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form

monovalent molecules, including single chain Fab and scFab), a single chain antibody, a Fab fragment (including monovalent fragments comprising the VL, VH, CL, and CHI domains), a F(ab')2 fragment (including bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region), a Fd fragment (including fragments comprising the VH and CHI fragment), a Fv fragment (including fragments comprising the VL and VH domains of a single arm of an antibody), a single-domain antibody (dAb or sdAb) (including fragments comprising a VH domain), an isolated complementarity determining region (CDR), a diabody (including fragments comprising bivalent dimers such as two VL and VH domains bound to each other and recognizing two different antigens), a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. In some instances, the libraries disclosed herein comprise nucleic acids encoding for an immunoglobulin, wherein the immunoglobulin is a Fv antibody, including Fv antibodies comprised of the minimum antibody fragment which contains a complete antigen-recognition and antigen-binding site. In some embodiments, the Fv antibody consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association, and the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. In some embodiments, the six hypervariable regions confer antigen-binding specificity to the antibody. In some embodiments, a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen, including single domain antibodies isolated from camelid animals comprising one heavy chain variable domain such as VHH antibodies or nanobodies) has the ability to recognize and bind antigen. In some instances, the libraries disclosed herein comprise nucleic acids encoding for an immunoglobulin, wherein the immunoglobulin is a single-chain Fv or scFv, including antibody fragments comprising a VH, a VL, or both a VH and VL domain, wherein both domains are present in a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains allowing the scFv to form the desired structure for antigen binding. In some instances, a scFv is linked to the Fc fragment or a VHH is linked to the Fc fragment (including minibodies). In some instances, the antibody comprises immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, e.g., molecules that contain an antigen binding site. Immunoglobulin molecules are of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG 2, IgG 3, IgG 4, IgA 1 and IgA 2), or subclass.

In some embodiments, libraries comprise immunoglobulins that are adapted to the species of an intended therapeutic target. Generally, these methods include “mammalization” and comprise methods for transferring donor antigen-binding information to a less immunogenic mammal antibody acceptor to generate useful therapeutic treatments. In some instances, the mammal is mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, or human. In some instances, provided herein are libraries and methods for felinization and caninization of antibodies.

“Humanized” forms of non-human antibodies can be chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human antibody (recipient antibody) in which residues from one or more CDRs are replaced by residues

from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. In some instances, these modifications are made to further refine antibody performance.

“Caninization” can comprise a method for transferring non-canine antigen-binding information from a donor antibody to a less immunogenic canine antibody acceptor to generate treatments useful as therapeutics in dogs. In some instances, caninized forms of non-canine antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-canine antibodies. In some instances, caninized antibodies are canine antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-canine species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties. In some instances, framework region (FR) residues of the canine antibody are replaced by corresponding non-canine FR residues. In some instances, caninized antibodies include residues that are not found in the recipient antibody or in the donor antibody. In some instances, these modifications are made to further refine antibody performance. The caninized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc) of a canine antibody.

“Felinization” can comprise a method for transferring non-feline antigen-binding information from a donor antibody to a less immunogenic feline antibody acceptor to generate treatments useful as therapeutics in cats. In some instances, felinized forms of non-feline antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-feline antibodies. In some instances, felinized antibodies are feline antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-feline species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties. In some instances, framework region (FR) residues of the feline antibody are replaced by corresponding non-feline FR residues. In some instances, felinized antibodies include residues that are not found in the recipient antibody or in the donor antibody. In some instances, these modifications are made to further refine antibody performance. The felinized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc) of a felinized antibody.

Provided herein are libraries comprising nucleic acids encoding for a non-immunoglobulin. For example, the non-immunoglobulin is an antibody mimetic. Exemplary antibody mimetics include, but are not limited to, anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, atrimers, DARPins, fynomers, Kunitz domain-based proteins, monobodies, anticalins, knottins, armadillo repeat protein-based proteins, and bicyclic peptides.

11

Libraries described herein comprising nucleic acids encoding for an immunoglobulin comprising variations in at least one region of the immunoglobulin. Exemplary regions of the antibody for variation include, but are not limited to, a complementarity-determining region (CDR), a variable domain, or a constant domain. In some instances, the CDR is CDR1, CDR2, or CDR3. In some instances, the CDR is a heavy domain including, but not limited to, CDRH1, CDRH2, and CDRH3. In some instances, the CDR is a light domain including, but not limited to, CDRL1, CDRL2, and CDRL3. In some instances, the variable domain is variable domain, light chain (VL) or variable domain, heavy chain (VH). In some instances, the VL domain comprises kappa or lambda chains. In some instances, the constant domain is constant domain, light chain (CL) or constant domain, heavy chain (CH).

Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for an immunoglobulin, wherein each nucleic acid encodes for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the variant library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon of a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.

In some instances, the at least one region of the immunoglobulin for variation is from heavy chain V-gene family, heavy chain D-gene family, heavy chain J-gene family, light chain V-gene family, or light chain J-gene family. In some instances, the light chain V-gene family comprises immunoglobulin kappa (IGK) gene or immunoglobulin lambda (IGL). Exemplary genes include, but are not limited to, IGHV1-18, IGHV1-69, IGHV1-8, IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV1-69, IGHV3-74, IGHV4-39, IGHV4-59/61, IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, IGLV2-14, IGLV1-40, and IGLV3-1. In some instances, the gene is IGHV1-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the gene is IGHV1-69 and IGHV3-30. In some instances, the gene is IGHJ3, IGHJ6, IGHJ, IGHJ4, IGHJ5, IGHJ2, or IGH1. In some instances, the gene is IGHJ3, IGHJ6, IGHJ, or IGHJ4.

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins, wherein the libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In

12

some instances, the fragments comprise framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the immunoglobulin libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.

Libraries comprising nucleic acids encoding for immunoglobulins as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 amino acids to about 75 amino acids. In some instances, the immunoglobulins comprise at least or about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, or more than 5000 amino acids.

A number of variant sequences for the at least one region of the immunoglobulin for variation are de novo synthesized using methods as described herein. In some instances, a number of variant sequences is de novo synthesized for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is at least or about 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, or more than 8000 sequences. In some instances, the number of variant sequences is about 10 to 500, 25 to 475, 50 to 450, 75 to 425, 100 to 400, 125 to 375, 150 to 350, 175 to 325, 200 to 300, 225 to 375, 250 to 350, or 275 to 325 sequences.

Variant sequences for the at least one region of the immunoglobulin, in some instances, vary in length or sequence. In some instances, the at least one region that is de novo synthesized is for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof. In some instances, the at least one region that is de novo synthesized is for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or more than 50 variant nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 additional nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 less nucleotides or amino acids as

13

compared to wild-type. In some instances, the libraries comprise at least or about 10^1 , 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , or more than 10^{10} variants.

Following synthesis of libraries described herein, libraries may be used for screening and analysis. For example, libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. In some instances, libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.

In some instances, the libraries are assayed for functional activity, structural stability (e.g., thermal stable or pH stable), expression, specificity, or a combination thereof. In some instances, the libraries are assayed for immunoglobulin (e.g., an antibody) capable of folding. In some instances, a region of the antibody is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof. For example, a VH region or VL region is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof.

GLP1R Libraries

Provided herein are GLP1R binding libraries comprising nucleic acids encoding for immunoglobulins (e.g., antibodies) that bind to GLP1R. In some instances, the immunoglobulin sequences for GLP1R binding domains are determined by interactions between the GLP1R binding domains and the GLP1R.

Provided herein are libraries comprising nucleic acids encoding immunoglobulins comprising GLP1R binding domains, wherein the GLP1R binding domains are designed based on surface interactions on GLP1R. In some instances, the GLP1R comprises a sequence as defined by SEQ ID NO: 1. In some instances, the GLP1R binding domains interact with the amino- or carboxy-terminus of the GLP1R. In some instances, the GLP1R binding domains interact with at least one transmembrane domain including, but not limited to, transmembrane domain 1 (TM1), transmembrane domain 2 (TM2), transmembrane domain 3 (TM3), transmembrane domain 4 (TM4), transmembrane domain 5 (TM5), transmembrane domain 6 (TM6), and transmembrane domain 7 (TM7). In some instances, the GLP1R binding domains interact with an intracellular surface of the GLP1R. For example, the GLP1R binding domains interact with at least one intracellular loop including, but not limited to, intracellular loop 1 (ICL1), intracellular loop 2 (ICL2), and intracellular loop 3 (ICL3). In some instances, the GLP1R binding domains interact with an extracellular surface of the GLP1R. For example, the GLP1R binding domains interact with at least one extracellular domain (ECD) or extracellular loop (ECL) of the GLP1R. The extracellular loops include, but are not limited to, extracellular loop 1 (ECL1), extracellular loop 2 (ECL2), and extracellular loop 3 (ECL3).

Described herein are GLP1R binding domains, wherein the GLP1R binding domains are designed based on surface interactions between a GLP1R ligand and the GLP1R. In some instances, the ligand is a peptide. In some instances,

14

the ligand is glucagon, glucagon-like peptide 1-(7-36) amide, glucagon-like peptide 1-(7-37), liraglutide, exendin-4, lixisenatide, T-0632, GLP1R0017, or BETP. In some instances, the ligand is a GLP1R agonist. In some instances, the ligand is a GLP1R antagonist. In some instances, the ligand is a GLP1R allosteric modulator. In some instances, the allosteric modulator is a negative allosteric modulator. In some instances, the allosteric modulator is a positive allosteric modulator.

Sequences of GLP1R binding domains based on surface interactions between a GLP1R ligand and the GLP1R are analyzed using various methods. For example, multispecies computational analysis is performed. In some instances, a structure analysis is performed. In some instances, a sequence analysis is performed. Sequence analysis can be performed using a database known in the art. Non-limiting examples of databases include, but are not limited to, NCBI BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi), UCSC Genome Browser (genome.ucsc.edu/), UniProt (uniprot.org/), and IUPHAR/BPS Guide to PHARMACOLOGY (guidetopharmacology.org/).

Described herein are GLP1R binding domains designed based on sequence analysis among various organisms. For example, sequence analysis is performed to identify homologous sequences in different organisms. Exemplary organisms include, but are not limited to, mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, fish, fly, and human.

Following identification of GLP1R binding domains, libraries comprising nucleic acids encoding for the GLP1R binding domains may be generated. In some instances, libraries of GLP1R binding domains comprise sequences of GLP1R binding domains designed based on conformational ligand interactions, peptide ligand interactions, small molecule ligand interactions, extracellular domains of GLP1R, or antibodies that target GLP1R. In some instances, libraries of GLP1R binding domains comprise sequences of GLP1R binding domains designed based on peptide ligand interactions. Libraries of GLP1R binding domains may be translated to generate protein libraries. In some instances, libraries of GLP1R binding domains are translated to generate peptide libraries, immunoglobulin libraries, derivatives thereof, or combinations thereof. In some instances, libraries of GLP1R binding domains are translated to generate protein libraries that are further modified to generate peptidomimetic libraries. In some instances, libraries of GLP1R binding domains are translated to generate protein libraries that are used to generate small molecules.

Methods described herein provide for synthesis of libraries of GLP1R binding domains comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the libraries of GLP1R binding domains comprise varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a GLP1R binding domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a GLP1R binding domain. An exemplary number of codons for varia-

15

tion include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.

Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for the GLP1R binding domains, wherein the libraries comprise sequences encoding for variation of length of the GLP1R binding domains. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.

Following identification of GLP1R binding domains, the GLP1R binding domains may be placed in immunoglobulins as described herein. In some instances, the GLP1R binding domains are placed in the CDRH3 region. GPCR binding domains that may be placed in immunoglobulins can also be referred to as a motif. Immunoglobulins comprising GLP1R binding domains may be designed based on binding, specificity, stability, expression, folding, or downstream activity. In some instances, the immunoglobulins comprising GLP1R binding domains enable contact with the GLP1R. In some instances, the immunoglobulins comprising GLP1R binding domains enables high affinity binding with the GLP1R. An exemplary amino acid sequence of GLP1R binding domain is described in Table 1.

TABLE 1

GLP1R amino acid sequences

SEQ ID NO	GPCR	Amino Acid Sequence
1352	GLP1R	RPQGATVSLWETVQKWRREYRRQCQRSLTEDEPPPATDLFCNRTFDEYA CWPDGEPGSFVNSCPWLPWASSVPQGHVYRRCATAEGLWLQKDNS SLPWRDLSECEESKRGERSSPEEQLLFLYIYTVEGYALSFSAVIAISAIL LGFRHLHCTRNYIHNLNFASIFILRALSVFIKDAALKWMMYSTAAQQHQ WDGLLSYQDSLSCRLVFLLMQYCVAANYWLLVEGVVLYTLLIAFSV LSEQWIFRFLYVSIGWGVPLFWVWPWGVIVKYLVEDEGCWTRNSNMNY WLIIRLPILFAIGVNELLIVFVRVICIVVSKLANKLMCKTDIJKRLAKSTLT LIPLLGTTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCF VNNEVQLEFRKSWERWRLEHLHIQRDSSMKPLKCPTSSLSSGATAGS SMYTATCQASC

50

Provided herein are immunoglobulins comprising GLP1R binding domains, wherein the sequences of the GLP1R binding domains support interaction with GLP1R. The sequence may be homologous or identical to a sequence of a GLP1R ligand. In some instances, the GLP1R binding domain sequence comprises at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1. In some instances, the GLP1R binding domain sequence comprises at least or about 95% homology to SEQ ID NO: 1. In some instances, the GLP1R binding domain sequence comprises at least or about 97% homology to SEQ ID NO: 1. In some instances, the GLP1R binding domain sequence comprises at least or about 99% homology to SEQ ID NO: 1. In some instances, the GLP1R binding domain sequence comprises at least or about 100% homology to SEQ ID NO: 1. In some

16

instances, the GLP1R binding domain sequence comprises at least a portion having at least or about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, or more than 400 amino acids of SEQ ID NO: 1.

The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software.

Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased

as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

The term "homology" or "similarity" between two proteins is determined by comparing the amino acid sequence

and its conserved amino acid substitutes of one protein sequence to the second protein sequence. Similarity may be determined by procedures which are well-known in the art, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information).

The terms "complementarity determining region," and "CDR," which are synonymous with "hypervariable region" or "HVR," are known in the art to refer to non-contiguous sequences of amino acids within antibody variable regions, which confer antigen specificity and/or binding affinity. In general, there are three CDRs in each heavy chain variable region (CDRH1, CDRH2, CDRH3) and three CDRs in each light chain variable region (CDRL1, CDRL2, CDRL3). "Framework regions" and "FR" are known in the art to refer to the non-CDR portions of the variable regions of the heavy and light chains. In general, there are four FRs in each full-length heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each full-length light chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4). The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography," J. Mol. Biol. 262, 732-745." ("Contact" numbering scheme); Lefranc M P et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol, 2003 January; 27 (1): 55-77 ("IMGT" numbering scheme); Honegger A and Plückthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol, 2001 Jun. 8; 309 (3): 657-70, ("Aho" numbering scheme); and Whitelegg N R and Rees A R, "WAM: an improved algorithm for modelling antibodies on the WEB," Protein Eng. 2000 December; 13 (12): 819-24 ("AbM" numbering scheme. In certain embodiments the CDRs of the antibodies described herein can be defined by a method selected from Kabat, Chothia, IMGT, Aho, AbM, or combinations thereof.

The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, "30a," and deletions appearing in some antibodies. The two schemes place certain insertions and deletions ("indels") at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.

Provided herein are GLP1R binding libraries comprising nucleic acids encoding for immunoglobulins comprising GLP1R binding domains comprise variation in domain type, domain length, or residue variation. In some instances, the domain is a region in the immunoglobulin comprising the GLP1R binding domains. For example, the region is the VH, CDRH3, or VL domain. In some instances, the domain is the GLP1R binding domain.

Methods described herein provide for synthesis of a GLP1R binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid 10 are generated by standard translation processes. In some instances, the GLP1R binding library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon 15 of a VH, CDRH3, or VL domain. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a GLP1R binding domain. For example, at least one single codon of a GLP1R binding domain as listed in Table 1 is varied. In some instances, the 20 variant library comprises sequences encoding for variation of multiple codons of a VH, CDRH3, or VL domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a GLP1R binding domain. An exemplary number of codons for variation 25 include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.

Methods described herein provide for synthesis of a 30 GLP1R binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence, wherein the GLP1R binding library comprises sequences encoding for variation of length of a domain. In some instances, the domain is VH, CDRH3, 35 or VL domain. In some instances, the domain is the GLP1R binding domain. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, 40 or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 45 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.

Provided herein are GLP1R binding libraries comprising nucleic acids encoding for immunoglobulins comprising GLP1R binding domains, wherein the GLP1R binding libraries are synthesized with various numbers of fragments. 50 In some instances, the fragments comprise the VH, CDRH3, or VL domain. In some instances, the GLP1R binding libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 55 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the 60 length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.

GLP1R binding libraries comprising nucleic acids encoding for immunoglobulins comprising GLP1R binding 65 domains as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the

amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 to about 75 amino acids.

GLP1R binding libraries comprising de novo synthesized variant sequences encoding for immunoglobulins comprising GLP1R binding domains comprise a number of variant sequences. In some instances, a number of variant sequences is de novo synthesized for a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or a combination thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, a number of variant sequences is de novo synthesized for a GPCR binding domain. For example, the number of variant sequences is about 1 to about 10 sequences for the VH domain, about 10^8 sequences for the GLP1R binding domain, and about 1 to about 44 sequences for the VK domain. The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is about 10 to 300, 25 to 275, 50 to 250, 75 to 225, 100 to 200, or 125 to 150 sequences.

Described herein are antibodies or antibody fragments thereof that binds GLP1R. In some embodiments, the antibody or antibody fragment thereof comprises a sequence as set forth in Tables 7-13. In some embodiments, the antibody or antibody fragment thereof comprises a sequence that is at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence as set forth in Tables 7-13.

In some instances, an antibody or antibody fragment described herein comprises a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, an antibody or antibody fragment described herein comprises a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798.

a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, an antibody or antibody fragment described herein comprises a CDRH3 sequence of any one of SEQ ID NOS: 799-977. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH3 sequence of any one of SEQ ID NOS: 799-977. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH3 sequence of any one of SEQ ID NOS: 799-977. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH3 sequence of any one of SEQ ID NOS: 799-977. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH3 sequence of any one of SEQ ID NOS: 799-977.

In some instances, an antibody or antibody fragment described herein comprises a CDRL1 sequence of any one of SEQ ID NOS: 978-1156. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL1 sequence of any one of SEQ ID NOS: 978-1156. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL1 sequence of any one of SEQ ID NOS: 978-1156. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL1 sequence of any one of SEQ ID NOS: 978-1156. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL1 sequence of any one of SEQ ID NOS: 978-1156. In some instances, an antibody or antibody fragment described herein comprises a CDRL2 sequence of any one of SEQ ID NOS: 1157-1335. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL2 sequence of any one of SEQ ID NOS: 1157-1335. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL2 sequence of any one of SEQ ID NOS: 1157-1335. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL2 sequence of any one of SEQ ID NOS: 1157-1335. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL2 sequence of any one of SEQ ID NOS: 1157-1335. In some instances, an antibody or antibody fragment described herein comprises a CDRL3 sequence of any one of SEQ ID NOS: 1336-1347 and 1353-1519. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL3 sequence of any one of SEQ ID NOS: 1336-1347 and 1353-1519. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL3 sequence of any one of SEQ ID NOS: 1336-1347 and 1353-1519. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL3 sequence of any one of SEQ ID NOS: 1336-1347 and 1353-1519. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL3 sequence of any one of SEQ ID NOS: 1336-1347 and 1353-1519.

In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complemen-

tarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 441-619; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 620-798; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 799-977; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 978-1156; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 1157-1335; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 1336-1347 and 1353-1519. In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 441-619; (b) an amino acid sequence of CDRH2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 620-798; (c) an amino acid sequence of CDRH3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 799-977; (d) an amino acid sequence of CDRL1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 978-1156; (e) an amino acid sequence of CDRL2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 1157-1335; and (f) an amino acid sequence of CDRL3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 1336-1347 and 1353-1519.

Described herein, in some embodiments, are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 58-77, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 92-111. In some instances, the antibodies or antibody fragments comprise VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 58-77, and VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 92-111.

The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. Typically, techniques for determining sequence identity include comparing two nucleotide or amino acid sequences and determining their percent identity. Sequence comparisons, such as for the purpose of assessing identities, may be performed by any suitable alignment algorithm, including but not limited to the Needleman-Wunsch algorithm (see, e.g., the EMBOSS Needle aligner available at ebi.ac.uk/Tools/psa/emboss_needle/, optionally with default settings), the BLAST algorithm (see, e.g., the BLAST alignment tool available at

blast.ncbi.nlm.nih.gov/Blast.cgi, optionally with default settings), and the Smith-Waterman algorithm (see, e.g., the EMBOSS Water aligner available at ebi.ac.uk/Tools/psa/emboss_water/, optionally with default settings). Optimal alignment may be assessed using any suitable parameters of a chosen algorithm, including default parameters. The "percent identity", also referred to as "percent homology", between two sequences may be calculated as the number of exact matches between two optimally aligned sequences divided by the length of the reference sequence and multiplied by 100. Percent identity may also be determined, for example, by comparing sequence information using the advanced BLAST computer program, including version 2.2.9, available from the National Institutes of Health. The BLAST program is based on the alignment method of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990) and as discussed in Altschul, et al., J. Mol. Biol. 215:403-410 (1990); Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993); and Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997). Briefly, the BLAST program defines identity as the number of identical aligned symbols (i.e., nucleotides or amino acids), divided by the total number of symbols in the shorter of the two sequences. The program may be used to determine percent identity over the entire length of the sequences being compared. Default parameters are provided to optimize searches with short query sequences, for example, with the blastp program. The program also allows use of an SEG filter to mask-off segments of the query sequences as determined by the SEG program of Wootton and Federhen, Computers and Chemistry 17:149-163 (1993). High sequence identity generally includes ranges of sequence identity of approximately 80% to 100% and integer values there between.

GLP1R binding libraries comprising de novo synthesized variant sequences encoding for immunoglobulins comprising GLP1R binding domains comprise improved diversity. For example, variants are generated by placing GLP1R binding domain variants in immunoglobulins comprising N-terminal CDRH3 variations and C-terminal CDRH3 variations. In some instances, variants include affinity maturation variants. Alternatively or in combination, variants include variants in other regions of the immunoglobulin including, but not limited to, CDRH1, CDRH2, CDRL1, CDRL2, and CDRL3. In some instances, the number of variants of the GLP1R binding libraries is at least or about 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , 10^{15} , 10^{16} , 10^{17} , 10^{18} , 10^{19} , 10^{20} , or more than 10^{20} non-identical sequences. For example, a library comprising about 10 variant sequences for a VH region, about 237 variant sequences for a CDRH3 region, and about 43 variant sequences for a VL and CDRL3 region comprises 10^5 non-identical sequences ($10 \times 237 \times 43$).

In some instances, the at least one region of the antibody for variation is from heavy chain V-gene family, heavy chain D-gene family, heavy chain J-gene family, light chain V-gene family, or light chain J-gene family. In some instances, the light chain V-gene family comprises immunoglobulin kappa (IGK) gene or immunoglobulin lambda (IGL). Exemplary regions of the antibody for variation include, but are not limited to,IGHV1-18, IGHV1-69, IGHV1-8, IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV1-69, IGHV3-74, IGHV4-39, IGHV4-59/61, IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, IGLV2-14, IGLV1-40, and IGLV3-1. In some instances, the gene is IGHV1-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the gene is IGHV1-

69 and IGHV3-30. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, IGHJ4, IGHJ5, IGHJ2, or IGH1. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, or IGHJ4. In some instances, the at least one region of the antibody for variation is IGHV1-69, IGHV3-23, IGKV3-20, IGVK1-39, or combinations thereof. In some instances, the at least one region of the antibody for variation is IGHV1-69 and IGKV3-20. In some instances, the at least one region of the antibody for variation is IGHV1-69 and IGVK1-39. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGKV3-20. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGVK1-39.

Provided herein are libraries comprising nucleic acids encoding for a GLP1R antibody comprising variation in at least one region of the antibody, wherein the region is the CDR region. In some instances, the GLP1R antibody is a single domain antibody comprising one heavy chain variable domain such as a VHH antibody. In some instances, the VHH antibody comprises variation in one or more CDR regions. In some instances, libraries described herein comprise at least or about 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2400, 2600, 2800, 3000, or more than 3000 sequences of a CDR1, CDR2, or CDR3. In some instances, libraries described herein comprise at least or about 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , 10^{15} , 10^{16} , 10^{17} , 10^{18} , 10^{19} , 10^{20} , or more than 10^{20} sequences of a CDR1, CDR2, or CDR3. For example, the libraries comprise at least 2000 sequences of a CDR1, at least 1200 sequences for CDR2, and at least 1600 sequences for CDR3. In some instances, each sequence is non-identical.

In some instances, the CDR1, CDR2, or CDR3 is of a variable domain, light chain (VL). CDR1, CDR2, or CDR3 of a variable domain, light chain (VL) can be referred to as CDRL1, CDRL2, or CDRL3, respectively. In some instances, libraries described herein comprise at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2400, 2600, 2800, 3000, or more than 3000 sequences of a CDR1, CDR2, or CDR3 of the VL. In some instances, libraries described herein comprise at least or about 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , 10^{15} , 10^{16} , 10^{17} , 10^{18} , 10^{19} , 10^{20} , or more than 10^{20} sequences of a CDR1, CDR2, or CDR3 of the VL. For example, the libraries comprise at least 20 sequences of a CDR1 of the VL, at least 4 sequences of a CDR2 of the VL, and at least 140 sequences of a CDR3 of the VL. In some instances, the libraries comprise at least 2 sequences of a CDR1 of the VL, at least 1 sequence of CDR2 of the VL, and at least 3000 sequences of a CDR3 of the VL. In some instances, the VL is IGVK1-39, IGVK1-9, IGVK2-28, IGVK3-11, IGVK3-15, IGVK3-20, IGVK4-1, IGLV1-51, IGLV2-14, IGLV1-40, or IGLV3-1. In some instances, the VL is IGVK2-28. In some instances, the VL is IGLV1-51.

In some instances, the CDR1, CDR2, or CDR3 is of a variable domain, heavy chain (VH). CDR1, CDR2, or CDR3 of a variable domain, heavy chain (VH) can be referred to as CDRH1, CDRH2, or CDRH3, respectively. In some instances, libraries described herein comprise at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2400, 2600, 2800, 3000, or more than 3000 sequences of a CDR1, CDR2, or CDR3 of the VH. In some instances, libraries described herein comprise at

least or about 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , 10^{15} , 10^{16} , 10^{17} , 10^{18} , 10^{19} , 10^{20} , or more than 10^{20} sequences of a CDR1, CDR2, or CDR3 of the VH. For example, the libraries comprise at least 30 sequences of a CDR1 of the VH, at least 570 sequences of a CDR2 of the VH, and at least 10^8 sequences of a CDR3 of the VH. In some instances, the libraries comprise at least 30 sequences of a CDR1 of the VH, at least 860 sequences of a CDR2 of the VH, and at least 10^7 sequences of a CDR3 of the VH. In some instances, the VH is IGHV1-18, IGHV1-69, IGHV1-8 IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV3-74, IGHV4-39, or IGHV4-59/61. In some instances, the VH is IGHV1-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the VH is IGHV1-69 or IGHV3-30. In some instances, the VH is IGHV3-23.

Libraries as described herein, in some embodiments, comprise varying lengths of a CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3. In some instances, the length of the CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 comprises at least or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or more than 90 amino acids in length. For example, the CDRH3 comprises at least or about 12, 15, 16, 17, 20, 21, or 23 amino acids in length. In some instances, the CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 comprises a range of about 1 to about 10, about 5 to about 15, about 10 to about 20, or about 15 to about 30 amino acids in length.

Libraries comprising nucleic acids encoding for antibodies having variant CDR sequences as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 amino acids to about 75 amino acids. In some instances, the antibodies comprise at least or about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, or more than 5000 amino acids.

Ratios of the lengths of a CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 may vary in libraries described herein. In some instances, a CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, or CDRH3 comprising at least or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or more than 90 amino acids in length comprises about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90% of the library. For example, a CDRH3 comprising about 23 amino acids in length is present in the library at 40%, a CDRH3 comprising about 21 amino acids in length is present in the library at 30%, a CDRH3 comprising about 17 amino acids in length is present in the library at 20%, and a CDRH3 comprising about 12 amino acids in length is present in the library at 10%. In some instances, a CDRH3 comprising about 20 amino acids in length is present in the library at 40%, a CDRH3 comprising about 16 amino acids in length is present in the library at 30%, a CDRH3 comprising about 15 amino acids in length is present in the library at 20%, and a CDRH3 comprising about 12 amino acids in length is present in the library at 10%.

Libraries as described herein encoding for a VHH antibody comprise variant CDR sequences that are shuffled to generate a library with a theoretical diversity of at least or about 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , 10^{15} , 10^{16} , 10^{17} , 10^{18} , 10^{19} , 10^{20} , or more than 10^{20} sequences. In some instances, the library has a final library diversity of at least or about 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , 10^{15} , 10^{16} , 10^{17} , 10^{18} , 10^{19} , 10^{20} , or more than 10^{20} sequences.

Provided herein are GLP1R binding libraries encoding for an immunoglobulin. In some instances, the GLP1R immunoglobulin is an antibody. In some instances, the GLP1R immunoglobulin is a VHH antibody. In some instances, the GLP1R immunoglobulin comprises a binding affinity (e.g., KD) to GLP1R of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 11 nm, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 1 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 1.2 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 2 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 5 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 10 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 13.5 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 15 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 20 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 25 nM. In some instances, the GLP1R immunoglobulin comprises a KD of less than 30 nM.

In some instances, the GLP1R immunoglobulin is a GLP1R agonist. In some instances, the GLP1R immunoglobulin is a GLP1R antagonist. In some instances, the GLP1R immunoglobulin is a GLP1R allosteric modulator. In some instances, the allosteric modulator is a negative allosteric modulator. In some instances, the allosteric modulator is a positive allosteric modulator. In some instances, the GLP1R immunoglobulin results in agonistic, antagonistic, or allosteric effects at a concentration of at least or about 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 160 nM, 180 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1000 nM, or more than 1000 nM. In some instances, the GLP1R immunoglobulin is a negative allosteric modulator. In some instances, the GLP1R immunoglobulin is a negative allosteric modulator at a concentration of at least or about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, or more than 100 nM. In some instances, the GLP1R immunoglobulin is a negative allosteric modulator at a concentration in a range of about 0.001 to about 100, 0.01 to about 90, about 0.1 to about 80, 1 to about 50, about 10 to about 40 nM, or about 1 to about 10 nM. In some instances, the GLP1R immunoglobulin comprises an EC₅₀ or IC₅₀ of at least or about 0.001, 0.0025, 0.005, 0.01, 0.025, 0.05, 0.06, 0.07, 0.08, 0.9, 0.1, 0.5, 1, 2, 3, 4, 5, 6, or more than 6 nM. In some instances, the GLP1R immunoglobulin comprises an EC₅₀ or IC₅₀ of at least or about 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, or more than 100 nM.

Provided herein are GLP1R binding libraries encoding for an immunoglobulin, wherein the immunoglobulin comprises a long half-life. In some instances, the half-life of the

GLP1R immunoglobulin is at least or about 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 140 hours, 160 hours, 180 hours, 200 hours, or more than 200 hours. In some instances, the half-life of the GLP1R immunoglobulin is in a range of about 12 hours to about 300 hours, about 20 hours to about 280 hours, about 40 hours to about 240 hours, or about 60 hours to about 200 hours.

GLP1R immunoglobulins as described herein may comprise improved properties. In some instances, the GLP1R immunoglobulins are monomeric. In some instances, the GLP1R immunoglobulins are not prone to aggregation. In some instances, at least or about 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the GLP1R immunoglobulins are monomeric. In some instances, the GLP1R immunoglobulins are thermostable. In some instances, the GLP1R immunoglobulins result in reduced non-specific binding.

Following synthesis of GLP1R binding libraries comprising nucleic acids encoding immunoglobulins comprising GLP1R binding domains, libraries may be used for screening and analysis. For example, libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. In some instances, the GLP1R binding libraries comprises nucleic acids encoding immunoglobulins comprising GPCR binding domains with multiple tags such as GFP, FLAG, and Lucy as well as a DNA barcode. In some instances, libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.

Expression Systems

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins comprising GLP1R binding domains, wherein the libraries have improved specificity, stability, expression, folding, or downstream activity. In some instances, libraries described herein are used for screening and analysis.

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins comprising GLP1R binding domains, wherein the nucleic acid libraries are used for screening and analysis. In some instances, screening and analysis comprise in vitro, in vivo, or ex vivo assays. Cells for screening include primary cells taken from living subjects or cell lines. Cells may be from prokaryotes (e.g., bacteria and fungi) or eukaryotes (e.g., animals and plants). Exemplary animal cells include, without limitation, those from a mouse, rabbit, primate, and insect. In some instances, cells for screening include a cell line including, but not limited to, Chinese Hamster Ovary (CHO) cell line, human embryonic kidney (HEK) cell line, or baby hamster kidney (BHK) cell line. In some instances, nucleic acid libraries described herein may also be delivered to a multicellular organism. Exemplary multicellular organisms include, without limitation, a plant, a mouse, rabbit, primate, and insect.

Nucleic acid libraries or protein libraries encoded thereof described herein may be screened for various pharmacological or pharmacokinetic properties. In some instances, the

libraries are screened using in vitro assays, in vivo assays, or ex vivo assays. For example, in vitro pharmacological or pharmacokinetic properties that are screened include, but are not limited to, binding affinity, binding specificity, and binding avidity. Exemplary in vivo pharmacological or pharmacokinetic properties of libraries described herein that are screened include, but are not limited to, therapeutic efficacy, activity, preclinical toxicity properties, clinical efficacy properties, clinical toxicity properties, immunogenicity, potency, and clinical safety properties.

Pharmacological or pharmacokinetic properties that may be screened include, but are not limited to, cell binding affinity and cell activity. For example, cell binding affinity assays or cell activity assays are performed to determine agonistic, antagonistic, or allosteric effects of libraries described herein. In some instances, the cell activity assay is a cAMP assay. In some instances, libraries as described herein are compared to cell binding or cell activity of ligands of GLP1R.

Libraries as described herein may be screened in cell-based assays or in non-cell-based assays. Examples of non-cell-based assays include, but are not limited to, using viral particles, using in vitro translation proteins, and using protealiposomes with GLP1R.

Nucleic acid libraries as described herein may be screened by sequencing. In some instances, next generation sequence is used to determine sequence enrichment of GLP1R binding variants. In some instances, V gene distribution, J gene distribution, V gene family, CDR3 counts per length, or a combination thereof is determined. In some instances, clonal frequency, clonal accumulation, lineage accumulation, or a combination thereof is determined. In some instances, number of sequences, sequences with VH clones, clones, clones greater than 1, clonotypes, clonotypes greater than 1, lineages, simpsons, or a combination thereof is determined. In some instances, a percentage of non-identical CDR3s is determined. For example, the percentage of non-identical CDR3s is calculated as the number of non-identical CDR3s in a sample divided by the total number of sequences that had a CDR3 in the sample.

Provided herein are nucleic acid libraries, wherein the nucleic acid libraries may be expressed in a vector. Expression vectors for inserting nucleic acid libraries disclosed herein may comprise eukaryotic or prokaryotic expression vectors. Exemplary expression vectors include, without limitation, mammalian expression vectors: pSF-CMV-NEO-NH2-PPT-3×FLAG, pSF-CMV-NEO-COOH-3×FLAG, pSF-CMV-PURO-NH2-GST-TEV, pSF-OXB20-COOH-TEV-FLAG (R)-6His, pCEP4 pDEST27, pSF-CMV-Ub-KrYFP, pSF-CMV-FMDV-daGFP, pEF1a-mCherry-N1 Vector, pEF1a-tdTomato Vector, pSF-CMV-FMDV-Hygro, pSF-CMV-PGK-Puro, pMCP-tag(m), and pSF-CMV-PURO-NH2-CMYC; bacterial expression vectors: pSF-OXB20-BetaGal, pSF-OXB20-Fluc, pSF-OXB20, and pSF-Tac; plant expression vectors: pRI 101-AN DNA and pCambia2301; and yeast expression vectors: pTYB21 and pKLAC2, and insect vectors: pAc5.1/V5-His A and pDEST8. In some instances, the vector is pcDNA3 or pcDNA3.1.

Described herein are nucleic acid libraries that are expressed in a vector to generate a construct comprising an immunoglobulin comprising sequences of GLP1R binding domains. In some instances, a size of the construct varies. In some instances, the construct comprises at least or about 500, 600, 700, 800, 900, 1000, 1100, 1300, 1400, 1500, 1600, 1700, 1800, 2000, 2400, 2600, 2800, 3000, 3200, 3400, 3600, 3800, 4000, 4200, 4400, 4600, 4800, 5000,

6000, 7000, 8000, 9000, 10000, or more than 10000 bases. In some instances, a the construct comprises a range of about 300 to 1,000, 300 to 2,000, 300 to 3,000, 300 to 4,000, 300 to 5,000, 300 to 6,000, 300 to 7,000, 300 to 8,000, 300 to 9,000, 300 to 10,000, 1,000 to 2,000, 1,000 to 3,000, 1,000 to 4,000, 1,000 to 5,000, 1,000 to 6,000, 1,000 to 7,000, 1,000 to 8,000, 1,000 to 9,000, 1,000 to 10,000, 2,000 to 3,000, 2,000 to 4,000, 2,000 to 5,000, 2,000 to 6,000, 2,000 to 7,000, 2,000 to 8,000, 2,000 to 9,000, 2,000 to 10,000, 3,000 to 4,000, 3,000 to 5,000, 3,000 to 6,000, 3,000 to 7,000, 3,000 to 8,000, 3,000 to 9,000, 3,000 to 10,000, 4,000 to 5,000, 4,000 to 6,000, 4,000 to 7,000, 4,000 to 8,000, 4,000 to 9,000, 4,000 to 10,000, 5,000 to 6,000, 5,000 to 7,000, 5,000 to 8,000, 5,000 to 9,000, 5,000 to 10,000, 6,000 to 7,000, 6,000 to 8,000, 6,000 to 9,000, 6,000 to 10,000, 7,000 to 8,000, 7,000 to 9,000, 7,000 to 10,000, 8,000 to 9,000, 8,000 to 10,000, or 9,000 to 10,000 bases.

Provided herein are libraries comprising nucleic acids encoding for immunoglobulins comprising GPCR binding domains, wherein the nucleic acid libraries are expressed in a cell. In some instances, the libraries are synthesized to express a reporter gene. Exemplary reporter genes include, but are not limited to, acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucuronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), cerulean fluorescent protein, citrine fluorescent protein, orange fluorescent protein, cherry fluorescent protein, turquoise fluorescent protein, blue fluorescent protein, horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), luciferase, and derivatives thereof. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), and antibiotic resistance determination.

Diseases and Disorders

Provided herein are GLP1R binding libraries comprising nucleic acids encoding for immunoglobulins (e.g., antibodies) comprising GLP1R binding domains that may have therapeutic effects. In some instances, the GLP1R binding libraries result in protein when translated that is used to treat a disease or disorder. In some instances, the protein is an immunoglobulin. In some instances, the protein is a peptidomimetic.

GLP1R libraries as described herein may comprise modulators of GLP1R. In some instances, the modulator of GLP1R is an inhibitor. In some instances, the modulator of GLP1R is an activator. In some instances, the GLP1R inhibitor is a GLP1R antagonist. In some instances, the GLP1R antagonist is GLP1R-3. Modulators of GLP1R, in some instances, are used for treating various diseases or disorders.

Exemplary diseases include, but are not limited to, cancer, inflammatory diseases or disorders, a metabolic disease or disorder, a cardiovascular disease or disorder, a respiratory disease or disorder, pain, a digestive disease or disorder, a reproductive disease or disorder, an endocrine disease or disorder, or a neurological disease or disorder. In some instances, the cancer is a solid cancer or a hematologic cancer. In some instances, a modulator of GLP1R as described herein is used for treatment of weight gain (or for inducing weight loss), treatment of obesity, or treatment of Type II diabetes. In some instances, the GLP1R modulator is used for treating hypoglycemia. In some instances, the

GLP1R modulator is used for treating post-bariatric hypoglycemia. In some instances, the GLP1R modulator is used for treating severe hypoglycemia. In some instances, the GLP1R modulator is used for treating hyperinsulinism. In some instances, the GLP1R modulator is used for treating congenital hyperinsulinism.

In some instances, the subject is a mammal. In some instances, the subject is a mouse, rabbit, dog, or human. Subjects treated by methods described herein may be infants, adults, or children. Pharmaceutical compositions comprising antibodies or antibody fragments as described herein may be administered intravenously or subcutaneously.

Described herein are pharmaceutical compositions comprising antibodies or antibody fragment thereof that binds GLP1R. In some embodiments, the antibody or antibody fragment thereof comprises a sequence as set forth in Tables 7-13. In some embodiments, the antibody or antibody fragment thereof comprises a sequence that is at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence as set forth in Tables 7-13.

In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRH1 sequence of any one of SEQ ID NOS: 441-619. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRH2 sequence of any one of SEQ ID NOS: 620-798. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH3 sequence of any one of SEQ ID NOS: 799-977. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 80% identical to a CDRH3 sequence of any one of SEQ ID NOS: 799-977. In some instances, a pharmaceutical composition comprises

an antibody or antibody fragment described herein comprising a sequence that is at least 85% identical to a CDRH3 sequence of any one of SEQ ID NOs: 799-977. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 90% identical to a CDRH3 sequence of any one of SEQ ID NOs: 799-977. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a sequence that is at least 95% identical to a CDRH3 sequence of any one of SEQ ID NOs: 799-977.

sequence that is at least 95% identical to a CDRL3 sequence of any one of SEQ ID NOs: 1336-1347 and 1353-1519.

In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 441-619; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 620-798; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 799-977; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 978-1156; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 1157-1335; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 1336-1347 and 1353-1519. In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 441-619; (b) an amino acid sequence of CDRH2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 620-798; (c) an amino acid sequence of CDRH3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 799-977; (d) an amino acid sequence of CDRL1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 978-1156; (e) an amino acid sequence of CDRL2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 1157-1335; and (f) an amino acid sequence of CDRL3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 1336-1347 and 1353-1519. Described herein, in some embodiments, are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 58-77, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 92-111. In some instances, the antibodies or antibody fragments comprise VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 58-77, and VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 92-111.

Described herein are pharmaceutical compositions comprising antibodies or antibody fragment thereof that binds GLP1R that comprise various dosages of the antibodies or antibody fragment. In some instances, the dosage is ranging from about 1 to 80 mg/kg, from about 1 to about 100 mg/kg, from about 5 to about 100 mg/kg, from about 5 to about 80 mg/kg, from about 5 to about 60 mg/kg, from about 5 to about 50 mg/kg or from about 5 to about 500 mg/kg which can be administered in single or multiple doses. In some instances, the dosage is administered in an amount of about 0.01 mg/kg, about 0.05 mg/kg, about 0.10 mg/kg, about 0.25 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg,

about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 105 mg/kg, about 110 mg/kg, about 115 mg/kg, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 240, about 250, about 260, about 270, about 275, about 280, about 290, about 300, about 310, about 320, about 330, about 340, about 350, about 360 mg/kg, about 370 mg/kg, about 380 mg/kg, about 390 mg/kg, about 400 mg/kg, 410 mg/kg, about 420 mg/kg, about 430 mg/kg, about 440 mg/kg, about 450 mg/kg, about 460 mg/kg, about 470 mg/kg, about 480 mg/kg, about 490 mg/kg, or about 500 mg/kg.

Variant Libraries Codon Variation

Variant nucleic acid libraries described herein may comprise a plurality of nucleic acids, wherein each nucleic acid encodes for a variant codon sequence compared to a reference nucleic acid sequence. In some instances, each nucleic acid of a first nucleic acid population contains a variant at a single variant site. In some instances, the first nucleic acid population contains a plurality of variants at a single variant site such that the first nucleic acid population contains more than one variant at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding multiple codon variants at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding up to 19 or more codons at the same position. The first nucleic acid population may comprise nucleic acids collectively encoding up to 60 variant triplets at the same position, or the first nucleic acid population may comprise nucleic acids collectively encoding up to 61 different triplets of codons at the same position. Each variant may encode for a codon that results in a different amino acid during translation. Table 2 provides a listing of each codon possible (and the representative amino acid) for a variant site.

TABLE 2

Amino Acids	One letter code	List of codons and amino acids						
		Three letter code	Codons					
Alanine	A	Ala	GCA	GCC	GCG	GCT		
Cysteine	C	Cys	TGC	TGT				
Aspartic acid	D	Asp	GAC	GAT				
Glutamic acid	E	Glu	GAA	GAG				
Phenylalanine	F	Phe	TTC	TTT				
Glycine	G	Gly	GGA	GGC	GGG	GGT		
Histidine	H	His	CAC	CAT				
Isoleucine	I	Iso	ATA	ATC	ATT			
Lysine	K	Lys	AAA	AAG				
Leucine	L	Leu	TTA	TTG	CTA	CTC	CTG	CTT
Methionine	M	Met	ATG					
Asparagine	N	Asn	AAC	AAT				
Proline	P	Pro	CCA	CCC	CCG	CCT		
Glutamine	Q	Gln	CAA	CAG				
Arginine	R	Arg	AGA	AGG	CGA	CGC	CGG	CGT
Serine	S	Ser	AGC	AGT	TCA	TCC	TCG	TCT
Threonine	T	Thr	ACA	ACC	ACG	ACT		
Valine	V	Val	GTA	GTC	GTG	GTT		
Tryptophan	W	Trp	TGG					
Tyrosine	Y	Tyr	TAC	TAT				

A nucleic acid population may comprise varied nucleic acids collectively encoding up to 20 codon variations at multiple positions. In such cases, each nucleic acid in the population comprises variation for codons at more than one position in the same nucleic acid. In some instances, each nucleic acid in the population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more codons in a single nucleic acid. In some instances, each variant long nucleic acid comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single long nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons in at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more codons in a single long nucleic acid.

Highly Parallel Nucleic Acid Synthesis

Provided herein is a platform approach utilizing miniaturization, parallelization, and vertical integration of the end-to-end process from polynucleotide synthesis to gene assembly within nanowells on silicon to create a revolutionary synthesis platform. Devices described herein provide, with the same footprint as a 96-well plate, a silicon synthesis platform capable of increasing throughput by a factor of up to 1,000 or more compared to traditional synthesis methods, with production of up to approximately 1,000,000 or more polynucleotides, or 10,000 or more genes in a single highly-parallelized run.

With the advent of next-generation sequencing, high resolution genomic data has become an important factor for studies that delve into the biological roles of various genes in both normal biology and disease pathogenesis. At the core of this research is the central dogma of molecular biology and the concept of “residue-by-residue transfer of sequential information.” Genomic information encoded in the DNA is transcribed into a message that is then translated into the protein that is the active product within a given biological pathway.

Another exciting area of study is on the discovery, development and manufacturing of therapeutic molecules focused on a highly-specific cellular target. High diversity DNA sequence libraries are at the core of development pipelines for targeted therapeutics. Gene mutants are used to express proteins in a design, build, and test protein engineering cycle that ideally culminates in an optimized gene for high expression of a protein with high affinity for its therapeutic target. As an example, consider the binding pocket of a receptor. The ability to test all sequence permutations of all residues within the binding pocket simultaneously will allow for a thorough exploration, increasing chances of success. Saturation mutagenesis, in which a researcher attempts to generate all possible mutations at a specific site within the receptor, represents one approach to this development challenge. Though costly and time- and labor-intensive, it enables each variant to be introduced into each position. In contrast, combinatorial mutagenesis, where a few selected positions or short stretch of DNA may be modified extensively, generates an incomplete repertoire of variants with biased representation.

To accelerate the drug development pipeline, a library with the desired variants available at the intended frequency in the right position available for testing—in other words, a precision library—enables reduced costs as well as turnaround time for screening. Provided herein are methods for

synthesizing nucleic acid synthetic variant libraries which provide for precise introduction of each intended variant at the desired frequency. To the end user, this translates to the ability to not only thoroughly sample sequence space but also be able to query these hypotheses in an efficient manner, reducing cost and screening time. Genome-wide editing can elucidate important pathways, libraries where each variant and sequence permutation can be tested for optimal functionality, and thousands of genes can be used to reconstruct entire pathways and genomes to re-engineer biological systems for drug discovery.

In a first example, a drug itself can be optimized using methods described herein. For example, to improve a specified function of an antibody, a variant polynucleotide library encoding for a portion of the antibody is designed and synthesized. A variant nucleic acid library for the antibody can then be generated by processes described herein (e.g., PCR mutagenesis followed by insertion into a vector). The antibody is then expressed in a production cell line and screened for enhanced activity. Example screens include examining modulation in binding affinity to an antigen, stability, or effector function (e.g., ADCC, complement, or apoptosis). Exemplary regions to optimize the antibody include, without limitation, the Fc region, Fab region, variable region of the Fab region, constant region of the Fab region, variable domain of the heavy chain or light chain (V_H or V_L), and specific complementarity-determining regions (CDRs) of V_H or V_L .

Nucleic acid libraries synthesized by methods described herein may be expressed in various cells associated with a disease state. Cells associated with a disease state include cell lines, tissue samples, primary cells from a subject, cultured cells expanded from a subject, or cells in a model system. Exemplary model systems include, without limitation, plant and animal models of a disease state.

To identify a variant molecule associated with prevention, reduction or treatment of a disease state, a variant nucleic acid library described herein is expressed in a cell associated with a disease state, or one in which a cell a disease state can be induced. In some instances, an agent is used to induce a disease state in cells. Exemplary tools for disease state induction include, without limitation, a Cre/Lox recombination system, LPS inflammation induction, and streptozotocin to induce hypoglycemia. The cells associated with a disease state may be cells from a model system or cultured cells, as well as cells from a subject having a particular disease condition. Exemplary disease conditions include a bacterial, fungal, viral, autoimmune, or proliferative disorder (e.g., cancer). In some instances, the variant nucleic acid library is expressed in the model system, cell line, or primary cells derived from a subject, and screened for changes in at least one cellular activity. Exemplary cellular activities include, without limitation, proliferation, cycle progression, cell death, adhesion, migration, reproduction, cell signaling, energy production, oxygen utilization, metabolic activity, and aging, response to free radical damage, or any combination thereof.

Substrates

Devices used as a surface for polynucleotide synthesis may be in the form of substrates which include, without limitation, homogenous array surfaces, patterned array surfaces, channels, beads, gels, and the like. Provided herein are substrates comprising a plurality of clusters, wherein each cluster comprises a plurality of loci that support the attachment and synthesis of polynucleotides. In some instances, substrates comprise a homogenous array surface. For example, the homogenous array surface is a homogenous

plate. The term "locus" as used herein refers to a discrete region on a structure which provides support for polynucleotides encoding for a single predetermined sequence to extend from the surface. In some instances, a locus is on a two-dimensional surface, e.g., a substantially planar surface. In some instances, a locus is on a three-dimensional surface, e.g., a well, microwell, channel, or post. In some instances, a surface of a locus comprises a material that is actively functionalized to attach to at least one nucleotide for polynucleotide synthesis, or preferably, a population of identical nucleotides for synthesis of a population of polynucleotides. In some instances, polynucleotide refers to a population of polynucleotides encoding for the same nucleic acid sequence. In some cases, a surface of a substrate is inclusive of one or a plurality of surfaces of a substrate. The average error rates for polynucleotides synthesized within a library described here using the systems and methods provided are often less than 1 in 1000, less than about 1 in 2000, less than about 1 in 3000 or less often without error correction.

Provided herein are surfaces that support the parallel synthesis of a plurality of polynucleotides having different predetermined sequences at addressable locations on a common support. In some instances, a substrate provides support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more non-identical polynucleotides. In some cases, the surfaces provide support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more polynucleotides encoding for distinct sequences. In some instances, at least a portion of the polynucleotides have an identical sequence or are configured to be synthesized with an identical sequence. In some instances, the substrate provides a surface environment for the growth of polynucleotides having at least 80, 90, 100, 120, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 bases or more.

Provided herein are methods for polynucleotide synthesis on distinct loci of a substrate, wherein each locus supports the synthesis of a population of polynucleotides. In some cases, each locus supports the synthesis of a population of polynucleotides having a different sequence than a population of polynucleotides grown on another locus. In some instances, each polynucleotide sequence is synthesized with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more redundancy across different loci within the same cluster of loci on a surface for polynucleotide synthesis. In some instances, the loci of a substrate are located within a plurality of clusters. In some instances, a substrate comprises at least 10, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 20000, 30000, 40000, 50000 or more clusters. In some instances, a substrate comprises more than 2,000; 5,000; 10,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,100,000; 1,200,000; 1,300,000; 1,400,000; 1,500,000; 1,600,000; 1,700,000; 1,800,000; 1,900,000; 2,000,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,

000; 4,000,000; 4,500,000; 5,000,000; or 10,000,000 or more distinct loci. In some instances, a substrate comprises about 10,000 distinct loci. The amount of loci within a single cluster is varied in different instances. In some cases, each cluster includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 150, 200, 300, 400, 500 or more loci. In some instances, each cluster includes about 50-500 loci. In some instances, each cluster includes about 100-200 loci. In some instances, each cluster includes about 100-150 loci. In some instances, each cluster includes about 109, 121, 130 or 137 loci. In some instances, each cluster includes about 19, 20, 61, 64 or more loci. Alternatively or in combination, polynucleotide synthesis occurs on a homogeneous array surface.

In some instances, the number of distinct polynucleotides synthesized on a substrate is dependent on the number of distinct loci available in the substrate. In some instances, the density of loci within a cluster or surface of a substrate is at least or about 1, 10, 25, 50, 65, 75, 100, 130, 150, 175, 200, 300, 400, 500, 1,000 or more loci per mm². In some cases, a substrate comprises 10-500, 25-400, 50-500, 100-500, 150-500, 10-250, 50-250, 10-200, or 50-200 mm². In some instances, the distance between the centers of two adjacent loci within a cluster or surface is from about 10-500, from about 10-200, or from about 10-100 um. In some instances, the distance between two centers of adjacent loci is greater than about 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some instances, the distance between the centers of two adjacent loci is less than about 200, 150, 100, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, each locus has a width of about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some cases, each locus has a width of about 0.5-100, 0.5-50, 10-75, or 0.5-50 um.

In some instances, the density of clusters within a substrate is at least or about 1 cluster per 100 mm², 1 cluster per 10 mm², 1 cluster per 5 mm², 1 cluster per 4 mm², 1 cluster per 3 mm², 1 cluster per 2 mm², 1 cluster per 1 mm², 2 clusters per 1 mm², 3 clusters per 1 mm², 4 clusters per 1 mm², 5 clusters per 1 mm², 10 clusters per 1 mm², 50 clusters per 1 mm² or more. In some instances, a substrate comprises from about 1 cluster per 10 mm² to about 10 clusters per 1 mm². In some instances, the distance between the centers of two adjacent clusters is at least or about 50, 100, 200, 500, 1000, 2000, or 5000 um. In some cases, the distance between the centers of two adjacent clusters is between about 50-100, 50-200, 50-300, 50-500, and 100-2000 um. In some cases, the distance between the centers of two adjacent clusters is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some cases, each cluster has a cross section of about 0.5 to about 2, about 0.5 to about 1, or about 1 to about 2 mm. In some cases, each cluster has a cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm. In some cases, each cluster has an interior cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm.

In some instances, a substrate is about the size of a standard 96 well plate, for example between about 100 and about 200 mm by between about 50 and about 150 mm. In some instances, a substrate has a diameter less than or equal to about 1000, 500, 450, 400, 300, 250, 200, 150, 100 or 50 mm. In some instances, the diameter of a substrate is between about 25-1000, 25-800, 25-600, 25-500, 25-400, 25-300, or 25-200 mm. In some instances, a substrate has a planar surface area of at least about 100; 200; 500; 1,000; 2,000; 5,000; 10,000; 12,000; 15,000; 20,000; 30,000;

40,000; 50,000 mm² or more. In some instances, the thickness of a substrate is between about 50-2000, 50-1000, 100-1000, 200-1000, or 250-1000 mm.

Surface Materials

Substrates, devices, and reactors provided herein are fabricated from any variety of materials suitable for the methods, compositions, and systems described herein. In certain instances, substrate materials are fabricated to exhibit a low level of nucleotide binding. In some instances, substrate materials are modified to generate distinct surfaces that exhibit a high level of nucleotide binding. In some instances, substrate materials are transparent to visible and/or UV light. In some instances, substrate materials are sufficiently conductive, e.g., are able to form uniform electric fields across all or a portion of a substrate. In some instances, conductive materials are connected to an electric ground. In some instances, the substrate is heat conductive or insulated. In some instances, the materials are chemical resistant and heat resistant to support chemical or biochemical reactions, for example polynucleotide synthesis reaction processes. In some instances, a substrate comprises flexible materials. For flexible materials, materials can include, without limitation: nylon, both modified and unmodified, nitrocellulose, polypropylene, and the like. In some instances, a substrate comprises rigid materials. For rigid materials, materials can include, without limitation: glass; fused silica; silicon, plastics (for example polytetrafluoroethylene, polypropylene, polystyrene, polycarbonate, and blends thereof, and the like); and metals (for example, gold, platinum, and the like). The substrate, solid support or reactors can be fabricated from a material selected from the group consisting of silicon, polystyrene, agarose, dextran, cellulosic polymers, polyacrylamides, polydimethylsiloxane (PDMS), and glass. The substrates/solid supports or the microstructures/reactors therein may be manufactured with a combination of materials listed herein or any other suitable material known in the art.

Surface Architecture

Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates have a surface architecture suitable for the methods, compositions, and systems described herein. In some instances, a substrate comprises raised and/or lowered features. One benefit of having such features is an increase in surface area to support polynucleotide synthesis. In some instances, a substrate having raised and/or lowered features is referred to as a three-dimensional substrate. In some cases, a three-dimensional substrate comprises one or more channels. In some cases, one or more loci comprise a channel. In some cases, the channels are accessible to reagent deposition via a deposition device such as a material deposition device. In some cases, reagents and/or fluids collect in a larger well in fluid communication one or more channels. For example, a substrate comprises a plurality of channels corresponding to a plurality of loci with a cluster, and the plurality of channels are in fluid communication with one well of the cluster. In some methods, a library of polynucleotides is synthesized in a plurality of loci of a cluster.

Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates are configured for polynucleotide synthesis. In some instances, the structure is configured to allow for controlled flow and mass transfer paths for polynucleotide synthesis on a surface. In some instances, the configuration of a substrate allows for the controlled and even distribution of mass transfer paths, chemical exposure times, and/or wash efficacy during polynucleotide synthesis. In some instances, the

configuration of a substrate allows for increased sweep efficiency, for example by providing sufficient volume for a growing polynucleotide such that the excluded volume by the growing polynucleotide does not take up more than 50, 45, 40, 35, 30, 25, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1%, or less of the initially available volume that is available or suitable for growing the polynucleotide. In some instances, a three-dimensional structure allows for managed flow of fluid to allow for the rapid exchange of chemical exposure.

Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates comprise structures suitable for the methods, compositions, and systems described herein. In some instances, segregation is achieved by physical structure. In some instances, segregation is achieved by differential functionalization of the surface generating active and passive regions for polynucleotide synthesis. In some instances, differential functionalization is achieved by alternating the hydrophobicity across the substrate surface, thereby creating water contact angle effects that cause beading or wetting of the deposited reagents. Employing larger structures can decrease splashing and cross-contamination of distinct polynucleotide synthesis locations with reagents of the neighboring spots. In some cases, a device, such as a material deposition device, is used to deposit reagents to distinct polynucleotide synthesis locations. Substrates having three-dimensional features are configured in a manner that allows for the synthesis of a large number of polynucleotides (e.g., more than about 10,000) with a low error rate (e.g., less than about 1:500, 1:1000, 1:1500, 1:2,000, 1:3,000, 1:5,000, or 1:10,000). In some cases, a substrate comprises features with a density of about or greater than about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400 or 500 features per mm².

A well of a substrate may have the same or different width, height, and/or volume as another well of the substrate. A channel of a substrate may have the same or different width, height, and/or volume as another channel of the substrate. In some instances, the diameter of a cluster or the diameter of a well comprising a cluster, or both, is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.05-1, 0.05-0.5, 0.05-0.1, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some instances, the diameter of a cluster or well or both is less than or about 5, 4, 3, 2, 1, 0.5, 0.1, 0.09, 0.08, 0.07, 0.06, or 0.05 mm. In some instances, the diameter of a cluster or well or both is between about 1.0 and 1.3 mm. In some instances, the diameter of a cluster or well, or both is about 1.150 mm. In some instances, the diameter of a cluster or well, or both is about 0.08 mm. The diameter of a cluster refers to clusters within a two-dimensional or three-dimensional substrate.

In some instances, the height of a well is from about 20-1000, 50-1000, 100-1000, 200-1000, 300-1000, 400-1000, or 500-1000 um. In some cases, the height of a well is less than about 1000, 900, 800, 700, or 600 um.

In some instances, a substrate comprises a plurality of channels corresponding to a plurality of loci within a cluster, wherein the height or depth of a channel is 5-500, 5-400, 5-300, 5-200, 5-100, 5-50, or 10-50 um. In some cases, the height of a channel is less than 100, 80, 60, 40, or 20 um.

In some instances, the diameter of a channel, locus (e.g., in a substantially planar substrate) or both channel and locus (e.g., in a three-dimensional substrate wherein a locus corresponds to a channel) is from about 1-1000, 1-500, 1-200, 1-100, 5-100, or 10-100 um, for example, to about 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the

diameter of a channel, locus, or both channel and locus is less than about 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the distance between the center of two adjacent channels, loci, or channels and loci is from about 1-500, 1-200, 1-100, 5-200, 5-100, 5-50, or 5-30, for example, to about 20 um.

Surface Modifications

Provided herein are methods for polynucleotide synthesis on a surface, wherein the surface comprises various surface modifications. In some instances, the surface modifications are employed for the chemical and/or physical alteration of a surface by an additive or subtractive process to change one or more chemical and/or physical properties of a substrate surface or a selected site or region of a substrate surface. For example, surface modifications include, without limitation, (1) changing the wetting properties of a surface, (2) functionalizing a surface, i.e., providing, modifying or substituting surface functional groups, (3) defunctionalizing a surface, i.e., removing surface functional groups, (4) otherwise altering the chemical composition of a surface, e.g., through etching, (5) increasing or decreasing surface roughness, (6) providing a coating on a surface, e.g., a coating that exhibits wetting properties that are different from the wetting properties of the surface, and/or (7) depositing particulates on a surface.

In some cases, the addition of a chemical layer on top of a surface (referred to as adhesion promoter) facilitates structured patterning of loci on a surface of a substrate. Exemplary surfaces for application of adhesion promotion include, without limitation, glass, silicon, silicon dioxide and silicon nitride. In some cases, the adhesion promoter is a chemical with a high surface energy. In some instances, a second chemical layer is deposited on a surface of a substrate. In some cases, the second chemical layer has a low surface energy. In some cases, surface energy of a chemical layer coated on a surface supports localization of droplets on the surface. Depending on the patterning arrangement selected, the proximity of loci and/or area of fluid contact at the loci are alterable.

In some instances, a substrate surface, or resolved loci, onto which nucleic acids or other moieties are deposited, e.g., for polynucleotide synthesis, are smooth or substantially planar (e.g., two-dimensional) or have irregularities, such as raised or lowered features (e.g., three-dimensional features). In some instances, a substrate surface is modified with one or more different layers of compounds. Such modification layers of interest include, without limitation, inorganic and organic layers such as metals, metal oxides, polymers, small organic molecules, and the like.

In some instances, resolved loci of a substrate are functionalized with one or more moieties that increase and/or decrease surface energy. In some cases, a moiety is chemically inert. In some cases, a moiety is configured to support a desired chemical reaction, for example, one or more processes in a polynucleotide synthesis reaction. The surface energy, or hydrophobicity, of a surface is a factor for determining the affinity of a nucleotide to attach onto the surface. In some instances, a method for substrate functionalization comprises: (a) providing a substrate having a surface that comprises silicon dioxide; and (b) silanizing the surface using a suitable silanizing agent described herein or otherwise known in the art, for example, an organofunctional alkoxysilane molecule. Methods and functionalizing agents are described in U.S. Pat. No. 5,474,796, which is herein incorporated by reference in its entirety.

In some instances, a substrate surface is functionalized by contact with a derivatizing composition that contains a

mixture of silanes, under reaction conditions effective to couple the silanes to the substrate surface, typically via reactive hydrophilic moieties present on the substrate surface. Silanization generally covers a surface through self-assembly with organofunctional alkoxysilane molecules. A variety of siloxane functionalizing reagents can further be used as currently known in the art, e.g., for lowering or increasing surface energy. The organofunctional alkoxysilanes are classified according to their organic functions.

10 Polynucleotide Synthesis

Methods of the current disclosure for polynucleotide synthesis may include processes involving phosphoramidite chemistry. In some instances, polynucleotide synthesis comprises coupling a base with phosphoramidite. Polynucleotide synthesis may comprise coupling a base by deposition of phosphoramidite under coupling conditions, wherein the same base is optionally deposited with phosphoramidite more than once, i.e., double coupling. Polynucleotide synthesis may comprise capping of unreacted sites. In some instances, capping is optional. Polynucleotide synthesis may also comprise oxidation or an oxidation step or oxidation steps. Polynucleotide synthesis may comprise deblocking, detritylation, and sulfurization. In some instances, polynucleotide synthesis comprises either oxidation or sulfurization. In some instances, between one or each step during a polynucleotide synthesis reaction, the device is washed, for example, using tetrazole or acetonitrile. Time frames for any one step in a phosphoramidite synthesis method may be less than about 2 min, 1 min, 50 sec, 40 sec, 30 sec, 20 sec and 10 sec.

Polynucleotide synthesis using a phosphoramidite method may comprise a subsequent addition of a phosphoramidite building block (e.g., nucleoside phosphoramidite) to a growing polynucleotide chain for the formation of a phosphite triester linkage. Phosphoramidite polynucleotide synthesis proceeds in 3' to 5' direction. Phosphoramidite polynucleotide synthesis allows for the controlled addition of one nucleotide to a growing nucleic acid chain per synthesis cycle. In some instances, each synthesis cycle comprises a coupling step. Phosphoramidite coupling involves the formation of a phosphite triester linkage between an activated nucleoside phosphoramidite and a nucleoside bound to the substrate, for example, via a linker. In some instances, the nucleoside phosphoramidite is provided to the device activated. In some instances, the nucleoside phosphoramidite is provided to the device with an activator. In some instances, nucleoside phosphoramidites are provided to the device in a 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100-fold excess or more over the substrate-bound nucleosides. In some instances, the addition of nucleoside phosphoramidite is performed in an anhydrous environment, for example, in anhydrous acetonitrile. Following addition of a nucleoside phosphoramidite, the device is optionally washed. In some instances, the coupling step is repeated one or more additional times, optionally with a wash step between nucleoside phosphoramidite additions to the substrate. In some instances, a polynucleotide synthesis method used herein comprises 1, 2, 3 or more sequential coupling steps. Prior to coupling, in many cases, the nucleoside bound to the device is de-protected by removal of a protecting group, where the protecting group functions to prevent polymerization. A common protecting group is 4,4'-dimethoxytrityl (DMT).

Following coupling, phosphoramidite polynucleotide synthesis methods optionally comprise a capping step. In a capping step, the growing polynucleotide is treated with a capping agent. A capping step is useful to block unreacted

substrate-bound 5'-OH groups after coupling from further chain elongation, preventing the formation of polynucleotides with internal base deletions. Further, phosphoramidites activated with 1H-tetrazole may react, to a small extent, with the O6 position of guanosine. Without being bound by theory, upon oxidation with I₂/water, this side product, possibly via O6-N7 migration, may undergo depurination. The apurinic sites may end up being cleaved in the course of the final deprotection of the polynucleotide thus reducing the yield of the full-length product. The O6 modifications may be removed by treatment with the capping reagent prior to oxidation with I₂/water. In some instances, inclusion of a capping step during polynucleotide synthesis decreases the error rate as compared to synthesis without capping. As an example, the capping step comprises treating the substrate-bound polynucleotide with a mixture of acetic anhydride and 1-methylimidazole. Following a capping step, the device is optionally washed.

In some instances, following addition of a nucleoside phosphoramidite, and optionally after capping and one or more wash steps, the device bound growing nucleic acid is oxidized. The oxidation step comprises a phosphite triester which is oxidized into a tetracoordinated phosphate triester, a protected precursor of the naturally occurring phosphate diester internucleoside linkage. In some instances, oxidation of the growing polynucleotide is achieved by treatment with iodine and water, optionally in the presence of a weak base (e.g., pyridine, lutidine, collidine). Oxidation may be carried out under anhydrous conditions using, e.g. tert-Butyl hydroperoxide or (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (CSO). In some methods, a capping step is performed following oxidation. A second capping step allows for device drying, as residual water from oxidation that may persist can inhibit subsequent coupling. Following oxidation, the device and growing polynucleotide are optionally washed. In some instances, the step of oxidation is substituted with a sulfurization step to obtain polynucleotide phosphorothioates, wherein any capping steps can be performed after the sulfurization. Many reagents are capable of the efficient sulfur transfer, including but not limited to 3-(Dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-3-thione, DDTT, 3H-1,2-benzodithiol-3-one 1,1-dioxide, also known as Beaucage reagent, and N,N,N',N'-Tetraethylthiuram disulfide (TETD).

In order for a subsequent cycle of nucleoside incorporation to occur through coupling, the protected 5' end of the device bound growing polynucleotide is removed so that the primary hydroxyl group is reactive with a next nucleoside phosphoramidite. In some instances, the protecting group is DMT and deblocking occurs with trichloroacetic acid in dichloromethane. Conducting detritylation for an extended time or with stronger than recommended solutions of acids may lead to increased depurination of solid support-bound polynucleotide and thus reduces the yield of the desired full-length product. Methods and compositions of the disclosure described herein provide for controlled deblocking conditions limiting undesired depurination reactions. In some instances, the device bound polynucleotide is washed after deblocking. In some instances, efficient washing after deblocking contributes to synthesized polynucleotides having a low error rate.

Methods for the synthesis of polynucleotides typically involve an iterating sequence of the following steps: application of a protected monomer to an actively functionalized surface (e.g., locus) to link with either the activated surface, a linker or with a previously deprotected monomer; deprotection of the applied monomer so that it is reactive with a

subsequently applied protected monomer; and application of another protected monomer for linking. One or more intermediate steps include oxidation or sulfurization. In some instances, one or more wash steps precede or follow one or all of the steps.

Methods for phosphoramidite-based polynucleotide synthesis comprise a series of chemical steps. In some instances, one or more steps of a synthesis method involve reagent cycling, where one or more steps of the method 10 comprise application to the device of a reagent useful for the step. For example, reagents are cycled by a series of liquid deposition and vacuum drying steps. For substrates comprising three-dimensional features such as wells, microwells, channels and the like, reagents are optionally passed 15 through one or more regions of the device via the wells and/or channels.

Methods and systems described herein relate to polynucleotide synthesis devices for the synthesis of polynucleotides. The synthesis may be in parallel. For example, at 20 least or about at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 10000, 50000, 75000, 100000 or more polynucleotides can be synthesized in 25 parallel. The total number polynucleotides that may be synthesized in parallel may be from 2-100000, 3-50000, 4-10000, 5-1000, 6-900, 7-850, 8-800, 9-750, 10-700, 11-650, 12-600, 13-550, 14-500, 15-450, 16-400, 17-350, 18-300, 19-250, 20-200, 21-150, 22-100, 23-50, 24-45, 30 25-40, 30-35. Those of skill in the art appreciate that the total number of polynucleotides synthesized in parallel may fall within any range bound by any of these values, for example 25-100. The total number of polynucleotides synthesized in parallel may fall within any range defined by any of the 35 values serving as endpoints of the range. Total molar mass of polynucleotides synthesized within the device or the molar mass of each of the polynucleotides may be at least or at least about 10, 20, 30, 40, 50, 100, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 50000, 75000, 100000 picomoles, or more. The length of each of the polynucleotides or average length of the polynucleotides within the device may be at least or about at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 400, 500 nucleotides, or more. The length of each 40 of the polynucleotides or average length of the polynucleotides within the device may be at most or about at most 500, 400, 300, 200, 150, 100, 50, 45, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 nucleotides, or less. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall from 10-500, 9-400, 11-300, 12-200, 13-150, 14-100, 15-50, 16-45, 17-40, 18-35, 19-25. Those of skill in the art appreciate that the length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any 50 range bound by any of these values, for example 100-300. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range defined by any of the values serving as endpoints of the range.)

Methods for polynucleotide synthesis on a surface provided herein allow for synthesis at a fast rate. As an example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175, 200 nucleotides per 60 hour, or more are synthesized. Nucleotides include adenine, guanine, thymine, cytosine, uridine building blocks, or analogs/modified versions thereof. In some instances, libraries

of polynucleotides are synthesized in parallel on substrate. For example, a device comprising about or at least about 100; 1,000; 10,000; 30,000; 75,000; 100,000; 1,000,000; 2,000,000; 3,000,000; 4,000,000; or 5,000,000 resolved loci is able to support the synthesis of at least the same number of distinct polynucleotides, wherein polynucleotide encoding a distinct sequence is synthesized on a resolved locus. In some instances, a library of polynucleotides is synthesized on a device with low error rates described herein in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours, or less. In some instances, larger nucleic acids assembled from a polynucleotide library synthesized with low error rate using the substrates and methods described herein are prepared in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours, or less.

In some instances, methods described herein provide for generation of a library of nucleic acids comprising variant nucleic acids differing at a plurality of codon sites. In some instances, a nucleic acid may have 1 site, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites 18 sites, 19 sites, 20 sites, 30 sites, 40 sites, 50 sites, or more of variant codon sites.

In some instances, the one or more sites of variant codon sites may be adjacent. In some instances, the one or more sites of variant codon sites may not be adjacent but are separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more codons.

In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein all the variant codon sites are adjacent to one another, forming a stretch of variant codon sites. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein none the variant codon sites are adjacent to one another. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein some the variant codon sites are adjacent to one another, forming a stretch of variant codon sites, and some of the variant codon sites are not adjacent to one another.

Referring to the Figures, FIG. 3 illustrates an exemplary process workflow for synthesis of nucleic acids (e.g., genes) from shorter nucleic acids. The workflow is divided generally into phases: (1) de novo synthesis of a single stranded nucleic acid library, (2) joining nucleic acids to form larger fragments, (3) error correction, (4) quality control, and (5) shipment. Prior to de novo synthesis, an intended nucleic acid sequence or group of nucleic acid sequences is preselected. For example, a group of genes is preselected for generation.

Once large nucleic acids for generation are selected, a predetermined library of nucleic acids is designed for de novo synthesis. Various suitable methods are known for generating high density polynucleotide arrays. In the workflow example, a device surface layer 301 is provided. In the example, chemistry of the surface is altered in order to improve the polynucleotide synthesis process. Areas of low surface energy are generated to repel liquid while areas of high surface energy are generated to attract liquids. The surface itself may be in the form of a planar surface or contain variations in shape, such as protrusions or microwells which increase surface area. In the workflow example, high surface energy molecules selected serve a dual function of supporting DNA chemistry, as disclosed in International Patent Application Publication WO/2015/021080, which is herein incorporated by reference in its entirety.

In situ preparation of polynucleotide arrays is generated on a solid support 301 and utilizes single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device, is 5 designed to release reagents in a step-wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 302. In some instances, polynucleotides are cleaved from the surface at this stage. Cleavage includes gas 10 cleavage, e.g., with ammonia or methylamine.

The generated polynucleotide libraries are placed in a reaction chamber. In this exemplary workflow, the reaction chamber (also referred to as “nanoreactor”) is a silicon coated well, containing PCR reagents and lowered onto the polynucleotide library 303. Prior to or after the sealing 304 of the polynucleotides, a reagent is added to release the polynucleotides from the substrate. In the exemplary workflow, the polynucleotides are released subsequent to sealing 15 of the nanoreactor 305. Once released, fragments of single stranded polynucleotides hybridize in order to span an entire long-range sequence of DNA. Partial hybridization 305 is 20 possible because each synthesized polynucleotide is designed to have a small portion overlapping with at least one other polynucleotide in the pool.

After hybridization, a PCA reaction is commenced. During the polymerase cycles, the polynucleotides anneal to complementary fragments and gaps are filled in by a polymerase. Each cycle increases the length of various fragments 25 randomly depending on which polynucleotides find each other. Complementarity amongst the fragments allows for formation of a complete large span of double stranded DNA 306.

After PCA is complete, the nanoreactor is separated from 30 the device 307 and positioned for interaction with a device having primers for PCR 308. After sealing, the nanoreactor is subject to PCR 309 and the larger nucleic acids are amplified. After PCR 310, the nanochamber is opened 311, error correction reagents are added 312, the chamber is sealed 313 and an error correction reaction occurs to remove mismatched base pairs and/or strands with poor complementarity from the double stranded PCR amplification products 314. The nanoreactor is opened and separated 315. Error corrected product is next subject to additional processing steps, such as PCR and molecular bar coding, and 35 then packaged 322 for shipment 323.

In some instances, quality control measures are taken. After error correction, quality control steps include for example interaction with a wafer having sequencing primers for amplification of the error corrected product 316, sealing the wafer to a chamber containing error corrected amplification product 317, and performing an additional round of amplification 318. The nanoreactor is opened 319 and the products are pooled 320 and sequenced 321. After an acceptable quality control determination is made, the packaged product 322 is approved for shipment 323.

In some instances, a nucleic acid generated by a workflow such as that in FIG. 3 is subject to mutagenesis using overlapping primers disclosed herein. In some instances, a library of primers is generated by in situ preparation on a solid support and utilize single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device, is designed to release reagents in a step wise fashion such that multiple 60 polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 302.

Computer Systems

Any of the systems described herein, may be operably linked to a computer and may be automated through a computer either locally or remotely. In various instances, the methods and systems of the disclosure may further comprise software programs on computer systems and use thereof. Accordingly, computerized control for the synchronization of the dispense/vacuum/refill functions such as orchestrating and synchronizing the material deposition device movement, dispense action and vacuum actuation are within the bounds of the disclosure. The computer systems may be programmed to interface between the user specified base sequence and the position of a material deposition device to deliver the correct reagents to specified regions of the substrate.

The computer system 400 illustrated in FIG. 4 may be understood as a logical apparatus that can read instructions from media 411 and/or a network port 405, which can optionally be connected to server 409 having fixed media 412. The system, such as shown in FIG. 4 can include a CPU 401, disk drives 403, optional input devices such as keyboard 415 and/or mouse 416 and optional monitor 407. Data communication can be achieved through the indicated communication medium to a server at a local or a remote location. The communication medium can include any means of transmitting and/or receiving data. For example, the communication medium can be a network connection, a wireless connection or an internet connection. Such a connection can provide for communication over the World Wide Web. It is envisioned that data relating to the present disclosure can be transmitted over such networks or connections for reception and/or review by a party 422 as illustrated in FIG. 4.

FIG. 5 is a block diagram illustrating a first example architecture of a computer system 500 that can be used in connection with example instances of the present disclosure. As depicted in FIG. 5, the example computer system can include a processor 502 for processing instructions. Non-limiting examples of processors include: Intel Xeon™ processor, AMD Opteron™ processor, Samsung 32-bit RISC ARM 1176JZ (F)-S v1.0™ processor, ARM Cortex-A8 Samsung S5PC100™ processor, ARM Cortex-A8 Apple A4™ processor, Marvell PXA 93014 processor, or a functionally-equivalent processor. Multiple threads of execution can be used for parallel processing. In some instances, multiple processors or processors with multiple cores can also be used, whether in a single computer system, in a cluster, or distributed across systems over a network comprising a plurality of computers, cell phones, and/or personal data assistant devices.

As illustrated in FIG. 5, a high-speed cache 504 can be connected to, or incorporated in, the processor 502 to provide a high speed memory for instructions or data that have been recently, or are frequently, used by the processor 502. The processor 502 is connected to a north bridge 506 by a processor bus 508. The north bridge 506 is connected to random access memory (RAM) 510 by a memory bus 512 and manages access to the RAM 510 by the processor 502. The north bridge 506 is also connected to a south bridge 514 by a chipset bus 516. The south bridge 514 is, in turn, connected to a peripheral bus 518. The peripheral bus can be, for example, PCI, PCI-X, PCI Express, or other peripheral bus. The north bridge and south bridge are often referred to as a processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus 518. In some alternative architectures, the functionality of the north bridge can be incorporated into the

processor instead of using a separate north bridge chip. In some instances, system 500 can include an accelerator card 522 attached to the peripheral bus 518. The accelerator can include field programmable gate arrays (FPGAs) or other hardware for accelerating certain processing. For example, an accelerator can be used for adaptive data restructuring or to evaluate algebraic expressions used in extended set processing.

Software and data are stored in external storage 524 and 10 can be loaded into RAM 510 and/or cache 504 for use by the processor. The system 500 includes an operating system for managing system resources; non-limiting examples of operating systems include: Linux®, Windows®, MACOS®, BlackBerry® OS™, BlackBerry® iOS®, and other functionally-equivalent operating systems, as well as application 15 software running on top of the operating system for managing data storage and optimization in accordance with example instances of the present disclosure. In this example, system 500 also includes network interface cards (NICs) 520 and 521 connected to the peripheral bus for providing 20 network interfaces to external storage, such as Network Attached Storage (NAS) and other computer systems that can be used for distributed parallel processing.

FIG. 6 is a diagram showing a network 600 with a 25 plurality of computer systems 602a, and 602b, a plurality of cell phones and personal data assistants 602c, and Network Attached Storage (NAS) 604a, and 604b. In example 30 instances, systems 602a, 602b, and 602c can manage data storage and optimize data access for data stored in Network Attached Storage (NAS) 604a and 604b. A mathematical model can be used for the data and be evaluated using distributed parallel processing across computer systems 602a, and 602b, and cell phone and personal data assistant systems 602c. Computer systems 602a, and 602b, and cell 35 phone and personal data assistant systems 602c can also provide parallel processing for adaptive data restructuring of the data stored in Network Attached Storage (NAS) 604a and 604b. FIG. 6 illustrates an example only, and a wide variety of other computer architectures and systems can be 40 used in conjunction with the various instances of the present disclosure. For example, a blade server can be used to provide parallel processing. Processor blades can be connected through a back plane to provide parallel processing. Storage can also be connected to the back plane or as 45 Network Attached Storage (NAS) through a separate network interface. In some example instances, processors can maintain separate memory spaces and transmit data through network interfaces, back plane or other connectors for parallel processing by other processors. In other instances, 50 some or all of the processors can use a shared virtual address memory space.

FIG. 7 is a block diagram of a multiprocessor computer system 700 using a shared virtual address memory space in 55 accordance with an example instance. The system includes a plurality of processors 702 that can access a shared memory subsystem 704. The system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) 706a-f in the memory subsystem 704. Each MAP 706a-f can comprise a memory 708a-f and one or more field 60 programmable gate arrays (FPGAs) 710a-f. The MAP provides a configurable functional unit and particular algorithms or portions of algorithms can be provided to the FPGAs 710a-f for processing in close coordination with a respective processor. For example, the MAPs can be used to 65 evaluate algebraic expressions regarding the data model and to perform adaptive data restructuring in example instances. In this example, each MAP is globally accessible by all of

the processors for these purposes. In one configuration, each MAP can use Direct Memory Access (DMA) to access an associated memory 708a-f, allowing it to execute tasks independently of, and asynchronously from the respective microprocessor 702a-f. In this configuration, a MAP can feed results directly to another MAP for pipelining and parallel execution of algorithms.

The above computer architectures and systems are examples only, and a wide variety of other computer, cell phone, and personal data assistant architectures and systems can be used in connection with example instances, including systems using any combination of general processors, coprocessors, FPGAs and other programmable logic devices, system on chips (SOCs), application specific integrated circuits (ASICs), and other processing and logic elements. In some instances, all or part of the computer system can be implemented in software or hardware. Any variety of data storage media can be used in connection with example instances, including random access memory, hard drives, flash memory, tape drives, disk arrays, Network Attached Storage (NAS) and other local or distributed data storage devices and systems.

In example instances, the computer system can be implemented using software modules executing on any of the above or other computer architectures and systems. In other instances, the functions of the system can be implemented partially or completely in firmware, programmable logic devices such as field programmable gate arrays (FPGAs) as referenced in FIG. 5, system on chips (SOCs), application specific integrated circuits (ASICs), or other processing and logic elements. For example, the Set Processor and Optimizer can be implemented with hardware acceleration through the use of a hardware accelerator card, such as accelerator card 522 illustrated in FIG. 5.

The following examples are set forth to illustrate more clearly the principle and practice of embodiments disclosed herein to those skilled in the art and are not to be construed as limiting the scope of any claimed embodiments. Unless otherwise stated, all parts and percentages are on a weight basis.

EXAMPLES

The following examples are given for the purpose of illustrating various embodiments of the disclosure and are not meant to limit the present disclosure in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the disclosure. Changes therein and other uses which are encompassed within the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art.

Example 1: Functionalization of a Device Surface

A device was functionalized to support the attachment and synthesis of a library of polynucleotides. The device surface was first wet cleaned using a piranha solution comprising 90% H₂SO₄ and 10% H₂O₂ for 20 minutes. The device was rinsed in several beakers with DI water, held under a DI water gooseneck faucet for 5 min, and dried with N₂. The device was subsequently soaked in NH₄OH (1:100; 3 mL: 300 mL) for 5 min, rinsed with DI water using a handgun, soaked in three successive beakers with DI water for 1 min each, and then rinsed again with DI water using the handgun.

The device was then plasma cleaned by exposing the device surface to O₂. A SAMCO PC-300 instrument was used to plasma etch O₂ at 250 watts for 1 min in downstream mode.

5 The cleaned device surface was actively functionalized with a solution comprising N-(3-triethoxysilylpropyl)-4-hydroxybutyramide using a YES-1224P vapor deposition oven system with the following parameters: 0.5 to 1 torr, 60 min, 10 70° C., 135° C. vaporizer. The device surface was resist coated using a Brewer Science 200X spin coater. SPR™ 3612 photoresist was spin coated on the device at 2500 rpm for 40 sec. The device was pre-baked for 30 min at 90° C. 15 on a Brewer hot plate. The device was subjected to photolithography using a Karl Suss MA6 mask aligner instrument. The device was exposed for 2.2 sec and developed for 1 min 20 in MSF 26A. Remaining developer was rinsed with the handgun and the device soaked in water for 5 min. The device was baked for 30 min at 100° C. in the oven, followed by visual inspection for lithography defects using a Nikon 25 L200. A descum process was used to remove residual resist using the SAMCO PC-300 instrument to O₂ plasma etch at 250 watts for 1 min.

30 The device surface was passively functionalized with a 100 μL solution of perfluoroctyltrichlorosilane mixed with 10 μL light mineral oil. The device was placed in a chamber, pumped for 10 min, and then the valve was closed to the pump and left to stand for 10 min. The chamber was vented to air. The device was resist stripped by performing two 35 soaks for 5 min in 500 mL NMP at 70° C. with ultrasonication at maximum power (9 on Crest system). The device was then soaked for 5 min in 500 mL isopropanol at room temperature with ultrasonication at maximum power. The 40 device was dipped in 300 mL of 200 proof ethanol and blown dry with N₂. The functionalized surface was activated to serve as a support for polynucleotide synthesis.

Example 2: Synthesis of a 50-mer Sequence on an Oligonucleotide Synthesis Device

50 A two-dimensional oligonucleotide synthesis device was assembled into a flowcell, which was connected to a flowcell (Applied Biosystems® “ABI394 DNA Synthesizer”). The two-dimensional oligonucleotide synthesis device was uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXYBUTYRAMIDE (Gelest) which was used to synthesize an exemplary polynucleotide of 50 bp (“50-mer polynucleotide”) using polynucleotide synthesis 55 methods described herein.

The sequence of the 50-mer was as described in SEQ ID NO: 1348. 5'AGACAAATCAACCAT-TTGGGGTGGACAGCCTTGACCTCTAGACTTCGG-CAT #TTTTTTT TTT3' (SEQ ID NO.: 1348), where #denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes), which is a cleavable linker enabling the release of oligos from the surface during deprotection.

60 65 The synthesis was done using standard DNA synthesis chemistry (coupling, capping, oxidation, and deblocking) according to the protocol in Table 3 and an ABI synthesizer.

TABLE 3

Synthesis protocols		
Table 3		
General DNA Synthesis Process Name	Process Step	Time (sec)
WASH (Acetonitrile Wash Flow)	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	23
	N2 System Flush	4
	Acetonitrile System Flush	4
DNA BASE ADDITION (Phosphoramidite + Activator Flow)	Activator Manifold Flush	2
	Activator to Flowcell	6
	Activator +	6
	Phosphoramidite to Flowcell	
	Activator to Flowcell	0.5
	Activator +	5
	Phosphoramidite to Flowcell	
	Activator to Flowcell	0.5
	Activator +	5
	Phosphoramidite to Flowcell	
	Activator to Flowcell	0.5
	Activator +	5
	Phosphoramidite to Flowcell	
	Activator to Flowcell	0.5
	Activator +	5
	Phosphoramidite to Flowcell	
	Incubate for 25 sec	25
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
DNA BASE ADDITION (Phosphoramidite + Activator Flow)	Activator Manifold Flush	2
	Activator to Flowcell	5
	Activator +	18
	Phosphoramidite to Flowcell	
	Incubate for 25 sec	25
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
WASH (Acetonitrile Wash Flow)	CapA + B to Flowcell	15
CAPPING (CapA + B, 1:1, Flow)	Acetonitrile System Flush	4
WASH (Acetonitrile Wash Flow)	Acetonitrile to Flowcell	15
OXIDATION (Oxidizer Flow)	Acetonitrile System Flush	4
WASH (Acetonitrile Wash Flow)	Oxidizer to Flowcell	18
	Acetonitrile System Flush	4
	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
DEBLOCKING (Deblock Flow)	Deblock to Flowcell	36
WASH (Acetonitrile Wash Flow)	Acetonitrile System Flush	4
	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	18
	N2 System Flush	4.13
	Acetonitrile System Flush	4.13
	Acetonitrile to Flowcell	15

The phosphoramidite/activator combination was delivered similarly to the delivery of bulk reagents through the flowcell. No drying steps were performed as the environment stays “wet” with reagent the entire time.

The flow restrictor was removed from the ABI 394 synthesizer to enable faster flow. Without flow restrictor, flow rates for amidites (0.1M in ACN), Activator, (0.25M Benzoylthiotetrazole (“BTT”; 30-3070-xx from GlenRe-

search) in ACN), and Ox (0.02M I2 in 20% pyridine, 10% water, and 70% THF) were roughly ~100 uL/sec, for acetonitrile (“ACN”) and capping reagents (1:1 mix of CapA and CapB, wherein CapA is acetic anhydride in 10% THF/Pyridine and CapB is 16% 1-methylimidazole in THF), roughly ~200 uL/sec, and for Deblock (3% dichloroacetic acid in toluene), roughly ~300 uL/sec (compared to ~50 uL/sec for all reagents with flow restrictor). The time to completely push out Oxidizer was observed, the timing for chemical flow times was adjusted accordingly and an extra ACN wash was introduced between different chemicals. After polynucleotide synthesis, the chip was deprotected in gaseous ammonia overnight at 75 psi. Five drops of water were applied to the surface to recover polynucleotides. The recovered polynucleotides were then analyzed on a BioAnalyzer small RNA chip.

Example 3: Synthesis of a 100-mer Sequence on an Oligonucleotide Synthesis Device

The same process as described in Example 2 for the synthesis of the 50-mer sequence was used for the synthesis of a 100-mer polynucleotide (“100-mer polynucleotide”; 5' CGGGATCCTTATCGTCATCGTCGTACA- 25 GATCCCACCCATTGCTGTCACCAGTCATG CTAGCCATACCATGATGATGATGATGAT- GAGAACCCCGCAT ##TTTTTTTTT3', where #denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes); SEQ ID NO.: 1349) on two different silicon chips, the first one uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXY-BUTYRAMIDE and the second one functionalized with 5/95 mix of 11-acetoxyundecyltriethoxysilane and n-decyltriethoxysilane, and the polynucleotides extracted from the surface were analyzed on a BioAnalyzer instrument.

All ten samples from the two chips were further PCR amplified using a forward (5'ATGCAGGGTTCTCAT-CATC3'; SEQ ID NO.: 1350) and a reverse (5'CGG-GATCCTTATCGTCATCG3'; SEQ ID NO.: 1351) primer in a 50 uL PCR mix (25 uL NEB Q5 mastermix, 2.5 uL 10 uM Forward primer, 2.5 uL 10 uM Reverse primer, 1 uL polynucleotide extracted from the surface, and water up to 50 uL) using the following thermal cycling program:

40 98° C., 30 sec
45 98° C., 10 sec; 63° C., 10 sec; 72° C., 10 sec; repeat 12 cycles
72° C., 2 min

50 The PCR products were also run on a BioAnalyzer, demonstrating sharp peaks at the 100-mer position. Next, the PCR amplified samples were cloned, and Sanger sequenced. Table 4 summarizes the results from the Sanger sequencing for samples taken from spots 1-5 from chip 1 and for samples taken from spots 6-10 from chip 2.

TABLE 4

Sequencing results			
	Spot	Error rate	Cycle efficiency
60	1	1/763 bp	99.87%
	2	1/824 bp	99.88%
	3	1/780 bp	99.87%
	4	1/429 bp	99.77%
	5	1/1525 bp	99.93%
	6	1/1615 bp	99.94%
	7	1/531 bp	99.81%

51

TABLE 4-continued

Sequencing results		
Spot	Error rate	Cycle efficiency
8	1/1769 bp	99.94%
9	1/854 bp	99.88%
10	1/1451 bp	99.93%

Thus, the high quality and uniformity of the synthesized polynucleotides were repeated on two chips with different surface chemistries. Overall, 89% of the 100-mers that were sequenced were perfect sequences with no errors, corresponding to 233 out of 262.

Table 5 summarizes error characteristics for the sequences obtained from the polynucleotide samples from spots 1-10.

52

cloned into pCDNA3.1 (+) vector (ThermoFisher) was transfected into suspension Chinese Hamster Ovary (CHO) cells to generate the stable cell line expressing GLP-1R. Target expression was confirmed by FACS. Cells expressing >80% of GLP-1R by GFP were then directly used for cell-based selections.

Germline heavy chain IGHV1-69, IGHV3-30 and germline light chain IGKV1-39, IGKV3-15, IGLV1-51, IGL V2-14 framework combinations were used in the GPCR-focused phage-displayed library, and all six CDR diversities were encoded by oligo pools synthesized similar to Examples 1-3 above. The CDRs were also screened to ensure they did not contain manufacturability liabilities, cryptic splice sites, or commonly used nucleotide restriction sites. The heavy chain variable region (VH) and light chain variable region (VL) were linked by (G4S)3 linker (SEQ ID

TABLE 5

Error characteristics											
Sample ID/Spot no.	OSA_0046/1	OSA_0047/2	OSA_0048/3	OSA_0049/4	OSA_0050/5	OSA_0051/6	OSA_0052/7	OSA_0053/8	OSA_0054/9	OSA_0055/10	
Total Sequences	32	32	32	32	32	32	32	32	32	32	32
Sequencing Quality	25 of 28	27 of 27	26 of 30	21 of 23	25 of 26	29 of 30	27 of 31	29 of 31	28 of 29	25 of 28	
Oligo Quality	23 of 25	25 of 27	22 of 26	18 of 21	24 of 25	25 of 29	22 of 27	28 of 29	26 of 28	20 of 25	
ROI Match Count	2500	2698	2561	2122	2499	2666	2625	2899	2798	2348	
ROI Mutation	2	2	1	3	1	0	2	1	2	1	
ROI Multi Base Deletion	0	0	0	0	0	0	0	0	0	0	
ROI Small Insertion	1	0	0	0	0	0	0	0	0	0	
ROI Single Base Deletion	0	0	0	0	0	0	0	0	0	0	
Large Deletion Count	0	0	1	0	0	1	1	0	0	0	
Mutation: G > A	2	2	1	2	1	0	2	1	2	1	
Mutation: T > C	0	0	0	1	0	0	0	0	0	0	
ROI Error Count	3	2	2	3	1	1	3	1	2	1	
ROI Error Rate	Err:~1 in 834	Err:~1 in 1350	Err:~1 in 1282	Err:~1 in 708	Err:~1 in 2500	Err:~1 in 2667	Err:~1 in 876	Err:~1 in 2900	Err:~1 in 1400	Err:~1 in 2349	
ROI Minus Primer Error Rate	MP Err: ~1 in 763	MP Err: ~1 in 824	MP Err: ~1 in 780	MP Err: ~1 in 429	MP Err: ~1 in 1525	MP Err: ~1 in 1615	MP Err: ~1 in 531	MP Err: ~1 in 1769	MP Err: ~1 in 854	MP Err: ~1 in 1451	

Example 4: Functional GLP-1R Antibodies Identified from a Synthetic GPCR-Focused Library Demonstrate Potent Blood Glucose Control

This example describes the identification of antagonistic and agonistic GLP-1R antibodies with *in vitro* and *in vivo* functional activity.

Materials and Method

Stable Cell Line and Phage Library Generation

The full length human GLP-1R gene (UniProt-P43220) with an N-terminal FLAG tag and C-terminal GFP tag

⁵⁵ NO: 1520). The resulting scFv (VH-linker-VL) gene library was cloned into a pADL 22-2c (Antibody Design Labs) phage display vector by NotI restriction digestion and electroporated into TG1 electro-competent *E. coli* cells. (Lucigen). The final library has a diversity of 1.1×10^{10} size, which
⁶⁰ was verified by NGS.

Panning and Screening Strategy Used to Isolate Agonist GLP-1R scFv Clones

Before panning on GLP-1R expressing CHO cells, phage particles were blocked with 5% BSA/PBS and depleted for non-specific binders on CHO parent cells. For CHO parent cell depletion, the input phage aliquot was rotated at 14 rpm/min with 1×10^8 CHO parent cells for 1 hour at room

temperature (RT). The cells were then pelleted by centrifuging at 1,200 rpm for 10 mins in a tabletop Eppendorf centrifuge 5920RS/4×1000 rotor to deplete the non-specific CHO cell binders. The phage supernatant, depleted of CHO cell binders, was then transferred to 1×10^8 GLP-1R expressing CHO cells. The phage supernatant and GLP-1R expressing CHO cells were rotated at 14 rpm/min for 1 hour at RT to select for GLP-1R binders. After incubation, the cells were washed several times with 1×PBS/0.5% Tween to remove non-binding clones. To elute the phage bound to the GLP-1R cells, the cells were incubated with trypsin in PBS buffer for 30 minutes at 37° C. The cells were pelleted by centrifuging at 1,200 rpm for 10 mins. The output supernatant enriched in GLP-1R binding clones was amplified in TG1 *E. coli* cells to use as input phage for the next round of selection. This selection strategy was repeated for five rounds. Every round was depleted against the CHO parent background. Amplified output phage from a round was used as the input phage for the subsequent round, and the stringency of washes were increased in each subsequent round of selections with more washes. After five rounds of selection, 500 clones from each of round 4 and round 5 were Sanger sequenced to identify unique clones.

Next-Generation Sequencing Analysis

The phagemid DNA was miniprepped from the output bacterial stocks of all panning rounds. The variable heavy chain (VH) was PCR amplified from the phagemid DNA using the Forward Primer ACAGAATTCTTAAAGAG-GAGAAATTAACC (SEQ ID NO: 1521) and reverse primer TGAACCGCCTCCACCGCTAG (SEQ ID NO: 1522). The PCR product was directly used for library preparation using the KAPA HyperPlus Library Preparation Kit (Kapa Biosystems, product #KK8514). To add diversity in the library, the samples were spiked with 15% PhiX Control purchased from Illumina, Inc. (product #FC-110-3001). The library was then loaded onto Illumina's 600 cycle MiSeqR Reagent Kit v3 (Illumina, product #MS-102-3003) and run on the MiSeqR instrument.

Reformatting and High Throughput (HT) IgG Purification

Expi293 cells were transfected using ExpiFectamine (ThermoFisher, A14524) with the heavy chain and light chain DNA at a 2:1 ratio and supernatants were harvested 4 days post-transfection before cell viability dropped below 80%. Purifications were undertaken using either King Fisher (ThermoFisher) with protein A magnetic beads or Phynexus protein A column tips (Hamilton). For large scale production of IgG clones that were evaluated in *in vivo* mouse studies, an Akta HPLC purification system (GE) was used.

IgG characterization and quality control. The purified IgGs for the positive GLP-1R binders (hits) were subjected to characterization for their purity by LabChip GXII Touch HT Protein Express high-sensitivity assay. Dithiothreitol (DTT) was used to reduce the IgG into VH and VL. IgG concentrations were measured using Lunatic (UnChain). IgG for *in vivo* mouse studies were further characterized by HPLC and tested for endotoxin levels (Endosafe® nexgen-PTST™ Endotoxin Testing, Charles River), with less than 5 EU per kg dosing.

Binding Assays and Flow Cytometry

GLP-1R IgG clones were tested in a binding assay coupled to flow cytometry analysis as follows: FLAG-GLP-1R-GFP expressing CHO cells (CHO-GLP-1R) and CHO-parent cells were incubated with 100 nM IgG for 1 h on ice, washed three times and incubated with Alexa 647 conjugated goat-anti-human antibody (1:200) (Jackson ImmunoResearch Laboratories, 109-605-044) for 30 min on ice, followed by three washes, centrifuging to pellet the cells

between each washing step. All incubations and washes were in buffer containing PBS+1% BSA. For titrations, IgG was serially diluted 1:3 starting from 100 nM down to 0.046 nM. Cells were analyzed by flow cytometry and hits (a hit is an IgG that specifically binds to CHO-GLP-1R) were identified by measuring the GFP signal against the Alexa 647 signal. Flow cytometry data of binding assays with 100 nM IgG are presented as dot plots. Analyses of binding assays with IgG titrations are presented as binding curves plotting IgG concentrations against MFI (mean fluorescence intensity).

Ligand Competition Assay

Ligand competition assays involved co-incubating the primary IgG with 1 μM GLP-1 (7-36). For each data point, IgG (600 nM) was prepared in Flow buffer (PBS+1% BSA) and diluted 1:3 down for 8 titration points. Peptide GLP-1 7-36 (2 μM) was prepared similarly with the Flow buffer (PBS+1% BSA). Each well contained 100,000 cells to which 50 μL of IgG and 50 μL of peptide (=plus) or buffer alone without peptide (=minus) were added. Cells and IgG/peptide mix were incubated for 1 hr on ice, and after washing, secondary antibody (goat anti-human APC, Jackson ImmunoResearch Laboratories, product #109-605-044) diluted 1:200 in PBS+1% BSA was added. This was incubated on ice for 30 mins (50 μL per well), before washing and resuspending in 60 μL buffer. Finally, the assay read-out was measured on an Intellicyt® iQue3 Screener at a rate of 4 seconds per well.

Cell-Based Functional Assays

cAMP assays. GLP-1R IgG clones were tested for their potential effects on GLP-1R signaling by performing cAMP assays obtained from Eurofins DiscoverXX. The technology involved in detecting cAMP levels is a no wash gain-of-signal competitive immunoassay based on Enzyme Fragment Complementation technology. Experiments were designed to test for either agonist or antagonist activity of the IgG clones. To test for agonist activity of the IgGs, cells were stimulated with IgG incubating for 30 min at 37° C. (titrations 1:3 starting from 100 nM and diluting down to 0.046 nM with PBS) or with the known agonist GLP-1 7-36 peptide (MedChemExpress, Cat. No.: HY-P005), titrated 1:6 starting from 12.5 nM and diluting down to 0.003 nM with PBS. To test for antagonist activity, cells were incubated with IgG at a fixed concentration of 100 nM for 1 h at room temperature to allow binding, followed by stimulation with GLP1 7-36 peptide (titrations 1:6 starting from 12.5 nM down to 0.003 nM in PBS) for 30 min at 37° C. Intracellular CAMP levels were detected by following the assay kit instructions.

Beta arrestin recruitment assay. β-arrestin recruitment assay was obtained from Eurofins DiscoverXX (Cat #93-0300E2) that utilized untagged GLP-1R overexpressing CHO-K1 cells. The experiment is to test if GLP1R-3 has an effect on GLP-1 7-36 agonist induced β-arrestin recruitment upon GLP-1R activation. Expanded cells were seeded into 96 well plates at 5,000 cells/well, and the experiment was performed 48 hours after plating cells. 100 nM IgG was pre-incubated for 1 hour at RT with plated cells in 50 ul volume, and then 5 ul of ligand GLP-1 7-36 was added for a further incubation for 30 min at 37° C. Add 22.5 uL of detection solution to each well, tap gently and briefly spin down. Then incubate plates at RT for 1 hour in the dark. The plates were then read by a Chemiluminescence plate reader, Molecular Devices SpectraMax® M5, and output relative light units (RLU) data were analyzed using GraphPad Prism™.

In Vivo Studies

Animals. All animal procedures were approved by Institutional Animal Care and Use Committee (IACUC) at the University of California San Francisco and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of laboratory Animals. C57BL/6NHsd (Envigo RMS, LLC) male littermates at 8-10 weeks of age, weighing ~20-28 grams, were used in all the studies described. The mice were housed in a room that was temperature (22-25 °C) and light controlled (12-h: 12-h light/dark cycle starting at 7 AM. The mice were fed with chow diet with 9% fat (PicoLab mouse Diet 20 (#5058), Lab Supply, Fortworth Texas, USA) for the duration of housing at the UCSF animal care facility.

Monoclonal Antibodies and Reagents. Anti-GLP-1 monoclonal antibodies (mAb) in PBS buffer were tested in these studies an agonist mAb, GLP1R-59-2 and one antagonist mAb, GLP1R-3. Mice were dosed prior to a Glucose Tolerance Test (GTT) or an Insulin Tolerance test (ITT) using the following regimen: Agonist GLP1R-59-2 mAb was dosed at 5 or 10 mg/kg at three different administration regimen groups prior to performing a GTT and with four different administration regimen groups in an Insulin Tolerance test (ITT). 1. mAb administered as a single dose, 15 hours prior to GTT and 21 hours prior to ITT. 2. mAb administered as a double dose, 15 hours prior to GTT and 21 hours prior to ITT plus a second mAb dose 2 hours prior to GTT and ITT. 3. mAb single dose 2 hours prior to GTT and ITT. 4. mAb single dose 6 hours prior to ITT only.

Antagonist GLP1R-3 mAb was dosed at 20 mg/kg at four different administration regimen groups. 1. mAb administered as a single dose, 15 hours prior to GTT and 21 hours prior to ITT. 2. mAb administered as a double dose, 15 hours prior to GTT and 21 hours prior to ITT plus a second mAb dose 2 hours prior to GTT and ITT. 3. mAb as a single dose 6 hours prior to GTT and ITT. 4. mAb single dose 2 hours prior to GTT and ITT.

Extendin 9-39 Peptide (MedChemExpress, Cat. No.: HY-P0264) were dosed at 1.0 or 0.23 mg/kg at three different administration regimen groups. 1. Extendin administered as a single dose, 21 hours prior to ITT. 2. Extendin administered as a double dose, 21 hours prior to ITT plus a second Extendin dose 2 hours prior to ITT. 3. mAb as a single dose 6 hours prior to ITT.

Glucose Tolerance Test

A Glucose Tolerance Test (GTT) was used to assess two different anti-GLP1 mAbs (Agonist and Antagonist) effect on glucose tolerance following an acute glucose administration. Intraperitoneal Glucose Tolerance Test (IP-GTT) was conducted in 8 or 10-week old male mice to assess glucose disposal after a glucose injection and measuring blood glucose level after mice were fasted overnight (14-16 hours). To avoid circadian variations in mouse blood glucose levels this testing was performed at fixed times. Mice were weighed after the overnight fast and baseline blood glucose levels (pre-glucose injection; Time 0 minutes) were measured. Mice were injected, i.p., with a single bolus (10 μ l/gram body weight) of 30% Dextrose solution (Hospira, Illinois) and blood glucose levels were measured at 15, 30, 60, 120 and 180-minutes post glucose administration. Blood samples were obtained by a tail nick and blood glucose levels were monitored using a OneTouch Ultra 2 glucose monitor (LifeScan, Inc.)

Insulin Tolerance Test

An Insulin Tolerance Test (ITT) was conducted to assess two different anti-GLP1 mAbs (agonist and antagonist) effect on insulin sensitivity following acute insulin admin-

istration. 8 or 10-week old male mice were fasted for 6 hours and body weight was recorded before and after fasting. To avoid circadian variations in mouse blood glucose levels this testing was performed at fixed times. Blood samples were collected by tail nick and baseline glucose was measured prior to insulin injection. Mice were injected, i.p., with a single bolus (0.75 U/Kg body weight) of human insulin (Novolin, Novo Nordisk) and blood glucose levels were measured at 15, 30, 45, 60 and 120 minutes after insulin injection. Blood glucose levels were monitored using a OneTouch Ultra 2 glucose monitor (LifeScan, Inc.).

ELISA for Pharmacokinetic (PK) Studies

The rat PK study was done at Charles River Laboratories, One Innovation Dr, 3 Biotech, Worcester, MA 01605. 5 Male Sprague-Dawley rats per group were allowed to acclimate after receiving at test facility for a minimum of 3 days before dosing. GLP1R-3 and GLP1R59-2 were dosed at 10 mg/kg by IV in 100 mM Hepes, 100 mM NaCl, 50 mM NaAc, pH 6.0 vehicle. Serial blood samples were collected via jugular vein cannula with ~250 μ l volume at each time point: pre-dose, 0.0833, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 168, 240 and 336 hours post dose. Blood samples were collected into K₂EDTA tubes and stored on wet ice until processed to plasma by centrifugation (3500 rpm for 10 minutes at 5° C.) within 30 minutes of collection. Plasma samples were then transferred into an appropriate tube containing DPP-4 (3.3 μ L for 100 μ L of plasma) and frozen on dry ice. To measure the human IgG in rat plasma samples, sheep anti-Human IgG (1 mg/mL) was used as coating reagent (The binding site, Lot No. AU003.M), and goat anti-Human IgG, HRP (H&L) (1 mg/mL) was used as detection reagent (Bethyl, cat #A80-319P) in an ELISA assay. Stock solutions of human IgG standards and QCs were prepared by spiking human IgG into rat plasma. A minimum of two wells were used to analyze each study samples, QC's, standards, and blank. A 4-parameter logistic (4PL) model was used to fit the sigmoid calibration curve. The semi-logarithmic sigmoid calibration curve was obtained by plotting the absorbance response against concentration. Concentrations of analyte in the test samples were determined by computer interpolation from the plot of the calibration curve.

Results

Design of GPCR-Focused Antibody Library is Based on GPCR Binding Motifs and GPCR Antibodies

All known GPCR interactions, which include interactions of GPCRs with ligands, peptides, antibodies, endogenous extracellular loops and small molecules were analyzed to map the GPCR binding molecular determinants. Crystal structures of almost 150 peptides, ligand or antibodies bound to ECDs of around 50 GPCRs (gpcrdb.org) were used to identify GPCR binding motifs. Over 1000 GPCR binding motifs were extracted from this analysis. In addition, by analysis of all solved structures of GPCRs (Zhang Lab at University of Michigan), over 2000 binding motifs from endogenous extracellular loops of GPCRs were identified. Finally, by analysis of structures of over 100 small molecule ligands bound to GPCR, a reduced amino acid library of 5 amino acids (Tyr, Phe, His, Pro and Gly) that may be able to recapitulate many of the structural contacts of these ligands was identified. A sub-library with this reduced amino acid diversity was placed within a CxxxxxC motif. In total, over 5000 GPCR binding motifs were identified (FIGS. 9A-9E). These binding motifs were placed in one of five different stem regions:

CARDLRELECEE-
WTxxxxxSRGPCVDPRGVAGSFDVW (SEQ ID NO:
1523),
CARDMYYDFxxxxEVVPADDAFDIW (SEQ ID NO:
1524),
CARDGRGSLPRPKGGPxxxxYDSSEDSGGAFDIW
(SEQ ID NO: 1525),
CARANQHFxxxxGYHYYGMDVW (SEQ ID NO:
1526),
CAKHMMSMQxxxxRADL VGDAFDVW (SEQ ID NO:
1527).

These stem regions were selected from structural antibodies with ultra-long HCDR3s. Antibody germlines were specifically chosen to tolerate these ultra-long HCDR3s. Structure and sequence analysis of human antibodies with longer than 21 amino acids revealed a V-gene bias in antibodies with long CDR3s. Finally, the germline IGHV (IGHV1-69 and IGHV3-30), IGKV (IGKV1-39 and IGKV3-15) and IGLV (IGLV1-51 and IGLV2-14) genes were chosen based on this analysis.

In addition to HCDR3 diversity, limited diversity was also introduced in the other 5 CDRs. There were 416 HCDR1 and 258 HCDR2 variants in the IGHV1-69 domain; 535 HCDR1 and 416 HCDR2 variants in the IGHV3-30 domain; 490 LCDR1, 420 LCDR2 and 824 LCDR3 variants in the IGKV1-39 domain; 490 LCDR1, 265 LCDR2 and 907 LCDR3 variants in the IGKV3-15 domain; 184 LCDR1, 151 LCDR2 and 824 LCDR3 variants in the IGLV1-51 domain; 967 LCDR1, 535 LCDR2 and 922 LCDR3 variants in the IGL V2-14 domain (FIG. 10). These CDR variants were selected by comparing the germline CDRs with the near-germline space of single, double and triple mutations observed in the CDRs within the V-gene repertoire of at least two out of 12 human donors. All CDRs have been pre-screened to remove manufacturability liabilities, cryptic splice sites or nucleotide restriction sites. The CDRs were synthesized as an oligo pool and incorporated into the selected antibody scaffolds. The heavy chain (VH) and light chain (VL) genes were linked by (G4S) 3 linker (SEQ ID NO: 1520). The resulting scFv (VH-linker-VL) gene pool was cloned into a phagemid display vector at the N-terminal of the M13 gene-3 minor coat protein. The final size of the GPCR library is 1×10^{10} in a scFv format. Next-generation sequencing (NGS) was performed on the final phage library to analyze the HCDR3 length distribution in the library for comparison with the HCDR3 length distribution in B-cell populations from three healthy adult donors. The HCDR3 sequences from the three healthy donors used were derived from a publicly available database with over 37 million B-cell receptor sequences³¹. The HCDR3 length in the GPCR library is much longer than the HCDR3 length observed in B-cell repertoire sequences. On average, the median HCDR3 length in the GPCR library (which shows a biphasic pattern of distribution) is two or three times longer (33 to 44 amino acids) than the median lengths observed in natural B-cell repertoire sequences (15 to 17 amino acids) (FIG. 11). The biphasic length distribution of HCDR3 in the GPCR library is mainly caused by the two groups of stems (8aa, 9aaxxxx10aa, 12aa) and (14aa, 16aa xxxx 18aa, 14aa) used to present the motifs within HCDR3.

Phage Panning Against GLP-1R Over-Expressing Cell Lines Resulted in Clonal Enrichment

A GLP-1R over-expressing CHO stable cell line was created with a FLAG tag presented on the N-terminus of the receptor in order to detect cell surface expression and an EGFP tag on the C-terminus to track total receptor expression. Flow cytometry analysis of these cells confirmed that

the majority of the receptor (>80%) was expressed at the cell surface (FIG. 12A). These GLP-1R-expressing CHO cells were used for five rounds of phage panning against the GPCR-focused library. The selection scheme is outlined in FIG. 12B. The variable heavy chain (VH) from the output of each panning round was PCR amplified and sequenced by MiSeq®. As the percent unique HCDR3 decreases in each round output pool NGS sequencing, significant clonal enrichment was observed from round 1 to round 5 (FIG. 13), indicating a target specific clonal selection in the panning process. Approx. 1000 clones in total (from round 4 and round 5) were picked for single clonal NGS sequencing and ~100 unique VH-VL pairs were selected to be reformatted and expressed as full length human IgG2 at 1 ml scale.

IgG Binders Directed to GLP-1R Contain Either GLP-1, GLP-2 or Unique HCDR3 Motifs Identified

Purified IgG clones were tested for specific binding to GLP-1R-expressing CHO cells. A single-point flow cytometry analysis using 100 nM of IgG concentration revealed that out of 100 IgG unique clones tested, 13 IgG clones bound specifically to GLP-1R-positive cells (GFP+) and not parental CHO cells (GFP-). The binding of these 13 hits was then further evaluated by 8-point titrations of each IgG clone starting from 200 nM (30 µg/mL) and the cell binding affinities were determined to be in the double-digit nM range. The average CHO parental cell background binding by all 13 IgG clones is shown as a black line and is minimal compared with specific binding to GLP-1R-expressing cells (FIG. 14). Full saturation was not observed, the plateau of the binding curve at the highest concentration, 200 nM used in the experiment. FIG. 15 shows the HCDR3 amino acid sequences of these 13 IgG clones. Six of these were found to include a GLP-1 motif, four included a GLP-2 motif, and three had unknown motif.

Eight IgGs of the 13 Binders are Negative Antagonists in GLP-1R Mediated cAMP Signaling

The 13 IgG binders were next assessed for their functional activity in the cAMP signaling pathway by using GLP-1R over-expressing CHO-K1 cells purchased from DiscoverX that are designed and validated for assessing GLP-1R-induced cAMP signaling. In the first instance, the IgG clones were tested for agonist activity as compared with the peptide agonist GLP-1 7-36 in dose titrations. While GLP-1 7-36 stimulation resulted in a cAMP signal, none was observed for the IgG clones, indicating that they are not activating. Subsequently, the panel of IgG clones were tested for antagonist activity by pre-incubating GLP-1R-expressing cells with a fixed concentration of IgG to allow binding to occur and then stimulating the cells with GLP-1 7-36 in a dose dependent manner. This allowed examination of the impact of the presence of IgG on GLP-1 7-36-induced GLP-1R cAMP signaling, thereby potentially revealing any potential competitive effects of the IgG. It was observed that the GLP-1 7-36 dose response curve shifted to the right in the presence of 8 out of the 13 IgG clones, suggesting that they act as negative antagonists of the GLP-1 7-36 response (data not shown). Similar observations were made regarding the effect of the 13 IgG clones on Exendin-4 induced GLP-1R cAMP signaling response (data not shown). The remaining five IgG clones appeared to have no significant effects on GLP-1R cAMP signaling (data not shown).

Characterization of Mechanisms of Action of the Antagonist IgG GLP1R-3

To determine the mechanism of action of these resulting functional hits, subsequent studies focused one of the GLP-1 motif-containing IgG clones that demonstrated high binding affinity, as well as functionality: GLP1R-3. Ligand compe-

tition binding assays, the IgG effects on the GLP-1 dose response in cAMP signaling, and beta-arrestin recruitment assays were conducted, resulting in characterization of GLP1R-3 as follows:

Competition with the endogenous ligand in GLP-1R binding assays. To determine if GLP1R-3 binds to the orthosteric site on the receptor, N-terminal FLAG-tagged and C terminal GFP-tagged GLP-1R over-expressing CHO cells were incubated with a dose titration of GLP1R-3 starting at 100 nM in the presence or absence of a fixed concentration of the peptide agonist GLP-1 7-36 (1 μ M). Flow cytometry analysis revealed significantly reduced binding of GLP1R-3 to GLP-1R (GFP+) in the presence of GLP-1 7-36. Whilst the presence of GLP-1 7-36 peptide does not completely ablate GLP1R-3 binding, this observation suggests that the antibody may bind to an overlapping epitope, or GLP1R-3 have stronger binding affinity for GLP-1 7-36 to compete for binding. (FIG. 16A).

GLP1R-3 antagonizes GLP-1 activated cAMP signaling. The next step was to determine if GLP1R-3 exhibits competitive antagonism for GLP-1R in a dose-dependent manner. GLP-1 7-36-induced cAMP signaling was examined in the presence of a constant concentration (100 nM) of GLP1R-3 with a dose titration of GLP-1 7-36 starting at 20 nM with a 3-fold down titration, and a clear dose-dependent inhibition of the cAMP signal was observed. The EC50 for GLP-1 7-36 peptide is 0.025 nM without presence of GLP1R-3, and 0.11 nM in the presence of 100 nM GLP1R-3 (FIG. 16B), supporting that GLP1R-3 is a competitive antagonist.

GLP1R-3 reduces β -arrestin recruitment upon GLP-1R activation. When a GPCR is activated by an agonist, β -arrestins are recruited to the GPCR from the cytosol, thereby excluding the receptor from further G protein interactions and leading to signal arrest, hence the name "arrestin". To determine if GLP1R-3 had any effects on β -arrestin recruitment by activated GLP-1R, GLP-1R over-expressing CHO-K1 cells (DiscoverX) that are specifically designed and validated for assessing GLP-1R β -arrestin recruitment were employed in the following manner. Cells were pre-incubated with a fixed concentration of GLP1R-3 (100 nM) for 1 hr at room temperature to allow binding to occur and then stimulated with GLP-1 7-36. GLP1R-3, showed inhibition of GLP-1 7-36 peptide-induced beta arrestin recruitment to GLP-1R as evidenced by the right shift of GLP-1 7-36 dose response curve for β -arrestin recruitment (FIG. 16C). This indicated that GLP1R-3 reduces β -arrestin recruitment to GLP-1R, which is consistent with the observed reduced receptor activation. Thus, these cell-based assays indicate that GLP1R-3 is a competitive antagonist to GLP-1 7-36 for GLP-1R.

Design and Characterization of a GLP-1R Agonist IgG GLP1R-59-2

Since none of the 13 IgG hits showed any agonist activity, a GLP-1R agonist antibody (GLP1R-59-2) by linking the native GLP-1 7-36 peptide to the light chain N-terminal of a functionally inactive but GLP-1R-specific binder GLP1R-2 (FIG. 17) was engineered. GLP-1R binding assays, cAMP assays, and β -arrestin recruitment assays were conducted, resulting in characterization of GLP1R-59-2 as described here:

GLP1R-59-2 specifically binds to GLP-1R-expressing CHO cells. Flow cytometry analysis revealed that GLP1R-59-2 bound specifically to GLP-1R-positive cells (GFP+) and not parental CHO cells (GFP-), specific binding was also confirmed by GLP1R-59-2 dose titrations producing an apparent binding EC₅₀ of 15.5 nM (FIG. 18A).

GLP1R-59-2 induces a GLP-1R CAMP response similar to GLP-1 7-36. GLP1R-59-2 was tested for agonist activity as compared with GLP-1 7-36 for stimulating GLP-1R over-expressing CHO-K1 cells (DiscoverX) with separate dose titration analyses conducted for both ligand and antibody. It was found that both induced similar cAMP signaling profile and their dose response curves had almost overlapping EC50 values, 0.042 nM for GLP1R-59-2 and 0.085 nM for GLP-1 7-36. (FIG. 18B) supporting the hypothesis that GLP1R-59-2 can act as an effective agonist for GLP-1R.

GLP1R-59-2 is less efficacious for β -arrestin recruitment to GLP-1R than GLP-1 7-36. To determine if GLP1R-59-2 was able to induce a similar level of β -arrestin recruitment to GLP-1R as GLP-1 7-36, GLP-1R over-expressing CHO-K1 cells (DiscoverX) were stimulated with dose titrations of each. It was found that less β -arrestin recruitment occurred with GLP1R-59-2 stimulation than with GLP-1 7-36 stimulation (FIG. 18C). Whilst GLP1R-59-2 is less efficacious than GLP-1 7-36 for the maximal β -arrestin recruitment, it would appear that the agonist IgG is slightly more potent with an EC50 of 0.042 nM, and 0.085 nM for GLP-1 7-36, respectively.

In Vivo PK and PD Testing of GLP1R-3 and GLP1R-59-2

Endogenous GLP-1 peptide has a very short serum half-life of only a few minutes, however GLP-1R antibodies can have significantly longer half-lives. This can be a considerable advantage over the current GLP-1 peptide analog therapeutics. An in vivo PK rat study was performed to evaluate the half-life of the antagonist GLP1R-3 and agonist GLP1R-59-2 in IgG format. In a 2-week PK study, GLP1R-3 exhibited an antibody-like in vivo half-life of ~1-week in rats, while the agonist GLP-1 peptide-antibody fusion, GLP1R-59-2 exhibited >2-day half-life in rats (FIGS. 19A-19B). Liraglutide, the approved GLP-1R agonist for the treatment of Type II diabetes has a 13-hour half-life.

Agonist GLP1R-59-2 was tested for its in vivo pharmacodynamic (PD) effects in Glucose tolerance test (GTT) using wild-type C57BL/6NHsd mouse model, in comparison with the vehicle control. Agonist mAb GLP1R-59-2 treatment, either dose (5 mg/kg and 10 mg/kg) or dosing regimen (2 hrs, 13+2 hrs, and 15 hrs before glucose challenge), significantly stabilized blood glucose even after a glucose challenge (FIG. 20A). Compared to control mice, GLP1R-59-2 treatments are all significant ($p<0.001$) at reducing Area Under the Curve (AUC) in an GTT (FIG. 20B). However, there is no significant difference between each individual treatment timing or dose.

Antagonist, GLP1R-3 mAb and GLP-1 peptide Exendin 9-39 treatment, with 19+2 hours dosing regimen before insulin challenge, significantly stabilizes a higher blood glucose in wild-type C57BL/6NHsd mice (FIG. 21A). Compared to control mice, GLP1R-3 mAb (20 mg/kg) and Exendin (1 mg/kg) treatments are both significant ($p<0.0001$) at stabilizing Area Under the Curve (AUC) in an ITT (FIG. 21B). However, there is no significant difference between GLP1R-3 and Control vs. Exendin (0.23 mg/kg) with 19+2 hour treatment.

Another experiment using a single 6 hour dosing regimen, antagonist, GLP1R-3 mAb treatment also significantly stabilizes a higher blood glucose after an insulin challenge compared to GLP-1 peptide Exendin 9-39 (1.0 or 0.23 mg/kg dose) or control (FIG. 22A). Compared to control mice, GLP1R-3 mAb (20 mg/kg) treatment at 6 hours significantly ($p<0.05$) stabilizes Area Under the Curve (AUC) in an ITT. However, there is no significant difference between Control vs. Exendin (1.0 and 0.23 mg/kg) with the single 6 hour treatment (FIG. 22B).

GLP1R-3 mAb treatment was also compared to a comparator antibody GLP1R-226-1 and GLP1R-226-2. GLP1R-3 mAb treatment in a single 6 hour dosing regimen significantly stabilized a higher blood glucose after an insulin challenge (at time 0) compared to GLP1R-226-1 (20 mg/kg) or control (FIGS. 23A-23B). Compared to control mice, GLP1R-3 mAb (20 mg/kg) treatment at 6 hours, significantly ($p<0.05$) stabilized Area Under the Curve (AUC) in an ITT. There was no significant difference ($p<0.05$) between control vs. GLP1R-226-1 or GLP1R-226-2 with a single 6 hour treatment.

TABLE 6B-continued

IgG	MFI Ratio	Subtraction
GLP1R-222-081	850.1807692	220787
GLP1R-222-056	946.2456522	217406.5

Example 5: GLP1R Variants

GLP1R-3 was optimized to generate additional GLP1R variants.

The panning strategy for GLP1R-221 and GLP1R-222 variants is seen in FIGS. 24A-24B. 768 clones from Round 4 and Round 5 were picked and sequenced on Miseq®. 95 unique clones were reformatted. Data for GLP1R-221 and GLP1R-222 variants is seen in Tables 6A-6H. Sequences for the GLP1R-221 and GLP1R-222 variants are seen in Tables 9-13.

TABLE 6A

IgG	MFI Ratio	Subtraction
GLP1R-3	993.31197	232201
GLP1R-221-065	914.54027	272235
GLP1R-221-075	1174.8495	241813
GLP1R-221-017	1484.8457	240383
GLP1R-221-033	1015.9153	239520
GLP1R-221-076	746.61867	235615.5
GLP1R-221-092	711.73926	231701
GLP1R-221-034	711.15764	222989.5
GLP1R-221-066	927.53542	222368.5
GLP1R-221-084	1067.8986	220848
GLP1R-221-009	1119.868	220417

TABLE 6B

IgG	MFI Ratio	Subtraction
GLP1R-3	740.2	223614
GLP1R-222-052	13.70825851	350309.5
GLP1R-222-016	773.9745223	242714
GLP1R-222-023	777.8080645	240810.5
GLP1R-222-014	794.2474916	237181
GLP1R-222-090	525.349537	226519
GLP1R-222-073	983.9519651	225096
GLP1R-222-012	774.5748709	224723.5
GLP1R-222-082	711.0952381	223680

TABLE 6C

15	Sample	Median RL1-H of Expressing Singlets	Median RL1-H of Parent Singlets	MFI Ratio
20	GLP1R221-017	240545	162	1484.8
20	GLP1R221-075	242019	206	1174.8
20	GLP1R221-009	220614	197	1119.9
20	GLP1R221-084	221055	207	1067.9
20	GLP1R221-044	217533.5	209	1040.8
20	GLP1R221-033	239756	236	1015.9
20	GLP1R01-3	232435	234	993.3
20	GLP1R221-014	200638	203	988.4
20	GLP1R221-083	212185	215	986.9
20	GLP1R221-043	195703	201	973.6
20	GLP1R221-082	195548	202	968.1
20	GLP1R221-018	160183	167	959.2
20	GLP1R221-001	200655	213	942.0
20	GLP1R221-066	222608.5	240	927.5
20	GLP1R221-065	272533	298	914.5
20	GLP1R221-051	212862.5	234	909.7
20	GLP1R221-003	203683.5	226	901.3
25	GLP1R221-019	197108	224	879.9
25	GLP1R221-088	197424	225.5	875.5
25	GLP1R221-020	175621	205	856.7
25	GLP1R221-021	163480.5	192	851.5
25	GLP1R221-077	197424	236	836.5
25	GLP1R221-069	191848	230	834.1
25	GLP1R221-002	181529	219	828.9
25	GLP1R221-040	208274	251.5	828.1
25	GLP1R221-027	197258.5	241	818.5
25	GLP1R221-094	203152	253	803.0
25	GLP1R221-042	214005.5	268	798.5
25	GLP1R221-022	199293	252	790.8
25	GLP1R221-012	217522	283	768.6
25	GLP1R221-031	168691	221	763.3
25	GLP1R221-079	195512.5	257	760.7
25	GLP1R221-059	194935.5	257	758.5
25	GLP1R221-086	173390.5	229.5	755.5
25	GLP1R221-076	235931.5	316	746.6
25	GLP1R221-016	162165.5	220.5	735.4
25	GLP1R221-054	163917	224	731.8
25	GLP1R221-036	191269	264	724.5
25	GLP1R221-072	218347	303	720.6
25	GLP1R221-038	178492	248	719.7
25	GLP1R221-092	232027	326	711.7
25	GLP1R221-034	223303.5	314	711.2
30	GLP1R221-058	168846	240	703.5
30	GLP1R221-057	185403	268.5	690.5
30	GLP1R221-090	183560	268	684.9
30	GLP1R221-063	184038	274	671.7
30	GLP1R221-029	197088	305	646.2
30	GLP1R221-013	171640	266	645.3
30	GLP1R221-030	160279	251	638.6
30	GLP1R221-011	175641	283	620.6
30	GLP1R221-060	178266.5	290	614.7
30	GLP1R221-039	132161.5	219	603.5
30	GLP1R221-015	176341.5	293	601.8
30	GLP1R221-091	174624	295	591.9
30	GLP1R221-074	173151	295.5	586.0
30	GLP1R221-035	184526	315	585.8
30	GLP1R221-041	101875	174	585.5
30	GLP1R221-028	158490.5	271.5	583.8
30	GLP1R221-046	137324.5	236	581.9
30	GLP1R221-052	205979	370	556.7
30	GLP1R221-073	102371	205	499.4
30	GLP1R221-053	146049.5	301.5	484.4
30	GLP1R221-056	197814	409	483.7
40	GLP1R221-058	168846	240	703.5
40	GLP1R221-057	185403	268.5	690.5
40	GLP1R221-090	183560	268	684.9
40	GLP1R221-063	184038	274	671.7
40	GLP1R221-029	197088	305	646.2
40	GLP1R221-013	171640	266	645.3
40	GLP1R221-030	160279	251	638.6
40	GLP1R221-011	175641	283	620.6
40	GLP1R221-060	178266.5	290	614.7
40	GLP1R221-039	132161.5	219	603.5
40	GLP1R221-015	176341.5	293	601.8
40	GLP1R221-091	174624	295	591.9
40	GLP1R221-074	173151	295.5	586.0
40	GLP1R221-035	184526	315	585.8
40	GLP1R221-041	101875	174	585.5
40	GLP1R221-028	158490.5	271.5	583.8
40	GLP1R221-046	137324.5	236	581.9
40	GLP1R221-052	205979	370	556.7
40	GLP1R221-073	102371	205	499.4
40	GLP1R221-053	146049.5	301.5	484.4
40	GLP1R221-056	197814	409	483.7
50	GLP1R221-058	168846	240	703.5
50	GLP1R221-057	185403	268.5	690.5
50	GLP1R221-090	183560	268	684.9
50	GLP1R221-063	184038	274	671.7
50	GLP1R221-029	197088	305	646.2
50	GLP1R221-013	171640	266	645.3
50	GLP1R221-030	160279	251	638.6
50	GLP1R221-011	175641	283	620.6
50	GLP1R221-060	178266.5	290	614.7
50	GLP1R221-039	132161.5	219	603.5
50	GLP1R221-015	176341.5	293	601.8
50	GLP1R221-091	174624	295	591.9
50	GLP1R221-074	173151	295.5	586.0
50	GLP1R221-035	184526	315	585.8
50	GLP1R221-041	101875	174	585.5
50	GLP1R221-028	158490.5	271.5	583.8
50	GLP1R221-046	137324.5	236	581.9
50	GLP1R221-052	205979	370	556.7
50	GLP1R221-073	102371	205	499.4
50	GLP1R221-053	146049.5	301.5	484.4
50	GLP1R221-056	197814	409	483.7
55	GLP1R221-058	168846	240	703.5
55	GLP1R221-057	185403	268.5	690.5
55	GLP1R221-090	183560	268	684.9
55	GLP1R221-063	184038	274	671.7
55	GLP1R221-029	197088	305	646.2
55	GLP1R221-013	171640	266	645.3
55	GLP1R221-030	160279	251	638.6
55	GLP1R221-011	175641	283	620.6
55	GLP1R221-060	178266.5	290	614.7
55	GLP1R221-039	132161.5	219	603.5
55	GLP1R221-015	176341.5	293	601.8
55	GLP1R221-091	174624	295	591.9
55	GLP1R221-074	173151	295.5	586.0
55	GLP1R221-035	184526	315	585.8
55	GLP1R221-041	101875	174	585.5
55	GLP1R221-028	158490.5	271.5	583.8
55	GLP1R221-046	137324.5	236	581.9
55	GLP1R221-052	205979	370	556.7
55	GLP1R221-073	102371	205	499.4
55	GLP1R221-053	146049.5	301.5	484.4
55	GLP1R221-056	197814	409	483.7
60	GLP1R221-058	168846	240	703.5
60	GLP1R221-057	185403	268.5	690.5
60	GLP1R221-090	183560	268	684.9
60	GLP1R221-063	184038	274	671.7
60	GLP1R221-029	197088	305	646.2
60	GLP1R221-013	171640	266	645.3
60	GLP1R221-030	160279	251	638.6
60	GLP1R221-011	175641	283	620.6
60	GLP1R221-060	178266.5	290	614.7
60	GLP1R221-039	132161.5	219	603.5
60	GLP1R221-015	176341.5	293	601.8
60	GLP1R221-091	174624	295	591.9
60	GLP1R221-074	173151	295.5	586.0
60	GLP1R221-035	184526	315	585.8
60	GLP1R221-041	101875	174	585.5
60	GLP1R221-028	158490.5	271.5	583.8
60	GLP1R221-046	137324.5	236	581.9
60	GLP1R221-052	205979	370	556.7
60	GLP1R221-073	102371	205	499.4
60	GLP1R221-053	146049.5	301.5	484.4
60	GLP1R221-056	197814	409	483.7
65	GLP1R221-058	168846	240	703.5
65	GLP1R221-057	185403	268.5	690.5
65	GLP1R221-090	183560	268	

US 12,391,762 B2

63

TABLE 6C-continued

Sample	Median RL1-H of Expressing Singlets	Median RL1-H of Parent Singlets	MFI Ratio	
GLP1R221-005	105542	226.5	466.0	
GLP1R221-087	178772	389	459.6	
GLP1R221-089	148048	325	455.5	
GLP1R221-071	138673	313	443.0	
GLP1R221-025	100871	233	432.9	5
GLP1R221-032	172291	399	431.8	
GLP1R221-055	137657	329	418.4	
GLP1R221-010	107233	285	376.3	
GLP1R221-078	108233.5	301.5	359.0	
GLP1R221-024	79574	225	353.7	
GLP1R221-050	65939	204	323.2	
GLP1R221-008	74751.5	239	312.8	10
GLP1R221-007	94850	358	264.9	
GLP1R221-062	59544	279	213.4	
GLP1R221-093	94190	444	212.1	
GLP1R221-068	56581	298	189.9	
GLP1R221-067	54810	300	182.7	
GLP1R221-085	201695	1352.5	149.1	15
GLP1R221-064	42803	308	139.0	
GLP1R221-023	155330	1174	132.3	
GLP1R221-080	196473	1547	127.0	
GLP1R221-061	47559	482	98.7	
GLP1R221-070	21104.5	224	94.2	20
GLP1R221-006	17593.5	286	61.5	
GLP1R221-045	603.5	174	3.5	
GLP1R221-004	519	164	3.2	
GLP1R221-047	397	167	2.4	
GLP1R221-048	214	142.5	1.5	
Stained Control	145	142	1.0	30

TABLE 6D

Sample	Median RL1-H of Expressing Singlets	Median RL1-H of Parent Singlets	MFI Ratio	
GLP1R222-005	203990	173	1179.1	
GLP1R222-058	217592	186	1169.8	
GLP1R222-004	201104	189	1064.0	
GLP1R222-035	180903	172	1051.8	
GLP1R222-069	193190	187	1033.1	
GLP1R222-001	195159	193	1011.2	
GLP1R222-077	207327.5	208	996.8	
GLP1R222-072	196881.5	198.5	991.8	
GLP1R222-062	207390	209.5	989.9	35
GLP1R222-073	225325	229	984.0	
GLP1R222-009	173411	176.5	982.5	
GLP1R222-064	207016	218	949.6	
GLP1R222-056	217636.5	230	946.2	
GLP1R222-089	196242	213	921.3	
GLP1R222-055	190727	209	912.6	40
GLP1R222-046	204177	225.5	905.4	
GLP1R222-008	210228	234	898.4	
GLP1R222-078	176537.5	198	891.6	
GLP1R222-092	212558	240.5	883.8	
GLP1R222-007	211051	239	883.1	
GLP1R222-010	171471	195	879.3	55
GLP1R222-081	221047	260	850.2	
GLP1R222-006	191343	227	842.9	
GLP1R222-066	189419	227	834.4	
GLP1R222-079	170284	206	826.6	
GLP1R222-042	214181	261	820.6	
GLP1R222-036	172934	214.5	806.2	60
GLP1R222-014	237480	299	794.2	
GLP1R222-087	200143	252	794.2	
GLP1R222-086	181615.5	230	789.6	
GLP1R222-033	181334	230	788.4	
GLP1R222-074	205325	261	786.7	
GLP1R222-070	166040	212	783.2	
GLP1R222-002	192431	246	782.2	65
GLP1R222-023	241120.5	310	777.8	

64

TABLE 6D-continued

Sample	Median RL1-H of Expressing Singlets	Median RL1-H of Parent Singlets	MFI Ratio	
GLP1R222-012	225014	290.5	774.6	
GLP1R222-016	243028	314	774.0	
GLP1R222-063	214679.5	278	772.2	
GLP1R222-011	185538	242	766.7	
GLP1R222-028	182568	242	754.4	
GLP1R222-085	177368	239	742.1	
GLP1R01-3	223916.5	302.5	740.2	
GLP1R222-045	179811	246	730.9	
GLP1R222-054	153121	211	725.7	
GLP1R222-083	195648.5	274.5	712.7	
GLP1R222-082	223995	315	711.1	
GLP1R222-084	172287	247	697.5	
GLP1R222-076	186158	269	692.0	
GLP1R222-029	204757	300	682.5	
GLP1R222-060	113206.5	167	677.9	
GLP1R222-038	158998.5	236	673.7	
GLP1R222-026	154255.5	229	673.6	
GLP1R222-071	193867	288	673.1	
GLP1R222-053	131845	196	672.7	
GLP1R222-051	149756.5	224	668.6	
GLP1R222-093	152427	232	657.0	
GLP1R222-075	194948.5	297	656.4	
GLP1R222-065	184054.5	281	655.0	
GLP1R222-032	165221	255	647.9	
GLP1R222-059	142048	223	637.0	
GLP1R222-021	175543	278	631.4	
GLP1R222-025	134869	216	624.4	
GLP1R222-024	208523	345	604.4	
GLP1R222-022	200898	337	596.1	
GLP1R222-027	190430	326.5	583.2	
GLP1R222-015	187125	344.5	543.2	
GLP1R222-041	182770	344	531.3	
GLP1R222-090	226951	432	525.3	
GLP1R222-044	107845.5	208	518.5	
GLP1R222-040	167413.5	324	516.7	
GLP1R222-031	155641	331	470.2	
GLP1R222-088	170891	373	458.2	
GLP1R222-048	197618	441.5	447.6	
GLP1R222-018	126619	290	436.6	
GLP1R222-003	65950	155	425.5	
GLP1R222-080	96756.5	228	424.4	
GLP1R222-057	83288.5	204	408.3	
GLP1R222-047	118739	307	386.8	
GLP1R222-030	162896	506	321.9	
GLP1R222-091	56735.5	192	295.5	
GLP1R222-043	70814	406	174.4	
GLP1R222-037	58889	388	151.8	
GLP1R222-094	23462.5	176	133.3	
GLP1R222-068	135253	1167.5	115.8	
GLP1R222-019	39294	350	112.3	
GLP1R222-067	146186	1452	100.7	
GLP1R222-020	112537	1189	94.6	
GLP1R222-049	178616.5	2138.5	83.5	
GLP1R222-052	377875	27565.5	13.7	
Stained Control	127	121	1.0	

US 12,391,762 B2

65

66

TABLE 6E

Sample	GLP1 R221-009	GLP1 R221-017	GLP1 R221-033	GLP1 R221-034	GLP1 R221-065	GLP1 R221-066	GLP1 R221-075	GLP1 R221-076	GLP1 R221-084	GLP1 R221-092	GLP1 R01-3
EC ₅₀ [nM]	12.46	27.65	9.041	ND	ND	57.39	ND	ND	4.091	13.29	11.51
CHO GLPIR											
B _{max} CHO GLPIR	215146	249646	167203	932518	797529	171812	213495	799149	286814	144511	799671
EC ₅₀ [nM]	ND	ND									
CHO Parent											
B _{max} CHO Parent	267.4	228.7	146	279.8	261.9	112.1	234	183.2	266.6	291.2	268

TABLE 6F

Sample	GLP1 R222-012	GLP1 R222-014	GLP1 R222-016	GLP1 R222-023	GLP1 R222-052	GLP1 R222-056	GLP1 R222-073	GLP1 R222-081	GLP1 R222-082	GLP1 R222-090	GLP1 R01-3
EC ₅₀ [nM]	23.14	34.29	7.709	18.35	17.36	77.43	13.07	22.51	11.49	ND	15.4
CHO GLPIR											
B _{max} CHO GLPIR	233768	213081	129918	220325	228012	292619	150681	193955	134940	1078076	152782
EC ₅₀ [nM]	ND	ND	ND	89.37	ND	ND	ND	ND	ND	ND	ND
CHO Parent											
B _{max} CHO Parent	340.6	336.4	218.5	237.9	47529	237.5	228.4	243.4	305	413.4	265.3

TABLE 6G

[IgG] nM	GLP1 R221-009	GLP1 R221-017	GLP1 R221-033	GLP1 R221-034	GLP1R 221-065	GLP1R 221-066	GLP1R 221-075	GLP1R 221-076	GLP1R 221-084	GLP1R 221-092	GLP1R 01-3
100.00	1635.4	1844.6	1596.5	1015.0	1157.8	1056.4	834.9	1499.3	910.9	960.9	1193.7
33.33	1322.9	1303.9	1211.3	593.5	799.1	698.8	507.9	597.8	666.7	1019.4	1531.0
11.11	1058.6	707.5	1012.5	332.2	368.9	229.7	416.1	372.2	412.4	447.3	689.3
3.70	448.3	424.8	385.6	209.0	280.0	171.2	242.0	293.6	344.2	297.4	425.2
1.23	176.6	181.4	175.6	87.7	140.1	91.4	119.1	121.3	153.3	141.2	166.6
0.41	95.2	94.7	89.7	48.9	80.0	46.5	54.7	51.8	63.5	54.9	77.4
0.14	37.7	36.2	39.3	19.7	31.0	20.4	23.8	22.3	24.6	19.6	28.6
0.05	16.8	14.8	17.4	8.8	14.9	9.6	9.3	8.8	9.4	8.7	12.3

TABLE 6H

[IgG] nM	GLP1 R222-012	GLP1 R222-014	GLP1 R222-016	GLP1 R222-023	GLP1 R222-052	GLP1 R222-056	GLP1 R222-073	GLP1 R222-081	GLP1 R222-082	GLP1 R222-090	GLP1 R01-3
100.00	1281.5	952.5	1049.1	1804.8	8.0	1522.2	1264.2	1404.0	845.8	746.6	1047.7
33.33	916.5	913.2	1412.1	1277.6	19.8	815.1	1057.9	1181.5	1027.4	526.8	1040.9
11.11	626.0	432.9	743.0	699.7	57.9	421.2	680.4	528.8	567.7	336.3	567.3
3.70	300.5	190.8	335.9	300.6	37.6	193.8	296.5	244.0	233.4	165.8	265.1
1.23	144.0	85.2	154.9	140.3	43.8	79.0	115.5	99.2	125.3	70.6	124.6
0.41	67.4	45.3	75.9	55.8	28.7	32.8	55.6	50.4	53.5	31.6	66.6
0.14	26.1	17.3	28.1	26.4	14.5	13.2	20.5	16.5	15.8	8.8	22.9
0.05	12.3	7.2	14.2	11.4	7.3	6.4	9.2	7.9	8.1	4.4	10.1

The GLP1R-221 and GLP1R-222 variants were assayed in competition assays. Data is seen in FIGS. 25A-25B. The variants were also assayed in a cAMP assay. Briefly, cells were pre-incubated with anti-GLP1R antibody at 100 nM followed by agonist stimulation 3 \times titration from 12.5 nM. Data is seen in FIG. 26 with improved variants highlighted in green.

Example 6: Sequences

TABLE 7

Sequences of GLP1 embedded in CDRH3		
SEQ ID NO	Sequence	
1	CAKHMSMQEGAVTGEQAAKEFIawlVKGRVRADLVDGDAFDVW	
2	CARDGRGSLPRPKGGPQTVGEGQAAKEFIawlVKGGLTYSSEDGAFDIW	
3	CAKHMSMQDYLVIGEGQAAKEFIawlVKGGPARADLVDGDAFDVW	
4	CAKHMSMQEGAVTGEQDAKEFIawlVKGRVRADLVDGDAFDVW	
5	WAKHMSMQEGAVTGEQAAKEFIawlVKGRVRADLVDGDAFDVW	
6	CARDGRGSLPRPKGGPQTVGEGQAAKEFIawlVKGRVRADLVDGDAFDVW	
7	CARANQHFYEQEGTFTSDVSSYLEGQAAKEFIawlVKGGIRGYHYYGMDVW	
8	CARANQHFTELHGEQAAKEFIawlVKGRGQIDIGYHYYGMDVW	
9	CARANQHFLGAGVSSYLEGQAAKEFIawlVKGDTTGYHYYGMDVW	
10	CARANQHFLDKGTFSDVSSYLEGQAAKEFIawlVKGIYPGYHYYGMDVW	
11	CARANQHFGTLSAGEQAAKEFIawlVKGGSQYDSSEDGGAFDIW	
12	CARANQHFGGLHAQGEQAAKEFIawlVKGSCTGYHYYGMDVW	
13	CARANQHFGGKGEQAAKEFIawlVKGGSGAGYHYYGMDVW	
14	CAKQMSMQEGAVTGEQAAKEFIawlVKGRVRADLVDGDAFDVW	
15	CAKHMSMQEGAVTGEQAAKEFIawlVKGGPARADLVDGDAFDVW	
16	CAKHMSMQEGAVTGEQAAKEFIawlVKGGLTYSSEDGGAFDIW	
17	CAKHMSMQDYLVIGEGQAAKEFIawlVKGRVRADLVDGDAFDVW	

TABLE 8

GLP1R Variants CDRH3 Sequences		
Variant	SEQ ID NO.	Sequence
GLP1R-1	18	CARANQHFVLDLYWHGVPKGYHYYGMDVW
GLP1R-2	19	CARDMYDFETVVEGIQWYEALKAGKLGEVVPPADDADIW
GLP1R-3	20	CAKHMSMQEGAVTGEQAAKEFIawlVKGRVRADLVDGDAFDVW
GLP1R-8	21	CARDGRGSLPRPKGGPQTVGEGQAAKEFIawlVKGGLTYSSEDGGAFDIW
GLP1R-10	22	CARANQHFFVPGSLKVWLKGVAPESSSEYDSSEDGGAFDIW
GLP1R-25	23	CARANQHFLSHAGAARDFINWLIQTKITGLGSGYHYYGMDVW
GLP1R-26	24	CAKHMSMQEGLQGQIPSTIDWEGLLHLRADLVDGDAFDVW
GLP1R-30	25	CARDMYDFLKIGDNLAARDFINWLIQTKITDGTDTEVVPADDADIW
GLP1R-50	26	CARDGRGSLPRPKGGPKFVPGKHETYGHKTGYRLRPGYHYYGMDVW
GLP1R-56	27	CARANQHFFSGAECEGQAAKEFIawlVKGIIPGYHYYGMDVW

TABLE 8 -continued

GLP1R Variants CDRH3 Sequences		
Variant	SEQ ID NO.	Sequence
GLP1R-58	28	CARANQHFGLHAQGEGQAAKEFIAWLVKGS GTYGYHYGMDVW
GLP1R-60	29	CAKHMSMQDYL VIGEGQAAKEFIAWLVKGGPARADLVGDAFDVW
GLP1R-70	30	CARDGRGSLPRPKGGPPSSGRDFINWLIQT KITDGFRYDSSEDGGAPDIW
GLP1R-71	31	CARDLRELECEEWTRHGGKHHGKRQSNRAHQGHET YGHKTGSLVPSRGPCVD PRGVAGSF DVW
GLP1R-72	32	CARDMYYDFHPEGTFTSDVSSYLEGQAAKEFIAWLVKGS LIYEVVPADDADIW
GLP1R-80	33	CARANQHFGPVAGGATPSEEPGSQLTRAELGWDAPPQESLADELLQLGTEHGYH YYGMDVW
GLP1R-83	34	CAKHMSMQEGAVTGEGQAAKEFIAWLVKGRVRADLVGDAFDVW
GLP1R-93	35	CARANQHFLSHAGAARDFINWLIQT KITGLGSGYHYGMDVW
GLP1R-98	36	CARDGRGSLPRPKGGPHSGRLGSGYKS YDSEDGGAFDIW
GLP1R-238	37	CARANQHFSQAGRAARVPGPSSSLGPRGYHYGMDVW
GLP1R-239	38	CAKHMSMQSQGLDNLAARDFINWLIQT KITDG FELS RADLVGDAFDVW
GLP1R-240	39	CARDMYYDFGLGTFTSDVSSYLEGQAAKEFIAWLVKGV SPEVVPADDADIW
GLP1R-241	40	CAKHMSMQGSVAGGTFTSDVSSYLEGQAAKEFIAWLVKGGPSFIRADLVGDAPD VW
GLP1R-242	41	CAKHMSMQADTGTFTSDVSSYLEGQAAKEFIAWLVKGEFSSRADLVGDAFDVW
GLP1R-243	42	CARANQHFFGKD NLAARDFINWLIQT KITDG SNPGYHYGMDVW
GLP1R-244	43	CARANQHFAATGAGEGQAAKEFIAWLVKGRVEIGYHYGMDVW

*bold corresponds to GLP1 or GLP2 motif

TABLE 9

Variable Heavy Chain Sequences		
Variant	SEQ ID NO.	Variable Heavy Chain Sequence
GLP1R-238	44	MEWSWVFLFFLSVTGVHSQVQLVQSGAEVKPGSSVKVSCKASGGSFSSHAISW VRQAPGQGLEWNGGIIPIFGAPNYAQKFQGRVTITADESTS TAYMELSSLRSEDTA VYYCARANQHFSQAGRAARVPGPSSSLGPRGYHYGMDVWQGTLTVVSSASAS TKGPSVPLAPCRSTS ESTAALGCLVKDYFPEPVTVSWNSGALTGVHTFP AVLQSSGLYSLSSVVTVPSSNFGTQTYTCMVNDHKPSNTKVDKTVERKCCVECP APPV AGPSVFLPPPKD TLMISRTPEVTCVVVDVSHEDPEVQFNWYVGVEVHNAKTK PREEQFNSTFRRVSVLTVVHQDWLNGKEYKCKVSNKG LPAPIEKTISKTKGQPREP QVYTLPPSREEMTKQVSLTCLVKGFYPSDI AVEWESNGQ PENNYKTTPPML DSD GSFFFLYSKLTVDKSRWQQGNFSCVMHEALHNHYTQKSLSLSPG
GLP1R-239	45	MEWSWVFLFFLSVTGVHSQVQLVESGGGVQPGRSRLSCAASGFDFSNYGMH WVRQAPGKGLEWVADISYE GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAE DTAVYYCAKHMSMQSQGLDNLAARDFINWLIQT KITDG FELS RADLVGDAFDVW GQGTLTVVSSASASTKGPSVFLAPCRSRTSESTAALGCLVKDYFPEPVTV SWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCMVNDHKPSNTKVDKTVER KCCVECP APPVAGPSVFLPPPKD TLMISRTPEVTCVVVDVSHEDPEVQFNW YVDGVEVHNAKTKPREEQFNSTFRRVSVLTVVHQDWLNGKEYKCKVSNKG LPAPIEKTISKTKGQPREP QVYTLPPSREEMTKQVSLTCLVKGFYPSDI AVEWESNGQ PENNYKTTPPML DSD GSFFFLYSKLTVDKSRWQQGNFSCVMHEALHNHYTQKSLSLSPG

TABLE 9-continued

Variable Heavy Chain Sequences		
Variant NO.	SEQ ID	Variable Heavy Chain Sequence
GLP1R- 240	46	MEWSWVFLFFLSVTGVHSQVQLVQSGAEVKPGSSVKVSCKASGGTENNYGIS WVRQAPGQGLEWMGGIIPVFGTANYAQKFQGRVTITADESTSTAYMELSSLRSED TAVYYCAKHMMSMQGSVAGGTFTSDVSSYLEGQAACEFIAWLVKGVSPEVVPA FDIWGQGTLTVSSASASTKGPSVPLAPCSRSTSESTAALGCLVKDYFPEPV WNSGALTSGVHTFPAPLQSSGLYSLSSVTPSSNFTQTYTCNVDHKPNTKV KTVERKCCVECPCCPAPPVAGPSVFLFPPPKDMLMISRTPEVTCVVVDVSH QFNWYDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKV GLPAPIEKTIKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI NEQPNENNYKTTPPMLSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN QKSLSLSPG
GLP1R- 241	47	MEWSWVFLFFLSVTGVHSQVQLVQSGAEVKPGSSVKVSCKASGGTFS WVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSL AVYYCAKHMMSMQGSVAGGTFTSDVSSYLEGQAACEFIAWLVKGGSFIRAD DAFDVGQGTLTVSSASASTKGPSVPLAPCSRSTSESTAALGCLVKD VSNSGALTSGVHTFPAPLQSSGLYSLSSVTPSSNFTQTYTCNVDHKP VDKTVERKCCVECPCCPAPPVAGPSVFLFPPPKDMLMISRTPEV PEVQFNWYDGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNG SNKGLPAPIEKTIKTKGQPREPQVYTLPPSREEMTKNQVSLTCL WESNGQPNENNYKTTPPMLSDGSFFLYSKLTVDKSRWQQGNVFSC HYTQKSLSLSPG
GLP1R- 242	48	MEWSWVFLFFLSVTGVHSQVQLVQSGAEVKPGSSVKVSCKASGGTFS WVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADESTSTAYMELSSL AVYYCAKHMMSMQGSVAGGTFTSDVSSYLEGQAACEFIAWLVKG VWGQGTLTVSSASASTKGPSVPLAPCSRSTSESTAALGCLVKD VSNSGALTSGVHTFPAPLQSSGLYSLSSVTPSSNFTQTYTCNV SGALTSGVHTFPAPLQSSGLYSLSSVTPSSNFTQTYTCNV ERKCCVECPCCPAPPVAGPSVFLFPPPKDMLMISRTPEV WYDGVVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNG APIEKTIKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK LNSQPNENNYKTTPPMLSDGSFFLYSKLTVDKSRWQQGNVFSC LSLSPG
GLP1R- 243	49	MEWSWVFLFFLSVTGVHSQVQLVQSGAEVKPGSSVKVSCKASGGTFS WVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSL AVYYCARANQHFQGKDNLAAARDFINWLQTKIDGNSNP LVTGVSSASASTKGPSVPLAPCSRSTSESTAALGCLVKD VSNSGALTSGVHTFPAPLQSSGLYSLSSVTPSSNFTQTYTCNV ECPPCPAPPVAGPSVFLFPPPKDMLMISRTPEV VEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNG SKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK KTNQVSLTCLVKGFYPSDI LNSQPNENNYKTTPPMLSDGSFFLYSKLTVDKSRWQQGNVFSC LSPG
GLP1R- 244	50	MEWSWVFLFFLSVTGVHSQVQLVQSGAEVKPGSSVKVSCKASGGTFS WVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGRVTITADESTSTAYMELSSL AVYYCARANQHFATGAGEGQAAKEFIAWLVKG VSSASASTKGPSVPLAPCSRSTSESTAALGCLVKD VSNSGALTSGVHTFPAPLQSSGLYSLSSVTPSSN TFPAVLQSSGLYSLSSVTPSSNFTQTYTCNV ECPPCPAPPVAGPSVFLFPPPKDMLMISRTPEV HNAKTKPREEQFNSTFRVSVLTVVHQDWLNG KGQPREPQVYTLPPSREEMTKNQVSLTCLVK KTNQVSLTCLVKGFYPSDI LNSQPNENNYKTTPPMLSDGSFFLYSKLTVDKSRWQQGNVFSC LSPG
GLP1R- 59-2	51	QVQLVESGGVVQPGRSLRLSCAASGFTFSNYGMSWVRQAPGKGL AGNKYYADSVKGRFTIISRDNSKNTLYLQMNSLRAEDTAVYYCARD EGIQWYEALKAGKLGEVVPADDADIWGGQTLTVSSAS TAKGKPSVPLAPCSRSTSESTAALGCLVKD VSNSGALTSGVHTFPAPLQSSGLYSLSSVTPSSN FTQTYTCNV ESTAA LKGPSVPLAPCSRSTSESTAALGCLVKD VSNSGALTSGVHTFPAPLQSSGLYSLSSVTPSSN FTQTYTCNV DHKPNTKV DKTVERKCC V ECPPCPAPPVAGPSVFLFPPPKDMLMISRTPEV HNAKTKPREEQFNSTFRVSVLTVVHQDWLNG KGQPREPQVYTLPPSREEMTKNQVSLTCLVK KTNQVSLTCLVKGFYPSDI LNSQPNENNYKTT PPMLSDGSFFLYSKLTVDKSRWQQGNVFSC LSPG
GLP1R- 59-241	52	QVQLVQSGAEVKPGSSVKVSCKASGGTFS YAI SWVRQAPGQGLEWMGGIIPIF GTTNYAQKFQGRVTITADESTSTAYMELSSL SEDTAVYYCAKHMMSMQGSVAGG TFTSDVSSYLEGQAACEFIAWLVKG TFTSDVSSYLEGQAACEFIAWLVKG PSFIRADLVGDA STKGPSVPLAPCSRSTSESTAALGCLVKD VSNSGALTSGVHTFP QSSGLYSLSSVTPSSNFTQTYTCNV DHKPNTKV DKTVERKCC V ECPPCPAPP VAGPSVFLFPPPKDMLMISRTPEV HNAKTKPREEQFNSTFRVSVL VHQDWLNG KGQPREPQVYTL PPSREEMTKNQ VSLTCLVKGFYPS DI LNSQPNENNYKTT PPMLSDGSFFLYSKLTVD KSRWQQGNVFSC LSPG

TABLE 9-continued

Variable Heavy Chain Sequences		
Variant NO.	SEQ ID	Variable Heavy Chain Sequence
GLP1R- 59-243	53	QVQLVQSGAEVKPGSSVKVSCKASGGTFSTYGINWVRQAPGQGLEWMGGIIPIF GTANYAQKFQGRVTITADESTSTAYMELSLRSEDTAVYYCARANQHFFKGDNL AARDFINWLIQTKITDGSNPGYHYYGMDVWQGTLTVTSSASASTKGPSVFLAP CSRSTS ESTAALGCLVKDYPPEPVTVWSNSGALTSGVHTFPAVLQSSGLYSLSVV TPVSSNNGTQTYTCNVNDHKPSNTKVDKTVERKCCVECPCPAPPVAGPSVFLFPK PKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVGVEVHNAKTKPREEQFNSTR VVSVLTVVNHQDWLNKEYKCKVSNKGLPAPIEKTISKTKGQPREPVYTLP MTKNQVSLTCLVKGFYPSDIAVEWESENQGPENNYKTTPPMLSDGSFFLYSKLT DKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPG
GLP1R- 3	54	QVQLVESGGVVQPGRSRLSCAASGFTFSYGMHWVRQAPGKGLEWVSI SYDE SNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAVT GEGQAKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS SRSTS ESTAALGCLVKDYPPEPVTVWSNSGALTSGVHTFPAVLQSSGLYSLSVV VPSSNNGTQTYTCNVNDHKPSNTKVDKTVERKCCVECPCPAPPVAGPSVFLFPK KDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVGVEVHNAKTKPREEQFNSTR VSVLTVVHQDWLNKEYKCKVSNKGLPAPIEKTISKTKGQPREPVYTLP MTKNQVSLTCLVKGFYPSDIAVEWESENQGPENNYKTTPPMLSDGSFFLYSKLT DKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPGK
GLP1R- 43-8	55	MEWSWVPLFLS VTTGVHSEVQLVESGGGLVQAGGSRLSCAASGSISFRINAMGW FRQAPGKEREVVAIINNFGTTKYADSAKGRFTISADNAKNTVYLQMNSLKP VYCAVWRGPHNDDRYDWGGQTQVTVSSGGGGSEPKSSDKTHTCP GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVFKFNWYVGVEVHN KPREEQYNSTYRVSVSLTVLHQDWLNKEYKCKVSNKALPAPIEKTISKA KGQPREPVYTLP GSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSLSLSPG
GLP1R- 10	56	QVQLVESGGVVQPGRSRLSCAASGFTFSNYDMHWVRQAPGKGLEWVAVI SYE GSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARANQHFFV PGSL KVWLKGVAPESSSEYDSEDGGAFDIWGQGTLTVSS
GLP1R- 26	57	QVQLVQSGAEVKPGSSVKVSCKASGGTRSNYAINWVRQAPGQGLEWMGGIIPIL GTADYAQKFQGRVTITADESTSTAYMELSLRSEDTAVYYCAKHMSMQEGVLQG QIPSTIDWEGLLHLIRADLGDAFDVWQGTLTVSS
GLP1R- 221-065	58	QVQLVESGGVVQPGRSRLSCAASGFTFSNYAMHWVRQAPGKGLEWVAVI SY DRSNEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAV TGDGQAKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS
GLP1R- 221-075	59	QVQLVESGGVVQPGRSRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVI SYD ETNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAVT GEGQAKEFIAWLVKGI VRADLGDAFDVWQGTLTVSS
GLP1R- 221-017	60	QVQLVESGGVVQPGRSRLSCAASGFTFSDYGVHWVRQAPGKGLEWVAVI SYD ESNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAVT GEYQAKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS
GLP1R- 221-033	61	QVQLVESGGVVQPGRSRLSCAASGFSFSNYAMHWVRQAPGKGLEWVAVISHD RSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAVT GEGQAAKDFIAWLVKGRVRADLGDAFDVWQGTLTVSS
GLP1R- 221-076	62	QVQLVESGGVVQPGRSRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVI SYD ETNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAVT GEGQAKEFIAWLVKGI VRADLGDAFDVWQGTLTVSS
GLP1R- 221-092	63	QVQLVESGGVVQPGRSRLSCAASGFI FNNYGMHWVRQAPGKGLEWVAVI SYG GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAV TGEQQAVKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS
GLP1R- 221-034	64	QVQLVESGGVVQPGRSRLSCAASGFPFSNYGMHWVRQAPGKGLEWVAVI SHD RSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAVT GEGQAVKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS
GLP1R- 221-066	65	QVQLVESGGVVQPGRSRLSCAASGFTFNNYAMHWVRQAPGKGLEWVAVI SY DRSNEYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAV TGEQQAIKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS
GLP1R- 221-084	66	QVQLVESGGVVQPGRSRLSCAASGFAFSNYGMHWVRQAPGKGLEWVAVI S DENNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAV TGEMQAAKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS
GLP1R- 221-009	67	QVQLVESGGVVQPGRSRLSCAASGFI FNSYGMHWVRQAPGKGLEWVAVI SDE GSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKHMSMQEGAV TGAGQAAKEFIAWLVKGRVRADLGDAFDVWQGTLTVSS

TABLE 9-continued

Variable Heavy Chain Sequences			
Variant	SEQ ID NO.	Variable Heavy Chain Sequence	
GLP1R-222-052	68	QVQLVESGGVVQPGRSRLSCAASGFTFNNYPMHWVRQAPGKGLEWVAVISYD ESNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT GGGQAAKEFIAWLVKGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-016	69	QVQLVESGGVVQPGRSRLSCAASGFTFNNYAMHWVRQAPGKGLEWVAVISDE GSNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT TGEYQAAKEFIAWLVKGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-023	70	QVQLVESGGVVQPGRSRLSCAASGFSFSDYGMHWVRQAPGKGLEWVAVISYD ANNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT TGEWQAAKEFIAWLVKGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-014	71	QVQLVESGGVVQPGRSRLSCAASGFASFNSYGMHWVRQAPGKGLEWVFSISYD ESNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT TGEWQAAKEFIAWLVKGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-090	72	QVQLVESGGVVQPGRSRLSCAASGFSFSDYGIHWVRQAPGKGLEWVALISYEG SNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT GEKQAAKEFIAWLVKGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-073	73	QVQLVESGGVVQPGRSRLSCAASGFTFRDYGMHWVRQAPGKGLEWVAFIRYD EINKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT GEGQAAKEFIAWLVGGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-012	74	QVQLVESGGVVQPGRSRLSCAASGFTFNNYGMHWVRQAPGKGLEWVAVISDE GSNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT TGVGQAAKEFIAWLVKGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-082	75	QVQLVESGGVVQPGRSRLSCAASGFTSAYSIMHWVRQAPGKGLEWVALISYD ATNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT TGEFQAAKEFIAWLVKGRVRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-081	76	QVQLVESGGVVQPGRSRLSCAASGFTFDNYALHWVRQAPGKGLEWVALISYD AGNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT TGEGQAAKEFIAWLVKGFRADLVDGAFDVWGQGTLLTVSS	
GLP1R-222-056	77	QVQLVESGGVVQPGRSRLSCAASGFPFSSYAMHWVRQAPGKGLEWVAVISYD RSNKYYADSVKGRFTISRDNNSKNTLYLQMNSLRAEDTAVYYCAKHMMSMQEGAVT GYGQAAKEFIAWLVKGFRADLVDGAFDVWGQGTLLTVSS	

TABLE 10

Variable Light Chain Sequences

Variant	SEQ ID NO.	Variable Light Chain Sequence
GLP1R-238	78	MSVPTQVLGLLLLWLTDARCQSVLTQPPSVAAPGQKVТИCSGSTSNIANNYVSWYQQLPGTAKPLLIYANNRRPSGI PDRFSGSKSGTSATL GITGLQTGDEADYYCGAWDVRLDVGVFGGGTKLTVLGQPKAAPS VTLFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLS
GLP1R-239	79	MSVPTQVLGLLLLWLTDARCQSVLTQPPSVAAPGQKVТИCSGSTSNIEKNYVSWYQQLPGTAKPLLIYGNDRQPSGI PDRFSGSKSGTSATL GITGLQTGDEADYYCGTWENRLSAVVFGGGTKLTVLGQPKAAPS VTLFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
GLP1R-240	80	MSVPTQVLGLLLLWLTDARCQSVLTQPPSVAAPGQKVТИCSGSSSSIGNNYVSWYQQLPGTAKPLLIYANNRPSGI PDRFSGSKSGTSATL GITGLQTGDEADYYCATWSSSPRGWFGGGTKLTVLGQPKAAPS VTLFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
GLP1R-241	81	MSVPTQVLGLLLLWLTDARCQSVLTQPPSVAAPGQKVТИCSGISSNIGNNYVSWYQQLPGTAKPLLIYDDDQRPSGI PDRFSGSKSGTSATL GITGLQTGDEADYYCGTDNILSAVFGGGTKLTVLGQPKAAPS VTLFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

TABLE 10-continued

Variable Light Chain Sequences			
Variant	SEQ ID NO.	Variable Light Chain Sequence	
GLP1R-242	82	MSVPTQVLGLLLLWLTDARCQSVLTQPPSVAAPGQKVТИSCGSSSNIEENNDRWSWYQQLPGTAKPLIYGNDRQPSGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGTWDNTLSAGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-243	83	MSVPTQVLGLLLLWLTDARCQSVLTQPPSVAAPGQKVТИSCGSSRSNIKGNYVSWYQQLPGTAKPLIYENNERPSGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGSYTSNQVFQGGGTLKTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-244	84	MSVPTQVLGLLLLWLTDARCQSVLTQPPSVAAPGQKVТИSCGSSSNIGNNVWSWYQQLPGTAKPLIYNDKRRPSGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGSWDTLSVWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-59-243	85	HAEGTFTSDVSSYLEGQAACEFIAWLVKGRRGGGGSGGGGSQSVLTQPPSVSAAPGQKVТИSCGSSRSNIKGNYVSWYQQLPGTAKPLIYENNERPSGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGSYTSNQVFQGGGTLKTVLGQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-59-241	86	HAEGTFTSDVSSYLEGQAACEFIAWLVKGRRGGGGSGGGGSQSVLTQPPSVSAAPGQKVТИSCGSSRSNIKGNYVSWYQQLPGTAKPLIYDDDRQPSGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGTDWNLNIAAVFQGGGTLKTVLGQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-59-2	87	HGEGTFTSDVSSYLEGQAACEFIAWLVKGRRGGGGSGGGGSQSVLTQPPSVSGSPGSQITISCTGTSNDIGTYNYVSWYQOHPGKAPKLMIDVSGRPGSVSNRFSGSKGNTASLTISLQAEDEADYYCSSLTSSTEVFGGGTKLTVLGQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-59-2A	88	HAEGTFTSDVSSYLEGQAACEFIAWLVKGRRGGGGSGGGGSQSVLTQPPSVSGSPGSQITISCTGTSNDIGTYNYVSWYQOHPGKAPKLMIDVSGRPGSVSNRFSGSKGNTASLTISLQAEDEADYYCSSLTSSTEVFGGGTKLTVLGQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-3	89	QSVLTPPPSVAAPGQKVТИSCGSSSNIAIDNYVSWYQQLPGTAKPLIYDNNKRPSGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGTWDTLSAGAFGGGTLTVLQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-10	90	EIVMTQSPATLVSVPGERATLSCRASHSVSSDLAWYQQKPGQAPRLLIYSASSRATGIPARFSGSGSGTEFTLTISLQSEDFAVYYCQHYNWPLTFGGTKVEIK	
GLP1R-26	91	EIVMTQSPATLVSVPGERATLSCSASQSVSTKLAWYQQKPGQAPRLLIYGASTRAKGIPARFSGSGSGTEFTLTISLQSEDFAVYYCQHYNWPLTFGGTKVEIK	
GLP1R-221-065	92	QSVLTPPPSVAAPGQKVТИSCGSSNSIANNFVSWYQQLPGTAKPLIYDHNRPSGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGTWDTLSAGAFGGGTLTVLQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-221-075	93	QSVLTPPPSVAAPGQKVТИSCGSSNSIANNFVSWYQQLPGTAKPLIYDNDKRPAGIPDRFSGSKSGSATLGLITGLQQTGDEADYYCGTWDTLSNLYVFGGGTLTVLQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-221-017	94	QSVLTPPPSVAAPGQKVТИSCGSSNSIANNFVSWYQQLPGTAKPLIYDDYKRPSGIPDRFSGSKSGTSATLGLITGLQQTGDEADYYCATWDLNTGVFGGGTLTVLQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-221-033	95	QSVLTPPPSVAAPGQKVТИSCGSSNSIANNFVSWYQQLPGTAKPLIYDNNKRPSGIPDRFSGSKSGTSATLGLITGLQQTGDEADYYCATWDLNVGVFGGGTLTVLQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-221-076	96	QSVLTPPPSVAAPGQKVТИSCGSSNSIANNFVSWYQQLPGTAKPLIYENNRHSGIPDRFSGSKSGTSATLGLITGLQQTGDEADYYCLTDHSLTAYVFGGGTLTVLQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-221-092	97	QSVLTPPPSVAAPGQKVТИSCGSSNSIANNFVSWYQQLPGTAKPLIYDNNKRPPGIPDRFSGSKSGTSATLGLITGLQQTGDEADYYCGTWDTLSVGMFFGGGTLTVLQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	
GLP1R-221-034	98	QSVLTPPPSVAAPGQKVТИSCGSSNSIANNFVSWYQQLPGTAKPLIYEENDNRPSSGIPDRFSGSKSGTSATLGLITGLQQTGDEADYYCATWDGLSTGVFGGGTLTVLQPKAAPSVTLPFPSSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAASSYSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	

TABLE 10-continued

Variable Light Chain Sequences		
Variant	SEQ ID NO.	Variable Light Chain Sequence
GLP1R- 221-066	99	QSVLTQPPSVAAPGQKVТИCSGSSSNIGNNLYSLWYQQLPGTAPKLLIYENNKRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWSLVMFGGGTKLTVL
GLP1R- 221-084	100	QSVLTQPPSVAAPGQKVТИCSGSSSNADNYVSWYQQLPGTAPKLLIYENNRRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDVSLVGMFGGGTKLTVL
GLP1R- 221-009	101	QSVLTQPPSVAAPGQKVТИCSGSSSNIGNQYVSWYQQLPGTAPKLLIYDDHKRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSVGEFGGGTKLTVL
GLP1R- 222-052	102	QSVLTQPPSVAAPGQKVТИCSGSSSNIGKRSVSWYQQLPGTAPKLLIYDNNKRAS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSAGVPGGGTKLTVL
GLP1R- 222-016	103	QSVLTQPPSVAAPGQKVТИCSGSSNIENNDVSWYQQLPGTAPKLLIYDFNKRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSVGMFGGGTKLTVL
GLP1R- 222-023	104	QSVLTQPPSVAAPGQKVТИCSGSSNIGNNDVSWYQQLPGTAPKLLIYENTKRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDAGLSTGVPGGGTKLTVL
GLP1R- 222-014	105	QSVLTQPPSVAAPGQKVТИCSGSSNIGNHDVSWYQQLPGTAPKLLIYDNNKRH SGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSAGVPGGGTKLTVL
GLP1R- 222-090	106	QSVLTQPPSVAAPGQKVТИCSGSSNIADNYVSWYQQLPGTAPKLLIYDNNKRA SGIPDRFSGSKSGTSATLGITGLQTGDEADYYCATWDNRRLSAGVPGGGTKLTVL
GLP1R- 222-073	107	QSVLTQPPSVAAPGQKVТИCSGGSNIGNNDVSWYQQLPGTAPKLLIYDNNKRA SGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDGRPNTGVPGGGTKLTVL
GLP1R- 222-012	108	QSVLTQPPSVAAPGQKVТИCSGSSNIGNNDVSWYQQLPGTAPKLLIYDDDKRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSVGEFGGGTKLTVL
GLP1R- 222-082	109	QSVLTQPPSVAAPGQKVТИCSGSSNIGSKYVSWYQQLPGTAPKLLIYDNNKRPS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDISPSAWVPGGGTKLTVL
GLP1R- 222-081	110	QSVLTQPPSVAAPGQKVТИCSGSSNIGSDYVSWYQQLPGTAPKLLIYDNNKRSS GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDLSRWVPGGGTKLTVL
GLP1R- 222-056	111	QSVLTQPPSVAAPGQKVТИCSGSSNIGSNYISWYQQLPGTAPKLLIYDNDKRPA GIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDTSLSVGEFGGGTKLTVL

TABLE 11

GLP1R Sequences		
Variant	SEQ ID NO	Sequence
GLP1R-40- 01	112	EVQLVESGGGLVQPGGSLRLSCAASGFTCGDTMGMWFRQAPGKERELAAITSG GATTYYADNRKSRTISADNSKNTAYLQMNSLKPEDTAVYYCWAALDGYGGRW GQGTIVTVSS
GLP1R-40- 02	113	EVQLVESGGGLVQPGGSLRLSCAASGRTFRINRMGWFRQAPGKEREWVSTICSR GDTYYADSVKGRTFTISADNSKNTAYLQMNSLKPEDTAVYYCAATLDGYSGSWG QGTLTVTVSS
GLP1R-40- 03	114	EVQLVESGGGLVQPGGSLRLSCAASGRDFRVKNMGWFRQAPGKEREFVARITW NGGSAYYADSVKGRTFTISADNSKNTAYLQMNSLKPEDTAVYYCAARILSRNWG QGTLTVTVSS
GLP1R-40- 04	115	EVQLVESGGGLVQPGGSLRLSCAASGFTFSFYTMGMWFRQAPGKEREFVAAISGG RTSYADSVKGRTFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYEGSWQ GTLTVTVSS
GLP1R-40- 05	116	EVQLVESGGGLVQPGGSLRLSCAASGFTFSFYAMGMWFRQAPGKEREFVAAISGG RTRYADNVKGRTFTISADNSKNTAYLQMNSLKPEDTAVYYCAALDGYNGIWQ GTLTVTVSS
GLP1R-40- 06	117	EVQLVESGGGLVQPGGSLRLSCAASGHTSDTYIMGWFRQAPGKEREFVSLINWSS GKTIYADSVKGRTFTISADNSKNTAYLQMNSLKPEDTAVYYCAKGDYRGYYY QTSQWGQGTIVTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ NO	ID
GLP1R-40- 07	118	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYPMGWFRQAPGKEREFVATI PSGG STYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAALDGNGSWGQ GTLTVSS
GLP1R-40- 08	119	EVQLVESGGGLVQPGGSLRLSCAASGFTFGEPTMGWFRQAPGKERERVATITSGG STNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVDDYSGSWGQ GTLTVSS
GLP1R-40- 09	120	EVQLVESGGGLVQPGGSLRLSCAASGFTDGIDAMGWFRQAPGKEREVVAGIAW GDGITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASYNVYNN WGQQGTLTVSS
GLP1R-40- 10	121	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSGVMGWFRQAPGKEREFVAAINRS GSTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAKTKRTGIFTTAR MVDWGQGT
GLP1R-40- 11	122	EVQLVESGGGLVQPGGSLRLSCAASGVTLDYAMGWFRQAPGKEREFVAAINRS GSITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYTDYDEALE ETRGSYDWGQGT
GLP1R-40- 12	123	EVQLVESGGGLVQPGGSLRLSCAASGLTFGIYAMGWFRQAPGKEREFVATISRSG ASTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAIIVTYNDYDRGH DWGQGT
GLP1R-40- 13	124	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSDGMGWFRQAPGKERELVAAINRS GSTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAKTARPGIFTTAPV EDWGQGT
GLP1R-40- 14	125	EVQLVESGGGLVQPGGSLRLSCAASGFTCGNYTMGWFRQAPGKERESVASITS GRTNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAATLDGYTGSWG QGT
GLP1R-40- 15	126	EVQLVESGGGLVQPGGSLRLSCAASGFTFNYPMGWFRQAPGKEREWVATISR GGTYYADNVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAALDGYSIGWG QGT
GLP1R-40- 16	127	EVQLVESGGGLVQPGGSLRLSCAASGIIIGSFRTMGWFRQAPGKEREFVGFI TGSG GTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAARRYGNLYNT NNYDWGQGT
GLP1R-40- 17	128	EVQLVESGGGLVQPGGSLRLSCAASGIFTFRFKAMGWFRQAPGKEREFVAAISWR GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAATLGEPLVKY TWGQGT
GLP1R-40- 18	129	EVQLVESGGGLVQPGGSLRLSCAASGSFFSINAMGWFRQAPGKEREFVAGISSKG GSSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAHRIIVVGGTSS GDWRWGQGT
GLP1R-40- 19	130	EVQLVESGGGLVQPGGSLRLSCAASGRFSGRFNILNMGWFRQAPGKEREFVAAI SRSGDTTYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASLRNSGS NVEGRWGQGT
GLP1R-40- 20	131	EVQLVESGGGLVQPGGSLRLSCAASGGTSNSYRMGWFRQAPGKEREFVAVISWT GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVALDGYSGSW GQGT
GLP1R-40- 21	132	EVQLVESGGGLVQPGGSLRLSCAASGFNIGTYTMGWFRQAPGKEREFVAAIGSN GLANYADNVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAALDGYSGTWG QGT
GLP1R-40- 22	133	EVQLVESGGGLVQPGGSLRLSCAASGRTFSVYAMGWFRQAPGKEREFVAGIHS GSTLYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLDGYMGTWG QGT
GLP1R-40- 23	134	EVQLVESGGGLVQPGGSLRLSCAASGNIKSIDVMGWFRQAPGKERELVAARWS GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVVYGDWEG SEPVQHEYDWGQGT
GLP1R-40- 24	135	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMGWFRQAPGKEREFVAAIYCS DGSTQYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAEALDGYWGQG TLTVSS
GLP1R-40- 25	136	EVQLVESGGGLVQPGGSLRLSCAASGYTFRAYAMGWFRQAPGKEREMVAAMR WSGGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAQGSLYDD YDGLPIKYDWGQGT

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID
GLP1R-40-	137 26	EVQLVESGGGLVQPGGSLRLSCAASGLTFSSYAMGWFRQAPGKERECVTAIFSDG GTYYADNVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYNGYWG QGTLVTVSS
GLP1R-40-	138 27	EVQLVESGGGLVQPGGSLRLSCAASGIHFAISTMGWFRQAPGKEREVTAIWG ARTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAKFVNTDSTWS RSEMYTWGQGTLVTVSS
GLP1R-40-	139 28	EVQLVESGGGLVQPGGSLRLSCAASGLTFSSYAMGWFRQAPGKEREGVAVIDSD GTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAFLDGYSGSWG QGTLVTVSS
GLP1R-40-	140 29	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVAIRWSG GSTVYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIAEEGVYRW GQGTLVTVSS
GLP1R-40-	141 30	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSGVMGWFRQAPGKEREFVAAINS GSTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAKTKRTGIFTTWG QGTLVTVSS
GLP1R-40-	142 31	EVQLVESGGGLVQPGGSLRLSCAASGFTSSYAMGWFRQAPGKERELVAAISGG STSYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAMDGYSGSWGQ GTLVTVSS
GLP1R-40-	143 32	EVQLVESGGGLVQPGGSLRLSCAASGFTDGIDAMGWFRQAPGKEREVAAISGS GSITNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAANGIESYGWGN RHFNWGQGTLVTVSS
GLP1R-40-	144 33	EVQLVESGGGLVQPGGSLRLSCAASGFTDGIDAMGWFRQAPGKEREFVAAIRWS GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIFDVTDYER ADWGQGTLVTVSS
GLP1R-40-	145 34	EVQLVESGGGLVQPGGSLRLSCAASGFASYAMGWFRQAPGKEREFVAAISWS GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAFVTTNSDYDLG RDWGQGTLVTVSS
GLP1R-40-	146 35	EVQLVESGGGLVQPGGSLRLSCAASGIPASIRTMGWFRQAPGKEREGVSWISSL GSIYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCVAALDGYSGSWGQ GTLVTVSS
GLP1R-40-	147 36	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSLPMGWFRQAPGKERELVAIRWSG GSTVYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIEEGVYRW DWGQGTLVTVSS
GLP1R-40-	148 37	EVQLVESGGGLVQPGGSLRLSCAASGFNSGSYTMGWFRQAPGKEREGVSWISSL DGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYSIGIW GQGTLVTVSS
GLP1R-40-	149 38	EVQLVESGGGLVQPGGSLRLSCAASGFTFSVYAMGWFRQAPGKEREFVTAIDSES RTLYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAALLDGYLGTWQ GTLVTVSS
GLP1R-40-	150 39	EVQLVESGGGLVQPGGSLRLSCAASGSVKINVMGWFRQAPGKEREFLGSLILWSD DSTNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAANLKQGSYGYRF NDWGQGTLVTVSS
GLP1R-40-	151 40	EVQLVESGGGLVQPGGSLRLSCAASGTFIVNIHMGWFRQAPGKERELVAAITS STSYYADNVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAISGALRHFE YDWGQGTLVTVSS
GLP1R-40-	152 41	EVQLVESGGGLVQPGGSLRLSCAASGRSLGTYHMGWFRQAPGKEREGVSWISSL DGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVVLGDYSGSW GQGTLVTVSS
GLP1R-40-	153 42	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDTGMGWFRQAPGKEREFVAAIRWS GKETWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEDPSMYTL EEYEYDWGQGTLVTVSS
GLP1R-40-	154 43	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMGWFRQAPGKERECVAAISS GRTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYSGNWG QGTLVTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ NO	ID
GLP1R-40-	155	EVQLVESGGGLVQPGGSLRLSCAASGSIFRVNVMGWFRQAPGKEREFIATIFSGG
44		DTDYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIAHEEGVYRWD
		WGQGTLTVSS
GLP1R-40-	156	EVQLVESGGGLVQPGGSLRLSCAASGFTCGDYMGMWFRQAPGKEREIVASITSGG
45		RKNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDDYSGSWGQ
		GTLTVSS
GLP1R-40-	157	EVQLVESGGGLVQPGGSLRLSCAASGHSGFNGPMGWFRQAPGKEREVIAAIDWS
46		GGSTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAGKIGVYGW
		GQGTLTVSS
GLP1R-40-	158	EVQLVESGGGLVQPGGSLRLSCAASGSSFRFRAMGWFRQAPGKEREFVAAINRG
47		GKISHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIRPDYLSRD
		YRKYDWGQGTLTVSS
GLP1R-40-	159	EVQLVESGGGLVQPGGSLRLSCAASGFTWGDYTMGMWFRQAPGKEREFGVAIADS
48		DGRTRYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYSGSW
		GQGTLTVSS
GLP1R-40-	160	EVQLVESGGGLVQPGGSLRLSCAASGNILSNTMGWFRQAPGKEREFGVAGISWS
49		GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIVTSDYDLG
		NDWGQGTLTVSS
GLP1R-40-	161	EVQLVESGGGLVQPGGSLRLSCAASGIFTFRRYDMGMWFRQAPGKEREFGVAYISSD
50		GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIVLDYSGGWG
		QGTLTVSS
GLP1R-40-	162	EVQLVESGGGLVQPGGSLRLSCAASGLTLSNYAMGWFRQAPGKEREFGVAAISRS
51		GSSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEMSGISGWD
		WGQGTLTVSS
GLP1R-40-	163	EVQLVESGGGLVQPGGSLRLSCAASGYTTSINTMGWFRQAPGKEREVVAASIERTG
52		GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAASAIMSGALRRFE
		YDWGQGTLTVSS
GLP1R-40-	164	EVQLVESGGGLVQPGGSLRLSCAASGRTFSIDAMGWFRQAPGKEREFGVAAIKPDG
53		SITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASASYGLGLELF
		HDEYNWGQGTLTVSS
GLP1R-40-	165	EVQLVESGGGLVQPGGSLRLSCAASGSIFSINAMGWFRQAPGKEREELVAGISSKG
54		GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAFRGIMRPDWG
		QGTLTVSS
GLP1R-40-	166	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYRMGWFRQAPGKEREAVAAIASM
55		GGLTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYIGSW
		GQGTLTVSS
GLP1R-40-	167	EVQLVESGGGLVQPGGSLRLSCAASGFTFGAFTMGWFRQAPGKERERVAAITCS
56		GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYIGSW
		QGTLTVSS
GLP1R-40-	168	EVQLVESGGGLVQPGGSLRLSCAASGIPSTIRAMGWFRQAPGKEREVGRIYWRD
57		DNTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVIDGYIGSW
		QGTLTVSS
GLP1R-40-	169	EVQLVESGGGLVQAGGSLRLSCAASGFTDGIDAMGWFRQAPGKEREVVAGIAW
58		GDGTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAISVYNN
		YYPIISRDEYDWGQGTLTVSS
GLP1R-43-	170	EVQLVESGGGLVQAGGSLRLSCAASGRTIVPYTMGMWFRQAPGKEREVVAISWS
1		GKSTYYADSVRGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAQRWSQDW
		GQGTQTVSS
GLP1R-43-	171	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFGVAAISWS
2		GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVPTGRGERD
		YWGQGTQTVSS
GLP1R-43-	172	EVQLVESGGGLVQAGGSLRLSCAASGFTFSNYAMGWFRQAPGKEREFGVATITWS
3		GSSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVPTLYREGY
		WGQGTQTVSS
GLP1R-43-	173	EVQLVESGGGLVQAGGSLRLSCAASGSIFHINPMGWFRQAPGKEREFGVAAINF
4		TNYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVDGGPLWDDGY
		DWGQGTQTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ NO	ID
GLP1R-43-	174	EVQLVESGGGLVQAGGSLRLSCAASGSIFRINAMGWFRQAPGKEREGVASINIFG 5 TT KYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAVGWGP HNDDRY DWGQGTQVTVSS
GLP1R-43-	175	EVQLVESGGGLVQAGGSLRLSCAASGTTFSIYAMEWFRQAPGKERELVATISRSG 6 GTTYYADSVGGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA SWYRDDY WGQGTQVTVSS
GLP1R-43-	176	EVQLVESGGGLVQAGGSLRLSCAASGSIFRINAMGWFRQAPGKEREGVAAINNF 7 GTT KYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAVRWGP HNDDR YDWGQGTQVTVSS
GLP1R-43-	177	EVQLVESGGGLVQAGGSLRLSCAASGFILYGYAMGWFRQAPGKEREGVAAINNF 8 GTT KYADSAKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA VRWGP HNDDR YDWGQGTQVTVSS
GLP1R-43-	178	EVQLVESGGGLVQAGGSLRLSCAASGFILYGYAMGWFRQAPGKEREGVSSISP SD 9 AST YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA VLN TYSDSWG QGTQVTVSS
GLP1R-43-	179	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREGVTAISTS 10 DGST YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA RDG YSGSW GQGTQVTVSS
GLP1R-43-	180	EVQLVESGGGLVQAGGSLRLSCAASGYTITNSYRMGWF RQAPGKEREFVAGITM 11 SGPNTRYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA NRG LAGPA WGQGTQVTVSS
GLP1R-43-	181	EVQLVESGGGLVQAGGSLRLSCAASGFTFDDNAMGWFRQAPGKEREFVSGISTS 12 GST YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA AGGY DW GQGTQVTVSS
GLP1R-43-	182	EVQLVESGGGLVQAGGSLRLSCAASGRTFSYYHMGWFRQAPGKEREGVSWISSY 13 YS ST YYADSESGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA VLDG YSC SWG QGTQVTVSS
GLP1R-43-	183	EVQLVESGGGLVQAGGSLRLSCAASGSPFRLYTMGWF RQAPGKEREVVAH IYSY 14 GS IN YADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA ALW GHSGD WG QGTQVTVSS
GLP1R-43-	184	EVQLVESGGGLVQAGGSLRLSCAASGSTFDTYGMGWF RQAPGKEREFV ASITWS 15 GS ST YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA NR HWS GFYY WGQGTQVTVSS
GLP1R-43-	185	EVQLVESGGGLVQAGGSLRLSCAASGRTSSPYTMGWF RQAPGKEREFV SAI SWS 16 GG STV YADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCALI RRAP YSR LE TWGQGTQVTVSS
GLP1R-43-	186	EVQLVESGGGLVQAGGSLRLSCAASGSIFPINAMGWFRQAPGKEREGV AIT TNFG 17 TT KYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCA VRWGP RND HY DWGQGTQVTVSS
GLP1R-43-	187	EVQLVESGGGLVQAGGSLRLSCAASGRTFDTYAMGWFRQAPGKEREFV AITW 18 GGR RT YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCA VP RL RDY DYWGQGTQVTVSS
GLP1R-43-	188	EVQLVESGGGLVQAGGSLRLSCAASGRRF SAYGMGWF RQAPGKEREFV AA VSW 19 DGR NT YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCA ST DDYGV DW GQGTQVTVSS
GLP1R-43-	189	EVQLVESGGGLVQAGGSLRLSCAASGSTFDNYAMGWFRQAPGKEREFV SAI SGD 20 GG ST YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCA VP RL RD YWGQGTQVTVSS
GLP1R-43-	190	EVQLVESGGGLVQAGGSLRLSCAASGSIFRINAMGWFRQAPGKEREGV SITS FD 21 AST YYADSVRGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAA ALD G YSG SWG QGTQVTVSS
GLP1R-43-	191	EVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREFV STISTG 22 GS ST YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCA AV PT GR RRD YWGQGTQVTVSS
GLP1R-43-	192	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFV AA SWS 23 GG ST YYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCA AV PVP NT KD YWGQGTQVTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ NO	ID
GLP1R-43-	193 24	EVQLVESGGGLVQAGGSLRLSCAASGNVFMIKDMGWFRQAPGKEREWVTAISW NGGSTDYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVTYSYDL GNDWGQGTQVTVSS
GLP1R-43-	194 25	EVQLVESGGGLVQAGGSLRLSCAASGFPSIWPMSGWFRQAPGKEREFIATIFSGG DTDYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVTYSYDL WGQGTQVTVSS
GLP1R-43-	195 26	EVQLVESGGGLVQAGGSLRLSCAASGRGFSRYAMGWFRQAPGKEREFVAIRW SGKETTYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCALGPVRRSRLE WGQGTQVTVSS
GLP1R-43-	196 27	EVQLVESGGGLVQAGGSLRLSCAASGRTSIDYGMGWFRQAPGKEREFVARIW SGNTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVTYSYDL AGYDWGQGTQVTVSS
GLP1R-43-	197 28	EVQLVESGGGLVQAGGSLRLSCAASGNDFSFNSMGWFRQAPGKEREFLASVSWG FGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCARAYGNPTWQG GTQVTVSS
GLP1R-43-	198 29	EVQLVESGGGLVQAGGSLRLSCAASGRFTDYPGMWFRQAPGKERELESFVPIN GTSTYYADSDSGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAALDGYSCSW GQGTQVTVSS
GLP1R-43-	199 30	EVQLVESGGGLVQAGGSLRLSCAASGRTFSIYAMGWFRQAPGKEREFVATISRGG STYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAGPRSGKDYG QGTQVTVSS
GLP1R-43-	200 31	EVQLVESGGGLVQAGGSLRLSCAASGFIFQLYVMGWFRQAPGKEREGVITYINNI DGSTYYAYSVRGRTISADNAKNTVYLQMNSLKPEDTAVYYCAAVERDGYS GQGTQVTVSS
GLP1R-43-	201 32	EVQLVESGGGLVQAGGSLRLSCAASGSTFSSYAMEWFRQAPGKERELVATISRGG GRYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAANWYRYDY WGQGTQVTVSS
GLP1R-43-	202 33	EVQLVESGGGLVQAGGSLRLSCAASGFPRINAMGWFRQAPGKERELVTAISSSG SSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAASGYATYYGE RDYWGQGTQVTVSS
GLP1R-43-	203 34	EVQLVESGGGLVQAGGSLRLSCAASGFTLSSYTMGWFRQAPGKEREFVSAISRGG GNTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPSYAEYDY GQGTQVTVSS
GLP1R-43-	204 35	EVQLVESGGGLVQAGGSLRLSCAASGRFTSIYGMGWFRQAPGKEREGVAAING GDSTNYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAASAPYSGRN YWQGTQVTVSS
GLP1R-43-	205 36	EVQLVESGGGLVQAGGSLRLSCAASGLt fSTTVMGWFRQAPGKEREGDGYISITD GSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCSAALDGYSGSWG QGTQVTVSS
GLP1R-43-	206 37	EVQLVESGGGLVQAGGSLRLSCAASGRFTLENYRMGWFRQAPGKEREFVAAVSW SSGNAYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAANWKMLLG VENDWGQGTQVTVSS
GLP1R-43-	207 38	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISWS GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPTVYGERD YWQGTQVTVSS
GLP1R-43-	208 39	EVQLVESGGGLVQAGGSLRLSCAASGSILSISPMSGWFRQAPGKERELVAINFSWG TTDYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVTYSYDL WGQGTQVTVSS
GLP1R-43-	209 40	EVQLVESGGGLVQAGGSLRLSCAASGRFTSSYAMGWFRQAPGKEREFVAAISWS GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAERYRSGYY ARDSWGQGTQVTVSS
GLP1R-43-	210 41	EVQLVESGGGLVQAGGSLRLSCAASGFTLSDYAMGWFRQAPGKEREFVSAISR GTTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVTYSYDL YWQGTQVTVSS
GLP1R-43-	211 42	EVQLVESGGGLVQAGGSLRLSCAASGRDLYVMGWFRQAPGKERELVAIKFS GGTTDYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIVTYSYDL WDWGQGTQVTVSS

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID
GLP1R-43-	212	EVQLVESGGGLVQAGGSLRLSCAASGSIFTFNAMGWFRQAPGKEREVFAGITRSA
43		VSTSYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAFRGIMRPDWG
		QGTQVTVSS
GLP1R-43-	213	EVQLVESGGGLVQAGGSLRLSCAASGRTFDSSYAMGWFRQAPGKEREVFVAITSS
44		GGNTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPARYGARD
		YWQQGTQVTVSS
GLP1R-43-	214	EVQLVESGGGLVQAGGSLRLSCAASGRTFNNNDHMGWFRQAPGKEREVFVAVIEIG
45		GATNYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCATWDGRQVWQQ
		GTQVTVSS
GLP1R-43-	215	EVQLVESGGGLVQAGGSLRLSCAASGGTFRKLAMGWFRQAPGKEREFLVAAIRW
46		SGGITYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAATLAKGGGR
		WGQQGTQVTVSS
GLP1R-43-	216	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREVFVAIISWS
47		GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPRAPSIRD
		YWQQGTQVTVSS
GLP1R-43-	217	EVQLVESGGGLVQAGGSLRLSCAASGRTFRIYAMGWFRQAPGKEREFLVSSISWN
48		SGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAAYSYTQGTT
		YESWGQQGTQVTVSS
GLP1R-43-	218	EVQLVESGGGLVQAGGSLRLSCAASGRTFTSYRMGWFRQAPGKEREWMGTIDY
49		SGRTYYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAAMDGYSGSW
		GQQGTQVTVSS
GLP1R-43-	219	EVQLVESGGGLVQAGGSLRLSCAASGRTFSIYAMGWFRQAPGKEREVFVAAINWN
50		GDTTYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPRYSDYD
		WGQQGTQVTVSS
GLP1R-43-	220	EVQLVESGGGLVQAGGSLRLSCAASGRFFSTRVMGWFRQAPGKEREFLVAIKFSG
51		GTTDYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAIAHEEGVYRW
		DWGQQGTQVTVSS
GLP1R-43-	221	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREVFVAIISWS
52		GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPSVYGRD
		YWQQGTQVTVSS
GLP1R-43-	222	EVQLVESGGGLVQAGGSLRLSCAASGSTFSIDVMGWFRQAPGKERECSVYISMS
53		DGRTYYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAELDGYSGSW
		GQQGTQVTVSS
GLP1R-43-	223	EVQLVESGGGLVQAGGSLRLSCAASGLSFGSYTMGWFRQAPGKEREVVAIISRT
54		GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCALIQRAPYSRL
		ETWGQQGTQVTVSS
GLP1R-43-	224	EVQLVESGGGLVQAGGSLRLSCAASGSTLSIYGMWFRQAPGKEREVGVAIISWS
55		DGSTSYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVADIGLASDF
		DYGWQQGTQVTVSS
GLP1R-43-	225	EVQLVESGGGLVQAGGSLRLSCAASGSTFSNYAMGWFRQAPGKEREVFATITRSS
56		GNTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPKPYSYDY
		WGQQGTQVTVSS
GLP1R-43-	226	EVQLVESGGGLVQAGGSLRLSCAASGSTFSIYTMGWFRQAPGKEREVFVAIISGSS
57		DSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCATVPKTRYTRDY
		WGQQGTQVTVSS
GLP1R-43-	227	EVQLVESGGGLVQAGGSLRLSCAASGNTFSSYAMGWFRQAPGKEREVFVAAISRSG
58		GRTYYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAAPYNETNSWG
		QGTQVTVSS
GLP1R-43-	228	EVQLVESGGGLVQAGGSLRLSCAASGSTFSTYAMGWFRQAPGKEREVVAISRSG
59		GRTYYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAARYNERNSWG
		QGTQVTVSS
GLP1R-43-	229	EVQLVESGGGLVQAGGSLRLSCAASGGTLNNNPMAMGWFRQAPGKEREVFVAAISWS
60		YWSNGKTPYADSVKRRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAALDGYS
		GAWGQQGTQVTVSS
GLP1R-43-	230	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREVFVAIISWS
61		GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPRAPSERDY
		WGQQGTQVTVSS

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID Sequence
GLP1R-43-	231	EVQLVESGGGLVQAGGSLRLSCAASGRTFNNNDMGWFRQAPGKEREVFAVI KL GGATTYYDYSEGRFTISADNAKNTVYLQMNSLKPEDTAVYYCATWDARHVG QGTQTVSS
GLP1R-43-	232	EVQLVESGGGLVQAGGSLRLSCAASGRAFSYYNMGWFRQAPGKEREGVSWI SSS DGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVLDGCSGSW GQGTQTVSS
GLP1R-43-	233	EVQLVESGGGLVQAGGSLRLSCAASGSTFSTYAMGWFRQAPGKEREVFVAA INRS GASTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAALLGGRRGC GKGYWGQGTQTVSS
GLP1R-43-	234	EVQLVESGGGLVQAGGSLRLSCAASGSILDTYAMGWFRQAPGKEREVLSGINTS GDTTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVLAGYEYWG QGTQTVSS
GLP1R-43-	235	EVQLVESGGGLVQAGGSLRLSCAASGSTLSINAMGWFRQAPGKEREVFVAHMSHD GTTNYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCARLPNRYRGQGT QVTVSS
GLP1R-43-	236	EVQLVESGGGLVQAGGSLRLSCAASGSIFRLNAMGWFRQAPGKEREGVAA INNF DTTKYADSSKGRTFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVRWGPRSDDR WGQGTQTVSS
GLP1R-43-	237	EVQLVESGGGLVQAGGSLRLSCAASGLTNPPFDNPFMGWFRQAPGKEREVFAVIS WTGGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCPAVPRYYG DDDRPPVDWGQGTQTVSS
GLP1R-43-	238	EVQLVESGGGLVQAGGSLRLSCAASGPTFSKAVMGWFRQAPGKEREVFVAMNW SGRSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAATPAGRGGY WGQGTQTVSS
GLP1R-43-	239	EVQLVESGGGLVQAGGSLRLSCAASGSIFSDYAMGWFRQAPGKEREVFATINWG GGRTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPKTRYARD YWQGTQTVSS
GLP1R-43-	240	EVQLVESGGGLVQAGGSLRLSCAASGFILSDYAMGWFRQAPGKEREVFVAAISSE ASTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVRFWAGYDSW QGTQTVSS
GLP1R-43-	241	EVQLVESGGGLVQAGGSLRLSCAASGYTDYKYDMGWFRQAPGKEREVFVAAISW GGGLITVYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVATVTDYT GTYSDGWGQGTQTVSS
GLP1R-43-	242	EVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKEREVFATINW GGGNTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPKTRYAY DYWGQGTQTVSS
GLP1R-43-	243	EVQLVESGGGLVQAGGSLRLSCAASGRFTSRYYMGWFRQAPGKEREVLVAVI LRG GSTNYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAARRYGNLYNT NNYDWGQGTQTVSS
GLP1R-43-	244	EVQLVESGGGLVQAGGSLRLSCAASGSILSSYVMGWFRQAPGKEREVFSAISRG TSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPKTRYDRDY WGQGTQTVSS
GLP1R-43-	245	EVQLVESGGGLVQAGGSLRLSCAASGFTLDNYAMGWFRQAPGKEREVFVAAISWS GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPKTRYSYD YWQGTQTVSS
GLP1R-43-	246	EVQLVESGGGLVQAGGSLRLSCAASGNTYSYKVMGWFRQAPGKEREVFVIIIRN GDTTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAASPKYMTAYE RSYDWGQGTQTVSS
GLP1R-43-	247	EVQLVESGGGLVQAGGSLRLSCAASGSIFRNYYAMGWFRQAPGKEREVFATITSG GNTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPKTRYRRDY WGQGTQTVSS
GLP1R-43-	248	EVQLVESGGGLVQAGGSLRLSCAASGFTFGTTMGWFRQAPGKEREVVAAITGS GRSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAASAI GSGALRR FEYDWGQGTQTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ NO	ID
GLP1R-43-	249	EVQLVESGGGLVQAGGSLRLSCAASGGTFSAYAMGWFRQAPGKEREVAAIRW DGGYTRYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAATTPTTSYLP RSERQYEWGQGTQVTVSS
GLP1R-43-	250	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREVAAI SWS GGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVPSVYGERD YWQGTQVTVSS
GLP1R-43-	251	EVQLVESGGGLVQAGGSLRLSCAASGSFFSINAMGWFRQAPGKEREVAGI SQSG GSTAYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAHRIIVGGTSG DWRWGQGTQVTVSS
GLP1R-43-	252	EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYRMGWFRQAPGKEREVAAISRT KIPKYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAVWSGRDWGQGT QVTVSS
GLP1R-43-	253	EVQLVESGGGLVQAGGSLRLSCAASGFTFRRYVMGWFRQAPGKEREVAAISRD GDRTRYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCASTRLAGRWYR DSEYKWGQGTQVTVSS
GLP1R-43-	254	EVQLVESGGGLVQAGGSLRLSCAASGRTFSDNAMGWFRQAPGKEREVATISRG GSRTSYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAGPRSGRDYW GQGTQVTVSS
GLP1R-43-	255	EVQLVESGGGLVQAGGSLRLSCAASGFTFRSYAMGWFRQAPGKEREVATITRN GDNTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCATVGTRYNYW GQGTQVTVSS
GLP1R-43-	256	EVQLVESGGGLVQAGGSLRLSCAASGSTFSDYVMGWFRQAPGKEREVATISGTWN GDTTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAVVRLLGGDY WGQGTQVTVSS
GLP1R-43-	257	EVQLVESGGGLVQAGGSLRLSCAASGGIISNYHMGWFRQAPGKEREVATITRSG GSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAMAGRGRWGQG TQVTVSS
GLP1R-43-	258	EVQLVESGGGLVQAGGSLRLSCAASGFSDDDYVMGWFRQAPGKEREVATISGTWN WSGASTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAYTDYDE ALEETRGSYDWGQGTQVTVSS
GLP1R-43-	259	EVQLVESGGGLVQAGGSLRLSCAASGSTFPYAMGWFRQAPGKEREVWSGISSR DDTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCSAHRIVFRGTSV GDWRWGQGTQVTVSS
GLP1R-43-	260	EVQLVESGGGLVQAGGSLRLSCAASGRAFSYYNMGWFRQAPGKEREVWSISSL DGSTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVLDGYSGSW GQGTQVTVSS
GLP1R-43-	261	EVQLVESGGGLVQAGGSLRLSCAASGSTFSIDVMGWFRQAPGKEREVVAATGRR GGPTYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAARTSYSGTYD YGVWDWGQGTQVTVSS
GLP1R-43-	262	EVQLVESGGGLVQAGGSLRLSCAASGGTFSSYAMGWFRQAPGKEREVAAIWS GSITYYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAVGRSGRDYWG QGTQVTVSS
GLP1R-43-	263	EVQLVESGGGLVQAGGSLRLSCAASGSIFRINAMGWFRQAPGKEREVAAINNF GTTKYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAAVRWGPRNDDR YDWGQGTQVTVSS
GLP1R-43-	264	EVQLVESGGGLVQAGGSLRLSCAASGGTLNNNPAMGWFRQAPGKEREVVAI YWSNGKTQYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCAALDGY GSWGQGTQVTVSS
GLP1R-43-	265	EVQLVESGGGLVQAGGSLRLSCAASGRTFNNDHMGWFRQAPGKEREVAVIEIG GATNYADSVKGRFTISADNAKNTVYLQMNSLKPEDTAVYYCASWDGRQVWGQ GTQVTVSS
GLP1R-41-	266	EVQLVESGGGLVQPQGGSLRLSCAASGLTISTYIMGWFRQAPGKEREVARVS WDGRNAYYANSRFGRFTISADNSKNTAYLQMNSLKPEDTAVYYCPRYVSPARD HGCWGQGTQVTVSS
GLP1R-41-	267	EVQLVESGGGLVQPQGGSLRLSCAASGLTISTYIMGWFRQAPGKEREVAVVNWN GDSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYYTDXDEAL EETRGSYDWGQGTQVTVSS

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID Sequence
GLP1R-41- 03	268	EVQLVESGGGLVQPGGSLRLSCAASGTLFKINAMGWFRQAPGKERELVAAINRG GKITHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASLRNSGSNVE GRWGQGTLLTVSS
GLP1R-41- 04	269	EVQLVESGGGLVQPGGSLRLSCAASGVTLDDLYAMGWFRQAPGKEREFVAAISP AVITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYDYSDYPLP DANEYEWGQGTLLTVSS
GLP1R-41- 05	270	EVQLVESGGGLVQPGGSLRLSCAASGRTFSDDYIMGWFRQAPGKEREFVAVINRG STTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVQAYSNSDYY SQEGAYDWGQGTLLTVSS
GLP1R-41- 06	271	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYVMGWFRQAPGKEREGVSYISSL GRTHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLDGYNGSWG QGTLTVSS
GLP1R-41- 07	272	EVQLVESGGGLVQPGGSLRLSCAASGFTSFRFGMWFRQAPGKEREGVAAIGSD GSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCASGRDRYARDLSE YEYVWGQGTLLTVSS
GLP1R-41- 08	273	EVQLVESGGGLVQPGGSLRLSCAASGFTFRFNAMGWFRQAPGKEREFVAAINWR GSHPYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAATLGEPLVKY TWGQGTLLTVSS
GLP1R-41- 09	274	EVQLVESGGGLVQPGGSLRLSCAASGGTFGVYHMGWFRQAPGKEREFLASVTW GFGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAATTTRSYDDT YRNNSWVYNWGQGTLLTVSS
GLP1R-41- 10	275	EVQLVESGGGLVQPGGSLRLSCAASGFSFDDYAMGWFRQAPGKERELVAIRWS GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYGSGSDYLP MDWGQGTLLTVSS
GLP1R-41- 11	276	EVQLVESGGGLVQPGGSLRLSCAASGPTFTIYAMGWFRQAPGKEREFVGAISMSG EDTIYADSEKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYQAYTSNTNY NQEGAYDWGQGTLLTVSS
GLP1R-41- 12	277	EVQLVESGGGLVQPGGSLRLSCAASGPTFSNYVGWFRQAPGKEREFVAAILCSG GITCYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYIGTWQ GTLTVSS
GLP1R-41- 13	278	EVQLVESGGGLVQPGGSLRLSCAASGGTFSSIGMWFRQAPGKEREGVAAIGSD GSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAASDRYARVLTE YEYVWGQGTLLTVSS
GLP1R-41- 14	279	EVQLVESGGGLVQPGGSLRLSCAASGVTFNNYGMGWFRQAPGKERELVAIRW SGSATFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADDGARGSW GQGTLLTVSS
GLP1R-41- 15	280	EVQLVESGGGLVQPGGSLRLSCAASGRTFTMDGMGWFRQAPGKEREGVAAIGS DGSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGSNIGGSRWR YDWGQGTLLTVSS
GLP1R-41- 16	281	EVQLVESGGGLVQPGGSLRLSCAASGGIFRFNAMGWFRQAPGKERELVAASI LTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYLPSPYYSSYY DSTKYEWGQGTLLTVSS
GLP1R-41- 17	282	EVQLVESGGGLVQPGGSLRLSCAASGSGFPNVMGWFRQAPGKEREVVAAISWN GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASAIGSGALRR FEYDWGQGTLLTVSS
GLP1R-41- 18	283	EVQLVESGGGLVQPGGSLRLSCAASGFTFGFYAMGWFRQAPGKERELVAAISWS DASTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCALDNRRSYVDY YNVSEYDWGQGTLLTVSS
GLP1R-41- 19	284	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYPMGWFRQAPGKERECVSTIWSRG DTYYADNVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAALDGYSATWGQ GTLTVSS
GLP1R-41- 20	285	EVQLVESGGGLVQPGGSLRLSCAASGFTFDYYAMGWFRQAPGKERELVAAISWS NDITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCALDNRRSYVDY SVSEYDWGQGTLLTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ NO	ID
GLP1R-41-	286	EVQLVESGGGLVQPGGSLRLSCAASGGTFSTYTMGWFHQAPGKEREFVAGIYND
21		GTASYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAFDGYTGNDW
		GQQGTLTVSS
GLP1R-41-	287	EVQLVESGGGLVQPGGSLRLSCAASGVTLTDLYAMGWFRQAPGKEREWARMY
22		LDGDYPYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLDGYSG
		SWGQGTLTVSS
GLP1R-41-	288	EVQLVESGGGLVQPGGSLRLSCAASGRTISRYIMGWFRQAPGKERELVAAINRSG
23		KSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCASTRFAGRWYRDS
		EYKGWQGTLTVSS
GLP1R-41-	289	EVQLVESGGGLVQPGGSLRLSCAASGRTLSVYAMGWFRQAPGKEREFVAAVRW
24		SGGITWYVDSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAFDGYSGSD
		WGQQGTLTVSS
GLP1R-41-	290	EVQLVESGGGLVQPGGSLRLSCAASGSIFSITEMGWFRQAPGKERELVAIAVGG
25		GITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAHDDDESPY
		YSGGYYRALYDWGQGTLTVSS
GLP1R-41-	291	EVQLVESGGGLVQPGGSLRLSCAASGSIFSITEMGWFRQAPGKERELVAIASPAA
26		LTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASMSLRPLDPAS
		YSPDIQPYDWGQGTLTVSS
GLP1R-41-	292	EVQLVESGGGLVQPGGSLRLSCAASGFTCGDYMGMWFRQAPGKERESVAAIDSD
27		GRTHYADSVISRPTISADNSKNTAYLQMNSLKPEDTAVYYCAALDGYSGDWGQ
		GTLTVSS
GLP1R-41-	293	EVQLVESGGGLVQPGGSLRLSCAASGRTLSFYAMGWFRQAPGKEREFVAAINRG
28		GRISHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGRRYGSPPHD
		GSSYEWGQGTLTVSS
GLP1R-41-	294	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMGWFRQAPGKEREFVAGISWT
29		GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVNFGFEWGQG
		TLTVSS
GLP1R-41-	295	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMGWFRQAPGKEREGVAAIGSD
30		GSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAATLRATITNFDEY
		VWGQGTLTVSS
GLP1R-41-	296	EVQLVESGGGLVQPGGSLRLSCAASGRTFNRYPMGWFRQAPGKEREFVAHMSH
31		DGTTWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAPGTRYYGSN
		QVNYNWGQGTLTVSS
GLP1R-41-	297	EVQLVESGGGLVQPGGSLRLSCAASGSIFSFNAMGWFRQAPGKEREFVAGITRRG
32		LSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAGKIGVYWG
		QGTLTVSS
GLP1R-41-	298	EVQLVESGGGLVQPGGSLRLSCAASGSISSINAMGWFRQAPGKERELVAGIITS
33		DSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGSAYVAGVRR
		RNAYHWGQGTLTVSS
GLP1R-41-	299	EVQLVESGGGLVQPGGSLRLSCAASGGTSADVNGWFRQAPGKEREFVAAISTG
34		SITYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATGYDSGLYFITDS
		NDYEWGQGTLTVSS
GLP1R-41-	300	EVQLVESGGGLVQPGGSLRLSCAASGFTFDAMGWFRQAPGKEREFVAAIRW
35		RGGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAQGTLYDDY
		DGLPIKYDWGQGTLTVSS
GLP1R-41-	301	EVQLVESGGGLVQPGGSLRLSCAASGDIIFNINAMGWFRQAPGKEREFVAAISPAA
36		LTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAATPIERLGLDAYE
		YDWGQGTLTVSS
GLP1R-41-	302	EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNMGWFRQAPGKEREFVAAINWS
37		GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEPPDSSWYLD
		GSPEFFWKWQGTLTVSS
GLP1R-41-	303	EVQLVESGGGLVQPGGSLRLSCAASGSISVFDAMGWFRQAPGKEREFVAGISGSG
38		GDTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASPKYSTHSIFD
		ASPYNWGQGTLTVSS
GLP1R-41-	304	EVQLVESGGGLVQPGGSLRLSCAASGFTSDDYAMGWFRQAPGKEREFVAAIRW
39		SSSNIDTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAATDLSGHG
		DVSEYEDWGQGTLTVSS

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID Sequence
GLP1R-41-	305 40	EVQLVESGGGLVQPGGSLRLSCAASGFTFSPNVMGWFRQAPGKEREVAAITSSG ETTWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEPYGSGSSLMS EYDWGQGTLTVSS
GLP1R-41-	306 41	EVQLVESGGGLVQPGGSLRLSCAASGRNLRMYRMGWFRQAPGKEREVAAINW SGDNTHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAANWKMLLG ENDWGQGTLTVSS
GLP1R-41-	307 42	EVQLVESGGGLVQPGGSLRLSCAASGDTFNCYAMGWFRQAPGKEREVAVINW SGDNTHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYTDYDEA LEETRGRYDWGQGTLTVSS
GLP1R-41-	308 43	EVQLVESGGGLVQPGGSLRLSCAASGSISTINVMGWFRQAPGKEREVAAISP VTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDLSGRGDVSE EYDWGQGTLTVSS
GLP1R-41-	309 44	EVQLVESGGGLVQPGGSLRLSCAASGRTLSKYRMGWFRQAPGKEREVAAIRWS GGITTWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAIPHGIAGRITWG QGTLTVSS
GLP1R-41-	310 45	EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYAMGWFRQAPGKEREVELVAGIDQS GGITTWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADDYLGGDNW YLGPYDWGQGTLTVSS
GLP1R-41-	311 46	EVQLVESGGGLVQPGGSLRLSCAASGFTIDDYAMGWFRQAPGKEREVAAVSGT GTIAYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYYIDYDEALE ETRGSYDWGQGTLTVSS
GLP1R-41-	312 47	EVQLVESGGGLVQPGGSLRLSCAASGRTFNNYVMGWFRQAPGKEREVELVAGITSG RDITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADGVLATLNW DWGQGTLTVSS
GLP1R-41-	313 48	EVQLVESGGGLVQPGGSLRLSCAASGSGISFNAMGWFRQAPGKEREVAAISRSG DTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADLTWADGPY RWGQGTLTVSS
GLP1R-41-	314 49	EVQLVESGGGLVQPGGSLRLSCAASGRTFSYAMGWFRQAPGKEREVAAINRG GKISHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVRRYGNPPHD GSSYEWGQGTLTVSS
GLP1R-41-	315 50	EVQLVESGGGLVQPGGSLRLSCAASGRTFSFYAMGMWFRQAPGKEREELVAIKFSGG TTDYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIAHEEGVYRWQ GTLTVSS
GLP1R-41-	316 51	EVQLVESGGGLVQPGGSLRLSCAASGGIFRFNAMGWFRQAPGKEREVLVAGISGSG GDTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAFRGIMRPDWG QGTLTVSS
GLP1R-41-	317 52	EVQLVESGGGLVQPGGSLRLSCAASGRTFSFYAMGWFRQAPGKEREVAAINRG GKISHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVRRYGSPPHD GSSYEWGQGTLTVSS
GLP1R-41-	318 53	EVQLVESGGGLVQPGGSLRLSCAASGSDFSLNAMGWFRQAPGKEREVAAISWS GGSTLYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCASNESDAYNWG QGTLTVSS
GLP1R-41-	319 54	EVQLVESGGGLVQPGGSLRLSCAASGRTLVNYDMGWFRQAPGKEREVAAIRW SGGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAFRGIMLPPW GQGTLTVSS
GLP1R-41-	320 55	EVQLVESGGGLVQPGGSLRLSCAASGRTFEKDAMGWFRQAPGKEREVMAAIRW SGGITCYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGYSLPDDYD GLECEYDWGQGTLTVSS
GLP1R-41-	321 56	EVQLVESGGGLVQPGGSLRLSCAASGSFFKINAMGWFRQAPGKEREVAGITRS GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAESLGRWWQG TLTVSS
GLP1R-41-	322 57	EVQLVESGGGLVQPGGSLRLSCAASGRTFSIDAMGWFRQAPGKEREVAAIRWS GGITTWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASHDSDWGQ TLTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ NO	ID
GLP1R-41-	323	EVQLVESGGGLVQPGGSLRLSCAASGRFTSIDAMGWFRQAPGKEREFVAAIRWS GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASHDSDYGGT NANLYDWGQGTLTVSS
58		
GLP1R-41-	324	EVQLVESGGGLVQPGGSLRLSCAASGRFTDRSNVMGWFQAPGKEREFVAAINRS GSTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAKTKRTGIFTTAR MVDWGQGTLTVSS
59		
GLP1R-41-	325	EVQLVESGGGLVQPGGSLRLSCAASGSFFSINVMGWFRQAPGKERELVAATGRR GGPTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAHRIVVGGTSV GDWRWGQGTLTVSS
60		
GLP1R-41-	326	EVQLVESGGGLVQPGGSLRLSCAASGFTWGDTYMGWFRQAPGKEREGVAAIDS DGRTRYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYSGNW GQGTLTVSS
61		
GLP1R-41-	327	EVQLVESGGGLVQPGGSLRLSCAASGNIFSNTMGWFRQAPGKEREFVAAINC8G NHPYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIVTYSDDDGRD NWGQGTLTVSS
62		
GLP1R-41-	328	EVQLVESGGGLVQPGGSLRLSCAASGSIFSNTAMGWFRQAPGKEREFVAAVGSG DDTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVQAYSSSDYY SQEGAYDWGQGTLTVSS
63		
GLP1R-41-	329	EVQLVESGGGLVQPGGSLRLSCAASGFTFPAYVMGWFQAPGKERELLAVITRD GSTHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVNGRWRIWSSR NPWGQGTLTVSS
64		
GLP1R-41-	330	EVQLVESGGGLVQPGGSLRLSCAASGFSFDDYVUMGWFQAPGKERELVAVIG WGGKETWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEDPSMGY YTLEEEYEDWGQGTLTVSS
65		
GLP1R-41-	331	EVQLVESGGGLVQPGGSLRLSCAASGPTFDTYVMGWFQAPGKEREFVAAISMS GDDTAYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDLRGGRDV8 EYEYDWGQGTLTVSS
66		
GLP1R-41-	332	EVQLVESGGGLVQPGGSLRLSCAASGRFTSIDAMGWFRQAPGKEREFVGAI TWG GGNTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIVTDGDYDG WGQGTLTVSS
67		
GLP1R-41-	333	EVQLVESGGGLVQPGGSLRLSCAASGNTFSINVMGWFRQAPGKEREFVAAINWN GGSTDYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIVTYSDYLD NDWGQGTLTVSS
68		
GLP1R-41-	334	EVQLVESGGGLVQPGGSLRLSCAASGFTSTHWMGWFRQAPGKEREFVAAIVYT DGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAN8YGLGSSI AYKWGQGTLTVSS
69		
GLP1R-41-	335	EVQLVESGGGLVQPGGSLRLSCAASGRFTSISAMGWFRQAPGKEREFVAAISRG GTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDEDYALGPNEY DWGQGTLTVSS
70		
GLP1R-41-	336	EVQLVESGGGLVQPGGSLRLSCAASGSTFRINAMGWFRQAPGKERELVAAISPAA LTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAEPYGSGLYDD YDGLPIKYDWGQGTLTVSS
71		
GLP1R-41-	337	EVQLVESGGGLVQPGGSLRLSCAASGFTDGDIDAMGWFRQAPGKEREFVAAISWS NDTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALSEVWRGSE NLREGYDWGQGTLTVSS
72		
GLP1R-41-	338	EVQLVESGGGLVQPGGSLRLSCAASGLPVDDYAMGWFRQAPGKERELVAAISGS GDSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAQTEDSASIFG YGMDWGQGTLTVSS
73		
GLP1R-41-	339	EVQLVESGGGLVQPGGSLRLSCAASGRFTLSTVNMGWFRQAPGKEREFVGAISRS GETTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVDCPDYSDY ECPLEWGQGTLTVSS
74		
GLP1R-41-	340	EVQLVESGGGLVQPGGSLRLSCAASGFSFDDYAMGWFRQAPGKERELVAAVRW SGGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGDTGGAAY GWGQGTLTVSS
75		
GLP1R-41-	341	EVQLVESGGGLVQPGGSLRLSCAASGSTLSINAMGWFRQAPGKEREGVSWISSL GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYSGRWG QGTLTVSS
76		

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID Sequence
GLP1R-41- 77	342	EVQLVESGGGLVQPGGSLRLSCAASGSSVIDAMGWFRQAPGKEREVFAGISRSGDTTYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAASYNVYNNYYPIISRDEYDWGQGTLVTVSS
GLP1R-41- 78	343	EVQLVESGGGLVQPGGSLRLSCAASGSIFRVNVMGWFRQAPGKEREVLVAVTWSGGSTNYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAIEEGVYRWDWGQGTLVTVSS
GLP1R-41- 79	344	EVQLVESGGGLVQPGGSLRLSCAASGRTFSFYAMGWFRQAPGKEREVFAVVNWSGRRTYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAASSRMGVDDPETYWGQGTLVTVSS
GLP1R-41- 80	345	EVQLVESGGGLVQPGGSLRLSCAASGFTDDAAMGWFRQAPGKEREVFVAARWRGGITTYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAQGSLYDDDGGLPIKYDWGQGTLVTVSS
GLP1R-41- 81	346	EVQLVESGGGLVQPGGSLRLSCAASGSIFRINAMGWFRQAPGKEREVLVAVSISRGFRTNYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAANGIESWGQGTLVTVSS
GLP1R-41- 82	347	EVQLVESGGGLVQPGGSLRLSCAASGFTWGDYTMGWFRQAPGKEREVFASITSGGRMYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYSGSWGQGQGTLVTVSS
GLP1R-41- 83	348	EVQLVESGGGLVQPGGSLRLSCAASGPRFSSYGMGWFRQAPGKEREVGVAIIGSDGSTSYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCASWDGRQVWGQGTLVTVSS
GLP1R-41- 84	349	EVQLVESGGGLVQPGGSLRLSCAASGRTFDNLYNMGWFRQAPGKEREVFVAAISWNGVTIYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAQGSLYDDWGQGQGTLVTVSS
GLP1R-41- 85	350	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYSMGWFRQAPGKEREVFVAAISGGFLKAYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAALDDYSGSWQGTLVTVSS
GLP1R-41- 86	351	EVQLVESGGGLVQPGGSLRLSCAASGYTFRAYVMGWFRQAPGKERESELLAVITRDGSTHYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAVNGRWSRSRNPWGQGTLVTVSS
GLP1R-41- 87	352	EVQLVESGGGLVQPGGSLRLSCAASGRTFSIYAMGWFRQAPGKEREVFVAAISRGNSSTDYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAIVTYTDYLWGQGTLVTVSS
GLP1R-41- 88	353	EVQLVESGGGLVQPGGSLRLSCAASGRTIISYYAMGWFRQAPGKEREVLVAAISKSSISTYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCALGPVRRSRLEWGQGTLVTVSS
GLP1R-41- 89	354	EVQLVESGGGLVQPGGSLRLSCAASGPTFDTYVMGWFRQAPGKEREVFVAAISWTGDSSSDGDTYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAIFI DVTDYERADWGQGTLVTVSS
GLP1R-41- 90	355	EVQLVESGGGLVQPGGSLRLSCAASGFTLGNYAMGWFRQAPGKEREELVSAITWSDGSSYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCASTRFAGRWGQGTLVTVSS
GLP1R-41- 91	356	EVQLVESGGGLVQPGGSLRLSCAASGNIDRLYAMGWFRQAPGKEREVPAAI SPAATVAGMTYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAYGSGSYYYTDDLEDWGQGTLVTVSS
GLP1R-41- 92	357	EVQLVESGGGLVQPGGSLRLSCAASGRTFGRRAMGWFRQAPGKEREVLVAAIRWSGKETWYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRTYCHSRARYEWGQGTLVTVSS
GLP1R-41- 93	358	EVQLVESGGGLVQPGGSLRLSCAASGRTFSIGAMGWFRQAPGKEREYVGSITWRGGNTYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCAAGVTGGAAYWGQGQGTLVTVSS
GLP1R-41- 94	359	EVQLVESGGGLVQPGGSLRLSCAASGLTFSTYWMGWFRQAPGKEREVVAVIYTS DGSTYYADSVKGRTFISADNSKNTAYLQMNSLKPEDTAVYYCATIDGSWREWGQGTLVTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ ID NO	Sequence
GLP1R-41- 95	360	EVQLVESGGGLVQPGGSLRLSCAASGFGIDfyAMGWFRQAPGKEREVAAI SGSG DDTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASASYGLGEL FHDEYNWGQGTLVTVSS
GLP1R-41- 96	361	EVQLVESGGGLVQPGGSLRLSCAASGNILSNTMGWFRQAPGKEREVAVTWG FGSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIIVTSDYDLG NDWGQGTLVTVSS
GLP1R-41- 97	362	EVQLVESGGGLVQPGGSLRLSCAASGSISYSLDAMGWFRQAPGKEREVAAISPAA LTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAGSSRIYIYSDLSE RSYDWGQGTLVTVSS
GLP1R-41- 98	363	EVQLVESGGGLVQPGGSLRLSCAASGRFTFSYGMGWFRQAPGKEREVAAIFSGG TTDYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIAHEEGVYRWD WGQGTLVTVSS
GLP1R-41- 99	364	EVQLVESGGGLVQPGGSLRLSCAASGRFTSKYAMGWFRQAPGKEREVAAIRWS GGTTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGGWTGRYN WGQGTLVTVSS
GLP1R-44- 01	365	EVQLVESGGGLVQPGGSLRLSCAASGSIFS IYAMDWFRQAPGKEREVAAISSDDS TTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCTAVLPAYDDWGQ TLVTVSS
GLP1R-44- 02	366	EVQLVESGGGLVQPGGSLRLSCAASGFNSGSYTMGWFRQAPGKEREVGVSYISSLGD GRITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGLNGAAAAGWG QGTLVTVSS
GLP1R-44- 03	367	EVQLVESGGGLVQPGGSLRLSCAASGRFTFSNPGMWFQAPGKEREVVAI STG GATNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCASWDGRQGWQ GTLVTVSS
GLP1R-44- 04	368	EVQLVESGGGLVQPGGSLRLSCAASGRALSSYSMGWFRQAPGKEREVVALITRG GTTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCALDNRHSYVDWG QGTLVTVSS
GLP1R-44- 05	369	EVQLVESGGGLVQPGGSLRLSCAASGSIGSINAMGWFRQAPGKEREVAAISWSG GATNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASVAYSYDLYG NDWGQGTLVTVSS
GLP1R-44- 06	370	EVQLVESGGGLVQPGGSLRLSCAASGLSFDDYAMGWFRQAPGKEREVAAISGR SGNITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCALIQRAPYSRLE TWGQGTLVTVSS
GLP1R-44- 07	371	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYAMGWFRQAPGKEREVGVAIISWS GGTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAAGWVAEYG YWGQGTLVTVSS
GLP1R-44- 08	372	EVQLVESGGGLVQPGGSLRLSCAASGGTFSSYAMGWFRQAPGKEREVATISSNG NTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADLRLVRLRRYE YNYWGQGTLVTVSS
GLP1R-44- 09	373	EVQLVESGGGLVQPGGSLRLSCAASGFTFRSNAMGWFRQAPGKEREVGVAIISTS GGIITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAERDGYGYWG QGTLVTVSS
GLP1R-44- 10	374	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMGWFRQAPGKEREVLVAGISWN GGIITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVVVRAGYDYWG QGTLVTVSS
GLP1R-44- 11	375	EVQLVESGGGLVQPGGSLRLSCAASGSTFSIYAMGWFRQAPGKEREWVATISWS GGSITNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVGRSGRDYWG QGTLVTVSS
GLP1R-44- 12	376	EVQLVESGGGLVQPGGSLRLSCAASGRAFESYAMGWFRQAPGKEREVAAIRWS GGSITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATGGWTGRYN WGQGTLVTVSS
GLP1R-44- 13	377	EVQLVESGGGLVQPGGSLRLSCAASGRIFSDYAMGWFRQAPGKEREVATINGD GDSTNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAANTYWYYTYD SWGQGTLVTVSS
GLP1R-44- 14	378	EVQLVESGGGLVQPGGSLRLSCAASGRIFSDYAMGWFRQAPGKEREVATINGD GDSTNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAANTYCNYTYD SWGQGTLVTVSS

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID Sequence
GLP1R-44- 15	379	EVQLVESGGGLVQPGGSLRLSCAASGRTLSRSNMGWFRQAPGKEREFVAAVRW SGGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCALGPVRRSRLE WGQGTLTVSS
GLP1R-44- 16	380	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMGWFRQAPGKEREFVAAITWS GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGRAGRDSWG QGTLTVSS
GLP1R-44- 17	381	EVQLVESGGGLVQPGGSLRLSCAASGRTFNSYAMGWFRQAPGKEREFVAGITRS AVSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAFRRGIMRPDWG QGTLTVSS
GLP1R-44- 18	382	EVQLVESGGGLVQPGGSLRLSCAASGFTFRNYVMGWFRQAPGKEREFVASITWS GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGRGSGRDYW GQGTLTVSS
GLP1R-44- 19	383	EVQLVESGGGLVQPGGSLRLSCAASGRALSSNSMGWFRQAPGKEREFVALITRG GTTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCALNNRRYVDWG QGTLTVSS
GLP1R-44- 20	384	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISWS GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVGRNGRDYWG QGTLTVSS
GLP1R-44- 21	385	EVQLVESGGGLVQPGGSLRLSCAASGSTFSIYAMGWFRQAPGKEREFVAAISWS GNTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAFTPATIYNTGYD YWQGQGTLTVSS
GLP1R-44- 22	386	EVQLVESGGGLVQPGGSLRLSCAASGRTEDDYAMGWFRQAPGKERELVSGITWS GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLGYDGYDY WGQGTLTVSS
GLP1R-44- 23	387	EVQLVESGGGLVQPGGSLRLSCAASGRTFSIYAMGWFRQAPGKERELVSAISTDD GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALPDDTYLATT YDYWGQGTLTVSS
GLP1R-44- 24	388	EVQLVESGGGLVQPGGSLRLSCAASGSIFSNDNVMGWFRQAPGKEREMVAIRWS GGITWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDLGIRDVSE YEYDWGQGTLTVSS
GLP1R-44- 25	389	EVQLVESGGGLVQPGGSLRLSCAASGEIASIIAMGWFRQAPGKEREWVSAINSGG DTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADRSRTIWPDWG QGTLTVSS
GLP1R-44- 26	390	EVQLVESGGGLVQPGGSLRLSCAASGRTFSTVSTMGWFRQAPGKERELVAAITWS SATYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAQRWSQDWGQ GTLTVSS
GLP1R-44- 27	391	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYAMGWFRQAPGKERELVAGITGG GSSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAATRYGYDYW GQGTLTVSS
GLP1R-44- 28	392	EVQLVESGGGLVQPGGSLRLSCAASGIPFRSRTMGWFRQAPGKEREFVAGITRNSI RTRYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAPRRPYLPIRID YIWGQGTLTVSS
GLP1R-44- 29	393	EVQLVESGGGLVQPGGSLRLSCAASGRTIVPYTMGWFRQAPGKEREFVAAISWS GASTIYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAIGGTLYDRRRFE WGQGTLTVSS
GLP1R-44- 30	394	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNNAMGWFRQAPGKEREGVAAINGS GSITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAARDDYGYWG QGTLTVSS
GLP1R-44- 31	395	EVQLVESGGGLVQPGGSLRLSCAASGRTFSIYGMGWFRQAPGKEREGVAGISWS DGSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAASDASFDYWG GQGTLTVSS
GLP1R-44- 32	396	EVQLVESGGGLVQPGGSLRLSCAASGGTFSDYGMGWFRQAPGKEREGVASICWS DGSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAATADYDYWG QGTLTVSS

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID Sequence
GLP1R-44- 33	397	EVQLVESGGGLVQPGGSLRLSCAASGSTFSTYAMGWFRQAPGKERELVAASI SWS SGTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLVTSDGVSE YNYWGQGTIVTVSS
GLP1R-44- 34	398	EVQLVESGGGLVQPGGSLRLSCAASGFLFDTSYAMGWFRQAPGKEREPVAAI SPA ALTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAYTDYDEALE ETRGSYDWGQGTIVTVSS
GLP1R-44- 35	399	EVQLVESGGGLVQPGGSLRLSCAASGFTLSNYAMGWFRQAPGKEREGVAAI SWN SGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDARRYGYWG QGTLVTIVSS
GLP1R-44- 36	400	EVQLVESGGGLVQPGGSLRLSCAASGSTFGNSYAMGWFRQAPGKEREFVAAI SRS GSITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDEDYALGPNE YDWGQGTIVTVSS
GLP1R-44- 37	401	EVQLVESGGGLVQPGGSLRLSCAASGRFTSIYAMGWFRQAPGKERELVAGI SWG GDSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAGNGYDYW GQGTLVTIVSS
GLP1R-44- 38	402	EVQLVESGGGLVQPGGSLRLSCAASGFNSGSYTMGWFRQAPGKEREGVSYI SSSD GRTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAALDGYSGSWG QGTLVTIVSS
GLP1R-44- 39	403	EVQLVESGGGLVQPGGSLRLSCAASGLTFWTSGMGWFRQAPGKEREFVAAI SRS GSLKGYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATVATALIWQGQ TLVTIVSS
GLP1R-44- 40	404	EVQLVESGGGLVQPGGSLRLSCAASGFTFSINAMGWFRQAPGKERELVSGI SWGG GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVNEDGFDYWG QGTLVTIVSS
GLP1R-44- 41	405	EVQLVESGGGLVQPGGSLRLSCAASGFTFDDNAMGWFRQAPGKERELVAAISTS GSNTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAELREYGYWG QGTLVTIVSS
GLP1R-44- 42	406	EVQLVESGGGLVQPGGSLRLSCAASGRTFTSYNMGWFRQAPGKEREFLGSILWS DDSTNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCASWDGRQVWQG GTLVTIVSS
GLP1R-44- 43	407	EVQLVESGGGLVQPGGSLRLSCAASGFTFRNYVMGWFRQAPGKEREFVAAINW NGSITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGRSARNYW GQGTLVTIVSS
GLP1R-44- 44	408	EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISTSG GITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDRIEYYSRGYD YWQGTLVTIVSS
GLP1R-44- 45	409	EVQLVESGGGLVQPGGSLRLSCAASGSTFRKYAMGWFRQAPGKEREFVAAISSG GGSTNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGRYRERDSW GQGTLVTIVSS
GLP1R-44- 46	410	EVQLVESGGGLVQPGGSLRLSCAASGSTFSIYAMGWFRQAPGKEREFVAAI SWG DTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAIDLPDDTYLATE YDWGQGTIVTVSS
GLP1R-44- 47	411	EVQLVESGGGLVQPGGSLRLSCAASGSGFSNVMGWFRQAPGKERELVAKFSG GTTDYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIAYEEGVYRW DWGQGTIVTVSS
GLP1R-44- 48	412	EVQLVESGGGLVQPGGSLRLSCAASGRTLTNHDMGWFRQAPGKEREGVSYISM DGRYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLDGYSGSW GQGTLVTIVSS
GLP1R-44- 49	413	EVQLVESGGGLVQPGGSLRLSCAASGSTFSIYAMGWFRQAPGKEREFVAAISRSG DSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVTLNDNYGYWG QGTLVTIVSS
GLP1R-44- 50	414	EVQLVESGGGLVQPGGSLRLSCAASGGTASSYHMGWFRQAPGKEREFVAFIHR GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADSIIDRRSVA VAHTSYYWGQGTIVTVSS
GLP1R-44- 51	415	EVQLVESGGGLVQPGGSLRLSCAASGLTFSTYAMGWFRQAPGKEREFVAAITWS GGITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAHGSILLDRIEW GQGTLVTIVSS

TABLE 11-continued

GLP1R Sequences		
GLP1R Variant	SEQ NO	ID
GLP1R-44-	416 52	EVQLVESGGGLVQPGGSLRLSCAASGGTFSIYAMGFRQAPGKERELVAAISSSG SITYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAAALDGPQDMY DWGQGTLTVSS
GLP1R-44-	417 53	EVQLVESGGGLVQPGGSLRLSCAASGGTFDNYAMGFRQAPGKERELVSGINS GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVPISSPSDRNY WGQGTLTVSS
GLP1R-44-	418 54	EVQLVESGGGLVQPGGSLRLSCAASGRTFSLTAMGFRQAPGKEREFVAAISPAA LTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCASRRAPRLSSDYE WGQGTLTVSS
GLP1R-44-	419 55	EVQLVESGGGLVQPGGSLRLSCAASGRNLRMRYRMGFRQAPGKEREFVAVN WNGDSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAANWKMLL GVENDWGQGTLTVSS
GLP1R-44-	420 56	EVQLVESGGGLVQPGGSLRLSCAASGFTFDIYAMGFRQAPGKERELVAGISSSG GSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLGTYDWGQ GTTLTVSS
GLP1R-44-	421 57	EVQLVESGGGLVQPGGSLRLSCAASGRTFDIYAMGFRQAPGKERELVAAINRD DSSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVAGLGNINY WGQGTLTVSS
GLP1R-44-	422 58	EVQLVESGGGLVQPGGSLRLSCAASGRSFSPNAMGFRQAPGKERELVAAITKL GFRNYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAASIEGVSGRWQ GTTLTVSS
GLP1R-44-	423 59	EVQLVESGGGLVQPGGSLRLSCAASGSFFSINAMGFRQAPGKERELVSASTWN GGYTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAHRIIVGGTSV GDWRWGQGTLTVSS
GLP1R-44-	424 60	EVQLVESGGGLVQPGGSLRLSCAASGRTFSDYAMGFRQAPGKEREFVAGITSS GGYTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVVYYGDWE GSEPVQHEYDWGQGTLTVSS
GLP1R-44-	425 61	EVQLVESGGGLVQPGGSLRLSCAASGSIFSERNAMGFRQAPGKEREFVAAIRWS GKETWYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAKTKRTGIFTTA RMVDWGQGTLTVSS
GLP1R-44-	426 62	EVQLVESGGGLVQPGGSLRLSCAASGGTFDTYAMGFRQAPGKEREFVAGISGD GTTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCATDNPYWSGNY WGQGTLTVSS
GLP1R-44-	427 63	EVQLVESGGGLVQPGGSLRLSCAASGGTFSNYAMGFRQAPGKERELVSGINS GGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVSTNDGYDY WGQGTLTVSS
GLP1R-44-	428 64	EVQLVESGGGLVQPGGSLRLSCAASGGIYRVNTMGFRQAPGKERELVAKIFSG GTTDYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIAHEEGVYRW DWGQGTLTVSS
GLP1R-44-	429 65	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMGFRQAPGKERELVAGISSSG SSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVVSDDGGYDWG QGTLTVSS
GLP1R-44-	430 66	EVQLVESGGGLVQPGGSLRLSCAASGRTSSIYNMGFRQAPGKEREFVAAISRSG RSTSADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAIIVTSDYDLGN DWGQGTLTVSS
GLP1R-44-	431 67	EVQLVESGGGLVQPGGSLRLSCAASGRALSSYSMGWFRQAPGKEREFVALITRSG GTTFYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCALDNRRSYVDWG QGTLTVSS
GLP1R-44-	432 68	EVQLVESGGGLVQPGGSLRLSCAASGRALSRYGMVFRQAPGKEREFVAAINRG GKISHYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAGNGGRNYGHS RARYEWGQGTLTVSS
GLP1R-44-	433 69	EVQLVESGGGLVQPGGSLRLSCAASGFKFNDSYMWRFRQAPGKEREFVVAINWS SGSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVNGPIFWGQ TLTVSS

TABLE 11-continued

GLP1R Sequences		
Variant	SEQ ID NO	Sequence
GLP1R-44- 70	434	EVQLVESGGGLVQPGGSLRLSCAASGRTLSDYALGWFRQAPGKERELVSGINTSGDTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAVTSSYDYWQGTTLTVSS
GLP1R-44- 71	435	EVQLVESGGGLVQPGGSLRLSCAASGTFDIYGMGWFQAPGKEREGVAITGDGSSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAADNDTEGYWGQGTLTVSS
GLP1R-44- 72	436	EVQLVESGGGLVQPGGSLRLSCAASGGTLDIYAMGWFRQAPGKEREFVAAISWSGSTTYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVLGYDRDYWGQGTLTVSS
GLP1R-44- 73	437	EVQLVESGGGLVQPGGSLRLSCAASGRPYSDAMGWFRQAPGKEREEIVAAISRTGSSIYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAQGSLYDDYDGLP1KYDWGQGTLTVSS
GLP1R-44- 74	438	EVQLVESGGGLVQPGGSLRLSCAASGRTFRTYGMGWFQAPGKEREGVAISWSGNSTSYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAARLSKRGNRSSRDYWQGTLTVSS
GLP1R-44- 75	439	EVQLVESGGGLVQPGGSLRLSCAASGTFDNYAMGWFRQAPGKERELVAGINWSDSSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAAGWGEYDWGQGTLTVSS
GLP1R-44- 76	440	EVQLVESGGGLVQPGGSLRLSCAASGTSIYAMGWFRQAPGKERELVAGINWSDSSTYYADSVKGRFTISADNSKNTAYLQMNSLKPEDTAVYYCAAVTDYDEYNWGQGTLTVSS

TABLE 12

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R-3	441	GFTFSSYG	620	ISYDESNK	799	AKHMSMQEGAVTGEQQAAKEFIAWLVKGVRVRAVLVGDADFV
GLP1R221- 065	442	GFTFSDYG	621	ISYDRSNE	800	AKHMSMQEGAVTGDGQAAKEFIAWLVKGVRVRAVLVGDADFV
GLP1R221- 075	443	GFTFSDYG	622	ISYDETNK	801	AKHMSMQEGAVTGEQQAAKEFIAWLVKGIVRRAVLVGDADFV
GLP1R221- 017	444	GFTFSDYG	623	ISYDESNK	802	AKHMSMQEGAVTGEYQAAKEFIAWLVKGVRVRAVLVGDADFV
GLP1R221- 033	445	GFTFSDYG	624	ISHDRSNK	803	AKHMSMQEGAVTGEQQAAKDFIAWLVKGRVRAVLVGDADFV
GLP1R221- 076	446	GFTFSDYG	625	ISYDETNK	804	AKHMSMQEGAVTGEQQAAKEFIAWLVKGIVRRAVLVGDADFV
GLP1R221- 092	447	GFTFSDYG	626	ISYGGSNK	805	AKHMSMQEGAVTGEQQAVKEFIAWLVKGVRVRAVLVGDADFV
GLP1R221- 034	448	GFTFSDYG	627	ISHDRSNK	806	AKHMSMQEGAVTGEQQAVKEFIAWLVKGVRVRAVLVGDADFV
GLP1R221- 066	449	GFTFSDYG	628	ISYDRSNE	807	AKHMSMQEGAVTGEQQAIKEFIAWLVKGVRVRAVLVGDADFV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ NO	SEQ ID CDR1	SEQ NO	SEQ ID CDR2	SEQ NO	SEQ ID CDR3
GLP1R221-084	450	GFTFSDYG	629	ISSDENNK	808	AKHMSMQEGAVTGEM QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-009	451	GFTFSDYG	630	ISDEGSNK	809	AKHMSMQEGAVTGAG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-072	452	GFTFSDYG	631	ISSDENNK	810	AKHMSMQEGAVTGEF QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-044	453	GFTFSDYG	632	TSYDESNK	811	AKHMSMQEGAVTGLEY QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-012	454	GFTFSDYG	633	ISSDASDK	812	AKHMSMQEGAVTGHEY QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-042	455	GFTFSDYG	634	TSYDESNK	813	AKHMSMQEGAVTGVG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-051	456	GFTFSDYG	635	ISYEGSNK	814	AKHMSMQEGAVTGMG QAAKEFIAWL1KGRVR ADLVGDAFDV
GLP1R221-083	457	GFTFSDYG	636	ISSDASDK	815	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-040	458	GFTFSDYG	637	ISYDESNE	816	AKHMSMQEGAVTGEH QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-052	459	GFTFSDYG	638	ISYDRSNE	817	AKHMSMQEGAVHGEG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-003	460	GFTFSDYG	639	ISDEGSNK	818	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-094	461	GFTFSDYG	640	ISSDENNK	819	AKHMSMQEGAVTGEF QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-001	462	GFTFSDYG	641	ISYDASNK	820	AKHMSMQEGAVTGEG QAVKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-014	463	GFTFSDYG	642	ISSDASDK	821	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-085	464	GFTFSDYG	643	ISHDRSNK	822	AKHMSMQEGAVTGLG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-022	465	GFTFSDYG	644	ISYDANNK	823	AKHMSMQEGAVTGEG QAAKEFIAWL1KGRVR ADLVGDAFDV
GLP1R221-056	466	GFTFSDYG	645	ISYEGSNQ	824	AKHMSMQEGAVTGIG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-088	467	GFTFSDYG	646	TSYDESNK	825	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-077	468	GFTFSDYG	647	ISYDATNK	826	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R221-027	469	GFTFSDYG	648	ISYHGSNK	827	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-019	470	GFTFSDYG	649	ISYDASNK	828	AKHMSMQEGAVTGYG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-029	471	GFTFSDYG	650	ISSDASDK	829	AKHMSMQEGAVTGEF QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-043	472	GFTFSDYG	651	TSYDESNK	830	AKHMSMQEGAVTGGG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-082	473	GFTFSDYG	652	ISSDASNK	831	AKHMSMQEGAVTGEG QAVKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-079	474	GFTFSDYG	653	ISYDANNK	832	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-080	475	GFTFSDYG	654	ISHDRSNK	833	AKHMSMQEGAVTGPG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-059	476	GFTFSDYG	655	IRYGGSNK	834	AKHMSMQEGAVTGEG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-069	477	GFTFSDYG	656	ISYDATNK	835	AKHMSMQEGAVTGYG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-036	478	GFTFSDYG	657	ISDEGSNK	836	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-057	479	GFTFSDYG	658	ISYEGSNQ	837	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-035	480	GFTFSDYG	659	ISDEGSNK	838	AKHMSMQEGAVTGLG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-063	481	GFTFSDYG	660	ISDEGSNK	839	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-090	482	GFTFSDYG	661	TSYDESNK	840	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-002	483	GFTFSDYG	662	ISSDASHK	841	AKHMSMQEGAVTWEG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-087	484	GFTFSDYG	663	ISYDETNK	842	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-038	485	GFTFSDYG	664	ISDEGSNK	843	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-060	486	GFTFSDYG	665	ISYGGSNK	844	AKHMSMQEGAVTNEG QAAKEFIAWLVKGRVR ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	SEQ ID NO	SEQ ID NO	CDR1	CDR2	CDR3
GLP1R221-015	487	GFTFSDYG	666	ISSDASHK	845	AKHMSMQEGAVTWEG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-020	488	GFTFSDYG	667	ISYDESNK	846	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-011	489	GFTFSDYG	668	ISSDASDK	847	AKHMSMQEGAVTGGG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-091	490	GFTFSDYG	669	ISYGGSNK	848	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-086	491	GFTFSDYG	670	TSYDESNK	849	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-074	492	GFTFSDYG	671	ISHDRSNK	850	AKHMSMQEGAVTGEG QALKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-032	493	GFTFSDYG	672	ISHDRSNK	851	AKHMSMQEGAVTGEG QAAKDFIAWLVKGRVR ADLVGDAFDV
GLP1R221-013	494	GFTFSDYG	673	ISSDASDK	852	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-058	495	GFTFSDYG	674	ISHDRSNK	853	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-031	496	GFTFSDYG	675	ISSDASDK	854	AKHMSMQEGAVTGEG QALKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-054	497	GFTFSDYG	676	ISSDASDK	855	AKHMSMQEGAVTGEG WAAKEFIAWLVKGRV RADLVGDAFDV
GLP1R221-021	498	GFTFSDYG	677	ISYDATNK	856	AKHMSMQEGAVTGEG QFAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-016	499	GFTFSDYG	678	ISSDASHK	857	AKHMSMQEGAVTWEG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-030	500	GFTFSDYG	679	ISSDASDK	858	AKHMSMQEGAVTGEG QALKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-018	501	GFTFSDYG	680	ISSDASDK	859	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-028	502	GFTFSDYG	681	ISYDAGNK	860	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-023	503	GFTFSDYG	682	TSYEESENK	861	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-089	504	GFTFSDYG	683	ISHDRSNK	862	AKHMSMQEGAVTGIG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-053	505	GFTFSDYG	684	ISSDASDK	863	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	SEQ ID NO	SEQ ID NO	CDR1	CDR2	CDR3
GLP1R221-071	506	GFTFSDYG	685	ISSDENNK	864	AKHMSMQEGAVTGIG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-055	507	GFTFSDYG	686	ISYGGSNK	865	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-046	508	GFTFSDYG	687	ISSDASNK	866	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-039	509	GFTFSDYG	688	IRYDESNK	867	AKHMSMQEGAVTGEG QALKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-078	510	GFTFSDYG	689	ISSDASNK	868	AKHMSMQEGAVMGEG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-010	511	GFTFSDYG	690	ISSDASDK	869	AKHMSMQEGAVTGIG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-005	512	GFTFSDYG	691	ISDEGSNK	870	AKHMSMQEGAVTGLG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-073	513	GFTFSDYG	692	ISHDRSNK	871	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-041	514	GFTFSDYG	693	ISYDETNK	872	AKHMSMQEGAVTGIG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-025	515	GFTFSDYG	694	ISYDESNK	873	AKHMSMQEGAVTEEG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-007	516	GFTFSDYG	695	ISDEGSNK	874	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-093	517	GFTFSDYG	696	ISYDESNK	875	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-024	518	GFTFSDYG	697	ISYDAGNK	876	AKHMSMQEGAVTGEG QAVKEFIAWLVKGDRV ADLVGDAFDV
GLP1R221-008	519	GFTFSDYG	698	ISDEGSNK	877	AKHMSMQEGAVTGLG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-050	520	GFTFSDYG	699	ISYDENNK	878	AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-062	521	GFTFSDYG	700	TSYDESNK	879	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-068	522	GFTFSDYG	701	ISYDAGNK	880	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-067	523	GFTFSDYG	702	ISNDENNK	881	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ NO	SEQ ID CDR1	SEQ NO	SEQ ID CDR2	SEQ NO	SEQ ID CDR3
GLP1R221-061	524	GFTFSDYG	703	TSYDESNK	882	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-064	525	GFTFSDYG	704	ISDEGSNK	883	AKHMSMQEGAVTGYG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-070	526	GFTFSDYG	705	ISYDATNK	884	AKHMSMQEGAVTGIG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-006	527	GFTFSDYG	706	ISDEGSNK	885	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-045	528	GFTFSDYG	707	ISSDASNK	886	AKHMSMQEGAVTGEG QAAKEFIAWLVFGRVR ADLVGDAFDV
GLP1R221-004	529	GFTFSDYG	708	ISDEGSNK	887	AKHMSMQEGAVTGFG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R221-047	530	GFTFSDYG	709	ISSDASDK	888	AKHMSMQEGAVTGEG QAWKEFIAWLVKGRV RADLVGDAFDV
GLP1R221-048	531	GFTFSDYG	710	ISSDASDK	889	AKHMSMQEGAVTGHEY QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-052	532	GPTFNNYP	711	ISYDESNK	890	AKHMSMQEGAVTGGG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-016	533	GPTFNNYA	712	ISDEGSNK	891	AKHMSMQEGAVTGEY QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-023	534	GPSFSDYG	713	ISYDANNK	892	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-014	535	GFAFSNYG	714	ISYDESNK	893	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-090	536	GFSFSDYG	715	ISYEGSNK	894	AKHMSMQEGAVTGEK QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-073	537	GPTFRDYG	716	IRYDEINK	895	AKHMSMQEGAVTGEKG QAAKEFIAWLVGGRVR ADLVGDAFDV
GLP1R-222-012	538	GPTFNNYG	717	ISDEGSNK	896	AKHMSMQEGAVTGVG QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-082	539	GPTFSAYS	718	ISYDATNK	897	AKHMSMQEGAVTGEF QAAKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-081	540	GPTFDNYA	719	ISYDAGNK	898	AKHMSMQEGAVTGEKG QAAKEFIAWLVKGFVR ADLVGDAFDV
GLP1R-222-056	541	GPFSSSYA	720	ISYDRSNK	899	AKHMSMQEGAVTGYG QAAKEFIAWLVKGFVR ADLVGDAFDV
GLP1R-222-058	542	GPTFRDYA	721	ISFDESNK	900	AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R-222-063	543	GFTFNNYP	722	ISHDRSNK	901	AKHMSMQEGAVTGTG QAAKEFIAWLVKGIVR ADLVGDAFDV
GLP1R-222-042	544	GLTFSNYA	723	TSYDESNK	902	AKHMSMQEGAVTREG QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-092	545	GFTFGSYA	724	TSYDESNK	903	AKHMSMQEGAVTGEG QAAKEFIAWLVVMGRVR ADLVGDAFDV
GLP1R-222-007	546	GFTFSSYG	725	ISSDASDK	904	AKHMSMQEGAVTGEG QAAKEFIAWLVKGWV RADLVGDAFDV
GLP1R-222-008	547	GFNFNNYG	726	ISYDASNK	905	AKHMSMQEGAVTGEF QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-024	548	GFTSSSYA	727	ISDEGSNK	906	AKHMSMQEGAVTGEG QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-062	549	GFTFSDYP	728	ISYDESNK	907	AKHMSMQEGAVTGEG QAAKEFIAWLVKGVR NDLVGDAFDV
GLP1R-222-077	550	GFTFGNYG	729	ISYDASNK	908	AKHMSMQEGAVTGEF QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-064	551	GFTFNNYA	730	ISYAGSNE	909	AKHMSMQEGAVTGEG QALKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-074	552	GFSFRSYG	731	ISSDASNK	910	AKHMSMQEGAQTGEG QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-029	553	GFSFSNYA	732	TSYDESNK	911	AKHMSMQEGAVTGEG QAAKEFIAWLLKGVR ADLVGDAFDV
GLP1R-222-046	554	GFAFSSYA	733	ISYDENNK	912	AKHMSMQEGAVTGYG QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-005	555	GFTFNNYP	734	IWSDASQK	913	AKHMSMQEGAVTGEG WAAKEFIAWLVKGVR RADLVGDAFDV
GLP1R-222-004	556	GFTFGNYA	735	ISSDASDK	914	AKHMSMQEGAVTGEW QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-022	557	GFAFSNYG	736	ISYDASNK	915	AKHMSMQEGAVTGEG QAAKNFIAWLVKGVR ADLVGDAFDV
GLP1R-222-087	558	GFTFSNYA	737	ISYDASNK	916	AKHMSMQEGAVTGYG QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-048	559	GFSFGSYA	738	TSYDESNK	917	AKHMSMQEGAVTGEW QAAKEFIAWLVKGVR ADLVGDAFDV
GLP1R-222-072	560	GFTFSSYP	739	ISYEGTNK	918	AKHMSMQEGAVTGEG QAAKDIFIWLVKGVR ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	SEQ ID NO	SEQ ID NO	CDR1	CDR2	CDR3
GLP1R-222-089	561	GFSFSNYA	740	ISYDESNE	919	AKHMSMQEGAVTGE G QAAKEFIAWLVKGDR V ADLVGDAFDV
GLP1R-222-083	562	GFSFSSYG	741	ISYGGSNK	920	AKHMSMQEGAVTGE W QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-001	563	GFSFSNYA	742	TSYDESNK	921	AKHMSMQEGAVTGE G QAAKEFIAWLLKGVR V ADLVGDAFDV
GLP1R-222-075	564	GFTFSDYG	743	ISYDESNK	922	AKHMSMQEGAVTGE G WAAKEFIAWLVKGVR V RADLVGDAFDV
GLP1R-222-071	565	GFTFSDFA	744	ISYEGSNK	923	AKHMSMQEGAVQGE G QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-069	566	GFTFSDYP	745	ISDEGSNK	924	AKHMSMQEGAVTGEI Q AAKEFIAWLVKGVR A DLVGDAFDV
GLP1R-222-002	567	GFTFRDYA	746	ISYDATNK	925	AKHMSMQEGAVTGMG QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-006	568	GFTFNRYG	747	ISYDASNK	926	AKHMSMQEGAVTGE G QAAWEFIAWLVKGVR V RADLVGDAFDV
GLP1R-222-055	569	GPPFSSYG	748	ISYDATNK	927	AKHMSMQEGAVTGE G QAAKSFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-027	570	GFSFGSYA	749	ISYDASNK	928	AKHMSMQEGAVTGMG QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-066	571	GFTFSNYD	750	ISYAGSNK	929	AKHMSMQEGAVTGTG QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-015	572	GFSFRTYG	751	ISDEGSNK	930	AKHMSMQEGAVTGE G YAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-076	573	GFTFSTYG	752	ISYDANNK	931	AKHMSMQEGAVTGE G QAAVEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-011	574	GFSFSDYA	753	ISSDASNK	932	AKHMSMQEGAVTGYG QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-065	575	GFTFSNYA	754	ISYDATNK	933	AKHMSMQEGAVTGEA QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-041	576	GFTFSNYD	755	TSYDESKK	934	AKHMSMQEGAVTGKG QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-028	577	GFSFSNYA	756	TSYDESNK	935	AKHMSMQEGAVTGE G QAAYEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-086	578	GFTFSDYP	757	ISYAGSNE	936	AKHMSMQEGAVTGYG QAAKEFIAWLVKGVR V ADLVGDAFDV
GLP1R-222-033	579	GPPFSSYA	758	ISYDANNK	937	AKHMSMQEGAVTGYG QAAKEFIAWLVKGVR V ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ NO	SEQ ID CDR1	SEQ NO	SEQ ID CDR2	SEQ NO	SEQ ID CDR3
GLP1R-222-035	580	GFAFSSYA	759	ISYDESNK	938	AKHMSMQEGAVTGE G WAAKEFI FWLVKG VR ADLVGDAFDV
GLP1R-222-045	581	GFSFSNYA	760	ISFDESNK	939	AKHMSMQEGAVTGY G QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-085	582	GTFSDYP	761	ISYDRSNE	940	AKHMSMQEGAVTGT G QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-049	583	GFSFSNYG	762	ISSDASNK	941	AKHMSMQEGAVTGE W QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-078	584	GFSFRNYG	763	ISYDESNK	942	AKHMSMQEGAVTGE G QAAKEFI AWLVKG VR PDLVGDAFDV
GLP1R-222-021	585	GTFNDYG	764	ISSDASNK	943	AKHMSMQEGAVTGT G QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-009	586	GTFGNYA	765	ISSDASNK	944	AKHMSMQEGAVTGE F QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-036	587	GFTFTNYG	766	ISSDASDK	945	AKHMSMQEGAVTG MG QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-084	588	GFSFSNYG	767	ISYGGSNK	946	AKHMSMQEGAVTGE G FAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-010	589	GTFSDYP	768	ISSDASDK	947	AKHMSMQEGAVTGE G QAAKEFI AWLVKG WV RADLVGDAFDV
GLP1R-222-088	590	GFSFSNYA	769	ISYDASNK	948	AKHMSMQEGAVTGG G QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-079	591	GPPFSNYA	770	ISSDASNK	949	AKHMSMQEGAVTGE W QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-040	592	GFSFSDYG	771	ISYDANNK	950	AKHMSMQEGAVTGL G QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-070	593	GTFGSYG	772	ISDEGSNK	951	AKHMSMQEGAVTNEG G QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-032	594	GTFNDYG	773	ISSDENNK	952	AKHMSMQEGAVTGE G QAAKEFI AWLVKG RV RADLVGDAFDV
GLP1R-222-030	595	GTFRDYG	774	ISSDENNK	953	AKHMSMQEGAVTG WG QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-038	596	GTFGNYG	775	ISSDASHK	954	AKHMSMQEGAVTW EG QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-031	597	GTFSGYA	776	ISSDENNK	955	AKHMSMQEGAVTG WG QAAKEFI AWLVKG VR ADLVGDAFDV
GLP1R-222-026	598	GTFFSNYA	777	ISDEGSNK	956	AKHMSMQEGAVTG AG QAAKEFI AWLVKG VR ADLVGDAFDV

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	SEQ ID NO CDR1	SEQ ID NO CDR2	SEQ ID NO CDR3		
GLP1R-222-054	599	GFnFNNYG	778 ISYDESNK	957 AKHMSMQEGAVTGEW QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-093	600	GFTFSDYP	779 ISSDASDK	958 AKHMSMQEGAVTGHG QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-051	601	GFTFNNYP	780 ISYGGSDK	959 AKHMSMQEGAVTGE WAAKEFIAWLVKGRV RADLVGDAFDV		
GLP1R-222-067	602	GFTFSDYA	781 IPYDESNK	960 AKHMSMQEGAVTGE QAAKNFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-059	603	GFAFSNYG	782 ISDEGSNK	961 AKHMSMQEGAVTGHG QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-025	604	GFTFNRYG	783 ISDEGSNK	962 AKHMSMQEGAVTGVG QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-068	605	GFIFSNYA	784 ISYDASNK	963 AKHMSMQEGAVTGEY QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-053	606	GFnFNNYG	785 ISSDASNK	964 AKHMSMQEGAVTGE QAVKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-018	607	GFTFGSYG	786 ISSDENNK	965 AKHMSMQEGAVTGE FAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-047	608	GFTFGSYA	787 TSYDESNK	966 AKHMSMQEGAVTGYG QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-060	609	GFTFSNYD	788 ISDEGSNK	967 AKHMSMQEGAVTGE WAAKEFIAWLVKGRV RADLVGDAFDV		
GLP1R-222-020	610	GFTFKNYG	789 ISYGGSNK	968 AKHMSMQEGAVTGE PAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-044	611	GFSFSDYA	790 ISDDGSNK	969 AKHMSMQEGAVTGE QAAKEFIAWLVKG ADLVGDAFDV		
GLP1R-222-080	612	GFSFSDYG	791 ISSDASDK	970 AKHMSMQEGAVTGE QALKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-057	613	GFTFGSYG	792 ISSDENNK	971 AKHMSMQEGAVTGMG QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-043	614	GFTLSNYA	793 IPYDESNK	972 AKHMSMQEGAVTGVG QAAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-003	615	GFTFSNFA	794 ISSDASNK	973 AKHMSMQEGAVTGE QSAKEFIAWLVKGRVR ADLVGDAFDV		
GLP1R-222-037	616	GFTFRNFG	795 ISSDASNK	974 AKHMSMQEGAVTGIG QAAKEFIAWLVKGRVR ADLVGDAFDV		

TABLE 12-continued

Variable Heavy Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R-222-091	617	GPTFGSHG	796	ISSDENNK	975	AKHMSMQEGAVTGE QAIKEFIAWLVKGRVR ADLVGDAFDV
GLP1R-222-019	618	GFNFNNYG	797	ISDEGSNK	976	AKHMSMQEGAVTGE QAAKEFIAWLVKGRVR PDLVGDAFDV
GLP1R-222-094	619	GPTFGSYG	798	ISYDASNK	977	AKHMSMQEGAVTGWG QAAKEFIAWLVKGRVR ADLVGDAFDV

TABLE 13

Variable Light Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R-3	978	SSNIADNY	1157	DNN	1336	GTWDNYLGAGV
GLP1R221-065	979	TSNIANNF	1158	DHN	1337	GTWDTSLSAGA
GLP1R221-075	980	GSNIGNND	1159	DND	1338	GTWDTSLSNYV
GLP1R221-017	981	SSNIGNTY	1160	DDY	1339	ATWDATLNTGV
GLP1R221-033	982	SSNIGNEY	1161	DNN	1340	ATWDTSLNVGV
GLP1R221-076	983	SSNIGNND	1162	ENN	1341	LTWDHSLTAYV
GLP1R221-092	984	TSNIANNF	1163	DNN	1342	GTWDTSLSVGM
GLP1R221-034	985	SSNIGNNP	1164	END	1343	ATWDRGLSTGV
GLP1R221-066	986	SSNIGNNY	1165	ENN	1344	GIWDRSLSAWV
GLP1R221-084	987	SSNIADNY	1166	ENN	1345	GTWDVSLSVGM
GLP1R221-009	988	SSNIGNQY	1167	DDH	1346	GTWDTSLSVGE
GLP1R221-072	989	SSNIGRNF	1168	DHN	1347	GTWDTVTLHTGV
GLP1R221-044	990	SSNIGNND	1169	DNN	1515	GTWDTSLSGGV
GLP1R221-012	991	SSTIGNNY	1170	EDD	1516	ATWDRGLSTGV
GLP1R221-042	992	SSNIGNKY	1171	DDD	1517	GTWDTSLSVGM
GLP1R221-051	993	SSNIGNDY	1172	DNN	1518	GTWDRGPNTGV
GLP1R221-083	994	SSNIGSKD	1173	DDD	1519	GTWDRSLGGWV
GLP1R221-040	995	SSNIGDND	1174	DNN	1353	GTWDRSLNVGV
GLP1R221-052	996	SSNIGSKY	1175	DNN	1354	GTWDRGPNTGV
GLP1R221-003	997	SSNIGNNP	1176	DND	1355	ATWDHSLRVGV
GLP1R221-094	998	SSNIGNKY	1177	DNN	1356	GTWDTALTAVGV
GLP1R221-001	999	SSNIGSHY	1178	DTN	1357	ATWDRGLSTGV
GLP1R221-014	1000	SSTIGNNY	1179	DND	1358	ATWDTSLNVGV
GLP1R221-085	1001	TSNIGNNH	1180	DNN	1359	GTWDRSLSSAV
GLP1R221-022	1002	SSNIGSNY	1181	DNN	1360	GTWDTSVSAGV
GLP1R221-056	1003	GSNIGNND	1182	DTN	1361	ATWDRTLSIGV
GLP1R221-088	1004	SSNIGSKY	1183	DNN	1362	GTWDTTLNIGV

TABLE 13-continued

Variant	Variable Light Chain CDRs					
	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R221-077	1005	SSNIGNND	1184	GDD	1363	ATWDRSLRAGV
GLP1R221-027	1006	SSNIGNDF	1185	DNN	1364	GTWDTSLSTGV
GLP1R221-019	1007	SSNIGNNF	1186	DNN	1365	GTWETSLSAGV
GLP1R221-029	1008	SSNIGNND	1187	EDN	1366	GTWVTSLSAGV
GLP1R221-043	1009	SSNIGNHD	1188	DNN	1367	GTWDRSLSGEV
GLP1R221-082	1010	SSNIGSNF	1189	DDK	1368	ATWDRGLSTGV
GLP1R221-079	1011	SSNIGDND	1190	DND	1369	ATWDRSLSAVV
GLP1R221-080	1012	SSNIGNND	1191	DDD	1370	GTWDKSLSAVV
GLP1R221-059	1013	SSNIGDND	1192	ENN	1371	GTWDTSLSGGV
GLP1R221-069	1014	SSNIGKNF	1193	DNN	1372	GTWDVTLHTGV
GLP1R221-036	1015	SSNIGNEY	1194	ENK	1373	GTWDASLSAGL
GLP1R221-057	1016	SSNIGSKY	1195	DNN	1374	GTWESSLSSAGV
GLP1R221-035	1017	SSDIGNKY	1196	ENN	1375	ATWDASLSGGV
GLP1R221-063	1018	SSNIGNNF	1197	ENN	1376	ATWDATLNTGV
GLP1R221-090	1019	SSNIGSNY	1198	DTD	1377	GTWDVSLNTQV
GLP1R221-002	1020	SSNIGNKY	1199	DTN	1378	ATWDATLNTGV
GLP1R221-087	1021	SSNIGKDY	1200	ENV	1379	GTWDASLSGVV
GLP1R221-038	1022	TSNIGNND	1201	DNN	1380	GTWDVTLHTGV
GLP1R221-060	1023	GSNIGNND	1202	ETN	1381	GTWDTGLSAGV
GLP1R221-015	1024	TSNIGNNY	1203	DTN	1382	ATWDATLNTGV
GLP1R221-020	1025	SSNIGRNF	1204	DNN	1383	GTWDTSLSRVY
GLP1R221-011	1026	SSNIGKDY	1205	DNY	1384	GTWDTSLSVGV
GLP1R221-091	1027	SSNIGSND	1206	VND	1385	GAWDRSLSAYV
GLP1R221-086	1028	SSNIGKHY	1207	DVD	1386	ATWDRGLSTGV
GLP1R221-074	1029	SSNIGSNY	1208	DNN	1387	GTWDTRLSVGV
GLP1R221-032	1030	SSNIGNNY	1209	DNN	1388	ATWDRSLRAGV
GLP1R221-013	1031	SSNIGNKY	1210	DDD	1389	ATWDTSLNVGV
GLP1R221-058	1032	SSNIGKYY	1211	DNN	1390	GTWDTSLATGL
GLP1R221-031	1033	SSNIGSNL	1212	DNN	1391	GTWDTSLSAGA
GLP1R221-054	1034	RSNIGNYY	1213	DHN	1392	ATWDRTLSIGV
GLP1R221-021	1035	SSNIGNNF	1214	DNN	1393	GAWDRSLSAGV
GLP1R221-016	1036	SSNIGNKY	1215	DND	1394	ATWDATLNTGV
GLP1R221-030	1037	SSNIENND	1216	ENN	1395	GTWDRSLSAAL
GLP1R221-018	1038	SSNIGSNH	1217	ENT	1396	ATWDATLNTGV
GLP1R221-028	1039	SSTIGNNY	1218	DND	1397	GTWDKSLSSAGV
GLP1R221-023	1040	SSNIGSKD	1219	DTN	1398	ATWDRGLSTGV
GLP1R221-089	1041	SSNIGKDF	1220	DND	1399	ATWDTSLSAEV

TABLE 13-continued

Variable Light Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R221-053	1042	SSNIGKDY	1221	EDN	1400	ATWDRTLSIGV
GLP1R221-071	1043	SSNIGSNY	1222	DDN	1401	GTWGSSLSSAGL
GLP1R221-055	1044	SSNIGSND	1223	DKN	1402	GAWDRSLSAGV
GLP1R221-046	1045	SSNIGNND	1224	DDD	1403	AAWDDYLSAVV
GLP1R221-039	1046	SSNIGNHF	1225	DNN	1404	GTWDRSLNVGV
GLP1R221-078	1047	SSNIGNNP	1226	ENI	1405	ATWDRSLRAGV
GLP1R221-010	1048	SSTIGNNY	1227	DNN	1406	GTWDASLSVWW
GLP1R221-005	1049	SSTIGNNY	1228	ENR	1407	GTWDNYLGAGV
GLP1R221-073	1050	SSNIGSNH	1229	END	1408	GTWDTSL SAYI
GLP1R221-041	1051	SSNIGSKY	1230	NDN	1409	GTWDTSLSVG M
GLP1R221-025	1052	SSNIGKYY	1231	DNY	1410	ATWDRGLSTGV
GLP1R221-007	1053	SSNIGNND	1232	ENT	1411	GTWDANLRAGV
GLP1R221-093	1054	SSNIENN H	1233	END	1412	ATWDTSLSEGV
GLP1R221-024	1055	SSNIGKYY	1234	DTN	1413	ATWDRGLSTGV
GLP1R221-008	1056	SSSIGNNY	1235	ANN	1414	GTWDISLSA AV
GLP1R221-050	1057	SSNIGNNF	1236	DKN	1415	ATWDTRL SAVV
GLP1R221-062	1058	SSNIGNNY	1237	ENN	1416	GTWDASLGAWV
GLP1R221-068	1059	SSNIGSND	1238	NNN	1417	GTWDARLGGAV
GLP1R221-067	1060	SSNIGNNY	1239	ANN	1418	GTWDARLGGAV
GLP1R221-061	1061	SSNIGTNF	1240	DNN	1419	GTWDNR LSGWV
GLP1R221-064	1062	SSNIGKDY	1241	ENT	1420	ATWDATLNTGV
GLP1R221-070	1063	SSNIENN H	1242	QNN	1421	GTWDVSLNTQV
GLP1R221-006	1064	SSNIGNNH	1243	GSN	1422	GTWDTSLNIGV
GLP1R221-045	1065	SSNIGNND	1244	GNN	1423	GTWDTSLSGGI
GLP1R221-004	1066	SSTIGNNY	1245	DND	1424	GTWESSL SAGV
GLP1R221-047	1067	SSNIGNEY	1246	GDD	1425	GTWDTSLSVG M
GLP1R221-048	1068	SSNIGNHD	1247	AND	1426	GTWDTSLSVGE
GLP1R-222-052	1069	SSNIGKRS	1248	DNN	1427	VTWDRSL SAGV
GLP1R-222-016	1070	SSNIENN D	1249	DFN	1428	GTWDTSLSVG M
GLP1R-222-023	1071	SSNIGNND	1250	ENT	1429	GTWDAGLSTGV
GLP1R-222-014	1072	SSNIGNHD	1251	DNN	1430	GTWDTSL SAGV
GLP1R-222-090	1073	SSNIADNY	1252	DNN	1431	ATWDNR LSA GV
GLP1R-222-073	1074	GSNIGNND	1253	DNN	1432	GTWDRGPNTGV
GLP1R-222-012	1075	SSNIGNND	1254	DDD	1433	GTWDTSLSVGE
GLP1R-222-082	1076	SSNIGSKY	1255	DNN	1434	GTWDISPSAWV
GLP1R-222-081	1077	SSNIGSDY	1256	DNN	1435	GTWDESLRSWV
GLP1R-222-056	1078	SSNIGSNY	1257	DND	1436	GTWDTSLSVG E
GLP1R-222-058	1079	SSNIGNNP	1258	DNN	1437	ATWDNKLTSGV

TABLE 13-continued

Variant	Variable Light Chain CDRs					
	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R-222-063	1080	SSNIGNYY	1259	DNN	1438	ATWDTSLNVGV
GLP1R-222-042	1081	SSNIGNND	1260	DDN	1439	GTWDTSL SAYI
GLP1R-222-092	1082	SSNIGSDY	1261	ENN	1440	GTWDRGPNTGV
GLP1R-222-007	1083	SSDIGNKY	1262	ENN	1441	GTWDTSL SAGA
GLP1R-222-008	1084	SSNIGSNH	1263	DNN	1442	GTWDTSL SVGE
GLP1R-222-024	1085	TSNIGSNF	1264	DEN	1443	ATWDATLNTGV
GLP1R-222-062	1086	SSNIENND	1265	DNN	1444	GTWDRSLNVGV
GLP1R-222-077	1087	SSSIGNNY	1266	ENN	1445	GTWDNNL GAGV
GLP1R-222-064	1088	SSNIGSKY	1267	DDN	1446	GTWDTSL STGV
GLP1R-222-074	1089	SSNIGNND	1268	DNN	1447	GTWDRGPNTGV
GLP1R-222-029	1090	SSNIGNNY	1269	END	1448	GTWDTSL ATGL
GLP1R-222-046	1091	TSNIGNNY	1270	ENT	1449	GTWDTTL SAGV
GLP1R-222-005	1092	SSNIGNDY	1271	DNN	1450	GTWDASLSAGL
GLP1R-222-004	1093	SSNIGNDY	1272	ENN	1451	GTWDASLSAGL
GLP1R-222-022	1094	SSNIGNND	1273	DND	1452	GTWDRTLSIGV
GLP1R-222-087	1095	SSNIENND	1274	DNN	1453	GTWDRRL SDVV
GLP1R-222-048	1096	RSNIGNNF	1275	DNN	1454	GTWDRSL SSAV
GLP1R-222-072	1097	SSSIGNNY	1276	DTN	1455	GTWDRSLNVGV
GLP1R-222-089	1098	SSNIGNND	1277	DTN	1456	GTWDISLSARV
GLP1R-222-083	1099	SSNIGSKY	1278	DND	1457	ATWDTSL SAGV
GLP1R-222-001	1100	SSNIGSKY	1279	DNN	1458	GTWDTSL ATGL
GLP1R-222-075	1101	SSNIGSKD	1280	DTY	1459	GTWDTSVSAGV
GLP1R-222-071	1102	TSNIGNNY	1281	DDN	1460	GTWDRSLNVGV
GLP1R-222-069	1103	SSNIGSHY	1282	DNN	1461	GTWHSSL SAGV
GLP1R-222-002	1104	SSDIGNKY	1283	DND	1462	GTWDTTL SAGV
GLP1R-222-006	1105	SSNIGNND	1284	DNN	1463	GAWDTSL SAVV
GLP1R-222-055	1106	TSNIGNNY	1285	DNN	1464	GTWDTSL SVGE
GLP1R-222-027	1107	TSNIGNNH	1286	EDN	1465	GTWDTSL ATGL
GLP1R-222-066	1108	SSTIGNNY	1287	DNN	1466	ATWDRGL STGV
GLP1R-222-015	1109	RSNIGNYY	1288	DND	1467	GTWDRSL SVGL
GLP1R-222-076	1110	SSNIGSKY	1289	DTY	1468	GTWDAGL STGV
GLP1R-222-011	1111	SSNIGSNY	1290	ENN	1469	GTWDTSL SVGE
GLP1R-222-065	1112	SSTIGNNY	1291	DNN	1470	ATWDRTLSIGV
GLP1R-222-041	1113	SSNIGSKD	1292	DDN	1471	GIWDRSL SAWV
GLP1R-222-028	1114	TSNIGNNH	1293	DNN	1472	GTWDTSL ATGL
GLP1R-222-086	1115	SSNIGNHF	1294	DTN	1473	GTWDRGPNTGV
GLP1R-222-033	1116	SSNIGKYY	1295	DNN	1474	GTWDVSL SVGM

TABLE 13-continued

Variable Light Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R-222-035	1117	SSNIGNND	1296	ENN	1475	GTWDVSLSVGM
GLP1R-222-045	1118	SSNIGNTY	1297	ENR	1476	ATWDTSLSEGV
GLP1R-222-085	1119	SSNIGSDY	1298	ANN	1477	GTWDVTLHAGV
GLP1R-222-049	1120	TSNIGKNF	1299	ENK	1478	ATWDRSLSAGV
GLP1R-222-078	1121	SSNIGKYY	1300	DTN	1479	GTWDNNLGAGV
GLP1R-222-021	1122	SSNIGDND	1301	ENR	1480	GTWDASLSAGL
GLP1R-222-009	1123	SSNIGKNF	1302	DTN	1481	GTWDTSLSVGE
GLP1R-222-036	1124	SSNIGSKY	1303	DNN	1482	ATWDDTLTAGV
GLP1R-222-084	1125	SSNIGSKD	1304	DNN	1483	GIWDTSLSAWV
GLP1R-222-010	1126	SSNIGNKY	1305	DNN	1484	GTWDNRLSAGV
GLP1R-222-088	1127	SSNIGNNF	1306	DND	1485	GTWDTSLRVVV
GLP1R-222-079	1128	SSNIGSND	1307	NNN	1486	GTWESGLSAGV
GLP1R-222-040	1129	SSNIGNQY	1308	DTY	1487	ATWDHSLRVGV
GLP1R-222-070	1130	SSNIGNND	1309	ANN	1488	GTWHSSLAGV
GLP1R-222-032	1131	SSNIGNNP	1310	END	1489	GTWDTRLSVGV
GLP1R-222-030	1132	SSNIGNNL	1311	DND	1490	GTWDTSLTAGV
GLP1R-222-038	1133	SSNIGNKY	1312	DTN	1491	ATWDATLNTGV
GLP1R-222-031	1134	SSNIGNNY	1313	DDN	1492	GTWDTSLSVGM
GLP1R-222-026	1135	SSNIGSKY	1314	DNN	1493	GTWDRGPNTGV
GLP1R-222-054	1136	SSNIGSKY	1315	DDY	1494	GTWDNRLSGWV
GLP1R-222-093	1137	RSNIGNNF	1316	DNY	1495	ATWDRGLSTGV
GLP1R-222-051	1138	RSNIGNNF	1317	DNN	1496	ATWDRSLSAGV
GLP1R-222-067	1139	RSNIGNNF	1318	DNN	1497	GTWDRRLSAVV
GLP1R-222-059	1140	SSNIGNEY	1319	ENN	1498	GTWDNYLGAVV
GLP1R-222-025	1141	SSNIGNEY	1320	DND	1499	ATWDATLNTGV
GLP1R-222-068	1142	RSNIGNNF	1321	ENN	1500	GSWDRSLSAVV
GLP1R-222-053	1143	SSNIGNND	1322	ASN	1501	ATWDNILSAVV
GLP1R-222-018	1144	SSNIGKNF	1323	ETN	1502	ATWDRGLSTGV
GLP1R-222-047	1145	SSNIGTNF	1324	ADN	1503	GTWDRTLSIGV
GLP1R-222-060	1146	SSNIGNNP	1325	GNN	1504	GTWDASLGAVV
GLP1R-222-020	1147	SSNIGNND	1326	DND	1505	GTWDAGLSTGV
GLP1R-222-044	1148	SSNIGNNH	1327	DFN	1506	ATWDRSLRAGV
GLP1R-222-080	1149	SSNIGNHD	1328	ENK	1507	GTWESGLSAGV
GLP1R-222-057	1150	SSNIGDHY	1329	ENN	1508	ATWDNKLTSGV
GLP1R-222-043	1151	SSNIGNNY	1330	DNN	1509	ATWDRSLRAGV
GLP1R-222-003	1152	SSNIGNHD	1331	ENN	1510	GTWDTSLAGV
GLP1R-222-037	1153	SSNIGNNP	1332	NNN	1511	ATWDTTLNTGV
GLP1R-222-091	1154	SSNIGSNY	1333	GND	1512	ASWDNRLTAVV

TABLE 13 -continued

Variable Light Chain CDRs						
Variant	SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
GLP1R-222-019	1155	SSNIGNNY	1334	DNN	1513	ATWDRGLSTGV
GLP1R-222-094	1156	SSNIGHTY	1335	ENK	1514	ATWDTSLSSEGKV

While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be under-

stood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

SEQUENCE LISTING

The patent contains a lengthy sequence listing. A copy of the sequence listing is available in electronic form from the USPTO web site (<https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US12391762B2>). An electronic copy of the sequence listing will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed is:

1. An antibody or antibody fragment that binds to glucagon-like peptide-1 receptor (GLP1R) comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH), and the light chain comprises a light chain variable region (VL), wherein:
 - (a) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 441, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 620, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 799, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 978, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1157, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1336;
 - (b) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 534, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 713, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 892, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1071, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1250, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1429;
 - (c) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 561, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 740, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 919, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1098, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1277, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1456; or
 - (d) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 592, a CDR-H2 com-
- prising the amino acid sequence of SEQ ID NO: 771, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 950, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1129, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1308, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1487.
2. The antibody or antibody fragment of claim 1, wherein the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 441, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 620, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 799, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 978, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1157, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1336.
 3. The antibody or antibody fragment of claim 1, wherein the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 534, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 713, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 892, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1071, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1250, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1429.
 4. The antibody or antibody fragment of claim 1, wherein the VH comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 70.
 5. The antibody or antibody fragment of claim 1, wherein the VH comprises the amino acid sequence of SEQ ID NO: 70.

147

6. The antibody or antibody fragment of claim 1, wherein the VL comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 104.
7. The antibody or antibody fragment of claim 1, wherein the VL comprises the amino acid sequence of SEQ ID NO: 104.
8. The antibody or antibody fragment of claim 1, wherein the VH comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 70, and wherein the VL comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 104.
9. The antibody or antibody fragment of claim 1, wherein the VH comprises the amino acid sequence of SEQ ID NO: 70, and wherein the VL comprises the amino acid sequence of SEQ ID NO: 104.
10. The antibody or antibody fragment of claim 1, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 54, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 89.
11. The antibody or antibody fragment of claim 1, wherein the antibody is a monoclonal antibody, a bi-specific anti-

148

- body, a multispecific antibody, a grafted antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab')2 fragment, a Fv fragment, a single-domain antibody, a diabody, disulfide-linked Fvs (sdFv), an intrabody, or an antigen-binding fragment thereof.
12. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment thereof is chimeric or humanized.
 13. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment has an EC50 less than about 20 nanomolar in a cAMP assay.
 14. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is an agonist of GLP1R.
 15. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is an antagonist of GLP1R.
 16. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is an allosteric modulator of GLP1R.

* * * * *